Radical-Mediated C–H Functionalization: A Strategy for Access to Modified Cyclodextrins

Dimitri Alvarez-Dorta,[†] Elisa I. León,[†] Alan R. Kennedy,[‡] Angeles Martín,^{*,†}
Inés Pérez-Martín,[†] and Ernesto Suárez^{*,†}

[†]Síntesis de Productos Naturales, Instituto de Productos Naturales y Agrobiología del CSIC
Carretera de La Esperanza 3, 38206, La Laguna, Tenerife (Spain)

[‡]WestCHEM Department of Pure and Applied Chemistry
University of Strathclyde, 295 Cathedral Street, Glasgow G1 1XL, Scotland (UK)

ABSTRACT

A simple and efficient radical C–H functionalization to access modified cyclodextrins (CDs) has been developed. The well-defined conformation of glycosidic and aglyconic bonds in α -, β -, and γ -CDs favors the intramolecular 1,8-hydrogen atom transfer (HAT) promoted by the 6^I-O-yl radical which abstracts regioselectively the hydrogen at C5^{II} of the contiguous pyranose. The C5^{II}-radical evolves by a polar crossover mechanism to a stable 1,3,5-trioxocane ring between two adjacent

glucoses or alternatively triggers the inversion of one α -D-glucose into a 5-C-acetoxy- β -L-idose unit possessing a 1C_4 conformation. The $6^{I,IV}$ - and $6^{I,III}$ -diols of α - and β -CDs behave similarly to the monoalcohols, forming mostly compounds originating from two 1,8-HAT consecutive processes. In the case of $6^{I,II}$ -diols the proximity of the two 6-*O*-yl radicals in adjacent sugar units allows the formation of unique lactone rings within the CD framework via a 1,8-HAT- β -scission tandem mechanism. X-Ray diffraction carried out on the crystalline 1,4-bis(trioxocane)- α -CD derivative shows a severe distortion toward a narrower elliptical shape for the primary face.

INTRODUCTION

Over the past decades, cyclodextrins (CDs) have been extensively investigated for their valuable applications in several areas.¹ These naturally-occurring cyclic oligosaccharides are composed of glucose units in 4C_1 chair conformations, with a hydrogen bond network formed between the secondary hydroxyl groups, creating a conical shape with an internal hydrophobic cavity, conferring the ability to form host-guest or inclusion complexes with a great variety of molecules and rendering them one of the most important supramolecular host families. Because of these inclusion properties, CDs are displayed as being potentially useful as drug and gene delivery systems,² artificial enzymes³ or catalysts,⁴ just to cite a few.

Considering their unique features and relevant applications, great effort has been invested in developing chemical modifications of native CDs to modulate their chemophysical properties, and thus achieve an enhancement of their solubility, a change in their cavity size or an improvement in their inclusion capability. The strategies are usually based on grafting a wide assortment of substituents taking into account the different accessibility and reactivity of the hydroxyl groups to

obtain diverse patterns of functionalization, which act as platforms to access amphiphilic CDs,⁵ and hence, sophisticated molecular architectures.⁶

It should be pointed out that most of these methodologies have addressed the structural changes retaining the 4C_1 chair conformation of the glucose units, but a few of them describe modifications of the cavity by altering the conformations of these units. Thus, the reported synthesis of 3,6-anhydro-CDs shows the conformational change of the pyranose units to 1C_4 , and consequently, a significant change in their binding properties.⁷ Moreover, the formation of a mono-2,3-epoxide- β -CD followed by a nucleophilic ring opening generates an altrose unit in a 1C_4 which distorts the cavity from conical to elliptical.⁸ The introduction of several altrose moieties reflects a rapid equilibrium between 1C_4 and 4C_1 conformers and their ratio depends on the number of residues and their position in the macromolecule.⁹ The cycloglycosylation syntheses of cyclodextrin analogues composed exclusively of L-sugars or incorporating both L- and D-sugars residues have been reported.^{7a} Finally, it has been found that in the crystalline structure of permethylated β -CD one of the D-glucose residues is inverted from the normal 4C_1 to the 1C_4 chair conformation.¹⁰

Interestingly, in the methodologies employed to create this structural diversity in CDs, regardless of conformational changes, radical reactions are practically unknown and this fact is not surprising if we consider that in simple carbohydrates they mainly involve the anomeric position which is committed in the cyclic CD structure.¹¹ Only one example has been reported in the literature and is focused on the intermolecular attack of reactive-oxygen-centered free radicals on CDs in aqueous solution using EPR detection experiments.¹²

During the last several years, our group has been immersed in the development of methods for the activation and functionalization of “inert” C–H bonds in carbohydrate chemistry.¹³ Of special

interest is a novel 1,8-hydrogen atom transfer reaction (1,8-HAT) which takes place, through a rather unusual nine-membered transition state (TS), between both pyranose units in a *Hexp*-(1→4)-*Hexp* disaccharide system. The hydrogen abstraction at C5^{II} is promoted, in a highly regioselective manner, by the electrophilic 6^I-*O*-yl radical **I** generated from the corresponding alcohol under oxidative conditions, producing a C5^{II} radical **II** (Scheme 1).

Scheme 1. Radical polar crossover mechanism for the HAT reaction promoted by 6-*O*-yl radicals in *Hexp*-(1→4)-*Hexp* systems of carbohydrates. DIB = (diacetoxyiodo)benzene.

This intermediate suffers a one-electron oxidation causing a crossover from the radical to the oxacarbenium ion **III** which is subsequently trapped by the alcohol to give the intramolecular bridged eight-membered 1,3,5-trioxocane **IV**. The obtained results show that this regioselectivity is highly dependent on both the four stereogenic centers implicated in the cyclization step (C5^{II},

C1^{II}, C4^I, and C5^I) as the conformation of the glycosidic ($\Phi = \text{H1}^{\text{II}}\text{--C1}^{\text{II}}\text{--O4}^{\text{I}}\text{--C4}^{\text{I}}$) and aglyconic ($\Psi = \text{C1}^{\text{II}}\text{--O4}^{\text{I}}\text{--C4}^{\text{I}}\text{--H4}^{\text{I}}$) bonds. In fact, when these stereochemical and conformational requisites are not suitable for the 1,8-HAT to take place, the alkoxyl radical **I** may alternatively abstract the hydrogen at C1^{II} via a 1,6-HAT to produce a new C1^{II} radical **V** which, after oxidation to the respective oxacarbenium ion **VI** and cyclization, gives the spiro ortho ester **VII**.

For the β -maltose disaccharide, $\alpha\text{-D-Glcp-(1}\rightarrow\text{4)-}\beta\text{-D-Glcp}$, the reaction proceed with complete regioselectivity, yielding compounds formed exclusively from the 1,8-HAT.^{13a} In this case, the corresponding glycosidic and aglyconic bonds in the TS involved ($\Phi = -32.7$, $\Psi = -37.3^\circ$) are arranged in an *exo-syn* conformation, where the alkoxyl radical and the H5^{II} are at an optimal distance of 3.1 Å for the initial abstraction step.¹⁴

With this result in mind, we decided to investigate whether this radical-polar crossover methodology could be extended to more complex carbohydrates such as CDs, since in these systems the D-glucose units are linked in a similar fashion (cyclo-[$\alpha\text{-D-Glcp-(1}\rightarrow\text{4)}_n$]). The measures of distances and angles made on the reported X-ray structure of permethylated $\beta\text{-CD}$ ¹⁵ as well as on its minimized structure indicate that there is sufficient inter-residue flexibility in the macromolecule to adopt an *exo-syn* conformation similar to β -maltose. Therefore, from a theoretical point of view, the 1,8-HAT process could take place between two vicinal units of the macrosystem to provide modified CDs on their primary face, which could exhibit important distortions in their cavities.

Preliminary results of this work have been described recently and we now present here the full details of the process and the extension to other positional isomeric diols and per-6-ol models.¹⁶

RESULTS AND DISCUSSIONS

Initially, the most common and readily available β -cyclodextrin was the substrate of choice in order to investigate the viability of this radical process. The corresponding monoalcohol 2^{I-VII}, 3^{I-VII}, 6^{II-VII}-icosa-*O*-methyl- β -CD (**1**) necessary to assay the reaction was prepared from the commercial β -CD following a well-known three-step sequence consisting in monosilylation of one primary alcohol, *O*-methylation of the remaining hydroxyl groups and finally removal of silyl-ether.¹⁷ This protocol has the advantage of using methyl ethers as protecting groups which usually allow an increase in solubility both in water and in organic solvent.¹⁸ To our delight, visible light irradiation of alcohol **1** with diacetoxyiodobenzene (DIB) (2.2 equiv) and iodine (1 equiv) at 30 °C proceeded nicely in 30 minutes delivering the expected 1,3,5-trioxocane **2** (36%) and the acetate **3** (61%) as the major compound (Table 1, entry 1).¹⁹ Lower reaction temperatures or fewer equivalents of reagents (DIB or I₂) only gave rise to slower and incomplete reactions while the increase in the reaction times or the amount of reagents allowed us to obtain exclusively trioxocane **2** in 60% yield (entry 2). The reaction is plausibly explained by a sequential intermolecular nucleophilic attack by acetate anion to give **3** followed by an intramolecular cyclization leading to **2**. A competitive addition of both nucleophiles to the oxacarbenium ion intermediate may also be considered.²⁰ Obviously, both products, **2** and **3**, derived from the same C5^{VII} radical intermediate, through an intramolecular 1,8-HAT reaction promoted by the 6^I-*O*-yl radical. No compounds resulting from abstraction at C1^{VII} via a 1,6-HAT process were detected.

In both compounds, the oxidation at C5^{VII} was clearly confirmed by 1D and 2D NMR experiments. Thus, for compound **2**, the HMBC correlation of the H1^{VII} proton signal at δ_H 5.06 ppm with the C5^{VII} quaternary carbon atom (δ_C 101.04 ppm) corroborates this C5^{VII} functionalization. Moreover,

all D-glucopyranose units are preferentially in 4C_1 chair conformations as we can be deduced from the values of the coupling constants of the anomeric hydrogens (${}^3J_{1,2} \approx 3.6$ Hz).

Table 1. 1,8-HAT for 6^I-ol-β-CD **1, 6^I-ol-α-CD **5**, and 6^I-ol-γ-CD **8**.^a**

entry	substrate	I(III)/I ₂ (equiv)	products (yield)
1	1 ; β-CD	DIB/I ₂ (2.2/1.0)	2 (36%) 3 ; R = Ac (61%)
2	1 ; β-CD	DIB/I ₂ (3.0/1.7)	2 (60%) —
3	1 ; β-CD	PhI(OCOAd) ₂ /I ₂ (2.2/1.0) ^b	No reaction
4	1 ; β-CD	PhI(OCO-2,4,6- <i>i</i> Pr ₃ Ph) ₂ /I ₂ (2.2/1.0)	No reaction
5	1 ; β-CD	PhI(OCO-4- <i>t</i> BuPh) ₂ /I ₂ (2.2/1.0)	2 (46%) n.d.
6	1 ; β-CD	PhI(OCO-2,4,6-Me ₃ Ph) ₂ /I ₂ (2.2/1.0)	2 (21%) 4 ; R = CO-2,4,6-Me ₃ Ph (33%)
7	5 ; α-CD	DIB/I ₂ (2.2/0.5)	6 (31%) 7 ; R = Ac (30%)
8	5 ; α-CD	DIB/I ₂ (2.2/1.0)	6 (59%) —
9	8 ; γ-CD	DIB/I ₂ (2.2/0.5)	9 (36%) 10 ; R = Ac (41%)
10	8 ; γ-CD	DIB/I ₂ (2.2/1.0)	9 (44%) —

^aReaction conditions: A solution of the alcohol in dry CH₂Cl₂ containing the organoiodine(III) reagent and I₂ was stirred under nitrogen while irradiated with two 80 W tungsten-filament lamps. n.d. = not determined. ^b Ad = 1-Adamantyl.

With respect to the acetyl derivative **3**, the deshielding observed for the ring protons of the unit VII bearing the acetyl group and the magnitude of the ${}^3J_{H,H}$ coupling constants [${}^3J_{1,2} = 1.9$ Hz (calcd 1.3 Hz), ${}^3J_{2,3} = 2.5$ Hz (calcd 2.6 Hz), and ${}^3J_{3,4} = 1.9$ Hz (calcd 3.3 Hz)] suggest that the ring exists substantially in a 1C_4 inverted chair conformation.²¹ Moreover, the NOE experiment shows an interaction between H1^{VII} and the acetyl methyl protons, thus tentatively establishing the stereochemistry at C5^{VII} as *R*. These data indicate that the acetate group has been incorporated with

inversion of configuration at C5^{VII} and consequently the original α -D-glucopyranose has been transformed into a 5-C-acetoxy- β -L-idopyranose unit,²² flipping from 4C_1 to 1C_4 chair conformation. As far as we know, this is the first precedent of a β -CD molecule having a β -L-idose unit in its structure. Conversely, in the formation of trioxocane **2**, the intramolecular nucleophilic addition to the oxacarbenium ion occurs with retention of configuration at C5^{VII} or by a double inversion if we consider **3** to be an intermediate.

To achieve additional insight into the incorporation of acetate, we decided to explore the reaction with different bis(acyloxyl) hypervalent iodine(III) reagents to evaluate the nucleophilic addition of other acyloxyl groups to the C5 position.²³ As depicted in Table 1, in the cases of the sterically demanding 1-adamantylcarboxyl (entry 3) or 2,4,6-triisopropylbenzoyloxyl (entry 4), the reaction did not proceed, recovering most of the unchanged starting material in both cases. This may be caused by the steric hindrance of the acyl hypiodite intermediate which precludes entirely the formation of the 6^I-O-yl radical.²⁴ When the ester was the 4-*tert*-butylbenzoyloxyl (entry 5), TLC analysis showed the completion of the reaction and the presence of two main products. However after chromatographic separation we were able to isolate only the cyclized compound **2** in 46% yield, presumably due to intramolecular hydrolytic cleavage of the ester. Only the reaction with bis(2,4,6-trimethylbenzoyloxy)iodobenzene allowed us to isolate both products, **2** and **4**, albeit in moderate yield, 21% and 33% respectively, together with a significant amount of starting material (39%) (entry 6). The NMR data for **4** show clearly that, also in this case, the ring chair conformation of unit VII has been inverted.

The effectiveness of this methodology was tested on α - and γ -CD models. The corresponding monoalcohols **5**²⁵ and **8**²⁶ were prepared following the same three-step protocol employed for the 6^I-ol- β -CD derivative **1**. Using similar amounts of DIB and iodine, both substrates behaved in an

analogous manner to the β -CD case, generating the corresponding trioxocane derivatives **6** and **9** and acetates **7** and **10**, albeit in somewhat lower overall yields (Table 1, entries 7–10). While the trioxocane derivatives are stable for long periods of time at room temperature and can be easily manipulated, the acetates seem to be acid- and base-sensitive compounds. The use of an excess of iodine (entries 8 and 10), aqueous work up or standard silica gel column chromatographic purification preclude their isolation and the reaction gives exclusively the respective trioxocane derivatives **6** and **9** in variable yields. Fortunately, pure acetates **7** and **10** could be obtained using 0.5 equiv of iodine, avoiding any work up and after careful flash chromatography employing silica gel scraped from commercially coated TLC plates (entries 7 and 9).

As described above for the β -CD derivative **3**, the structures and conformations of the acetyl derivatives **7** and **10** were corroborated by 1D TOCSY and 2D HSQC and HMBC experiments. Remarkably, the conformation of unit VI of compound **7** exhibits changes in the TOCSY experiments by varying from CDCl_3 to C_6D_6 . The observed values of the coupling constants of this unit in CDCl_3 [$^3J_{1,2} = 2.8$ Hz (calcd 1.4 Hz), $^3J_{2,3} = 3.2$ Hz (calcd 2.5 Hz), and $^3J_{3,4} = 2.8$ Hz (calcd 3.3 Hz)] indicate predominantly a 1C_4 conformation while in C_6D_6 these values [$^3J_{1,2} = 3.5$ Hz (calcd 3.2 Hz), $^3J_{2,3} = 8.5$ Hz (calcd 9.7 Hz), and $^3J_{3,4} = 7.9$ Hz (calcd 9.2 Hz)] preferentially point to a 4C_1 conformation.²¹ In contrast, the acetates **3**, **4**, and **10**, derived from β - and γ -CD, show the same 1C_4 conformation in both solvents. The inversion barrier seems to be significantly lower in the more strained hexameric ring.

Encouraged by these promising results with mono-alcohols, we decided to investigate what would happen in this HAT process if we have two primary hydroxyl groups in the molecule which can react simultaneously, a situation hitherto little studied.²⁷ Taking into account the structure of β - and α -CDs, there are three different positional isomers ($6^{\text{I,II}}$ -, $6^{\text{I,III}}$ -, and $6^{\text{I,IV}}$ -diol) for each of them.

With the aim of obtaining cyclized compounds, we examined the relative stability of the expected final products, the 1,4-, 1,3-, and 1,2-bis(1,3,5-trioxocane) compounds. A preliminary analysis using molecular mechanic calculations revealed that the energetic differences among the three isomers, in either β - or α -CD, are very small (approx. 2 kcal/mol), providing evidence for the thermodynamic feasibility of the cyclization step.²⁸

Therefore, we decided to synthesize the three isomeric diols of each CD using a similar protection-deprotection sequence employed for the monoalcohols, as has been described previously,^{17a} and assess the scope of this methodology.

The study was begun with the more distant 1,4-diol derivatives, that we believe have greater possibilities of success. Firstly, we carried out the reaction of the 6^{L,IV}-diol- β -CD derivative **11**^{17a} with DIB and I₂ as shown in Scheme 2. Gratifyingly, the process proceeded in good overall yield, affording the 1,4-bis(trioxocane) **12** (20%), the diacetate **13** (49%) as the main product, and a 3:2 chromatographically inseparable mixture of mono-trioxocane–mono-acetyl positional isomers (14%, not shown, see the Experimental Section) which could be transformed into **12** after treatment with iodine. Analogously, compound **12** was obtained when **13** was submitted to these iodine catalyzed conditions. The acetyl methyl protons at C5^{III} and C5^{VII} in compound **13** were readily assigned by 2D HSQC and HMBC experiments, whereas the ¹H NMR showed the deshielding of the ring protons in these units III and VII and the values of their coupling constants (³J_{H,H} $\approx$ 1.9–2.5 Hz) were consistent with the introduction of both acetates with inversion at C5 and thus, with the presence of two β -L-idose units in ¹C₄ conformations. Although no chair inversion was detected using C₆D₆ as solvent, the axial H1^{III} and H1^{VII} protons started to broaden at 18 °C suggesting that coalescence is just below this temperature, while the signals were sharpened by heating at 70 °C. Additionally, the stereochemistry of the quaternary centers C5^{III} and C5^{VII} were established

tentatively as *R* on the basis of NOE interactions between H1^{III} or H1^{VII} and the respective acetyl methyl protons.

Scheme 2. 1,8-HAT for the 6^{I,IV}-diol-β-CD **11 and 6^{I,IV}-diol-α-CD **14****

Next, we explored the behavior of 6^{I,IV}-diol-α-CD derivative **14**^{25,29} under these oxidative radical conditions. The reaction afforded the bis- and mono-trioxocanes **15** and **16** as sole compounds, not detecting any product from incorporation of acetate into the molecule, and thus, revealing the greater steric hindrance in this hexamer (Scheme 2). Moreover, compound **15** is a crystalline solid whose structure was unambiguously confirmed by X-ray crystallographic analysis, showing two trioxocane rings in a restricted boat-chair (BC) conformation with a guest *n*-hexane molecule in the CD cavity (Figure 1).³⁰ The simplified ¹H and ¹³C NMR spectra are consistent with the C₂ symmetry of the proposed structure.

The comparison of the geometrical structural parameters of **15** with those of the related permethylated α-CD³¹ shows that the presence of the two 1,3,5-trioxocane rings severely distort

the primary face of the molecule. This distortion is clearly observed when comparing the geometrical parameters of the irregular hexagon comprising the side-chain carbon atoms ($C6^n$), which points toward a much narrower elliptical shape for this rim (see Tables S2 and S3 in the Supporting Information). Conversely, the presence of the bis(trioxocane) rings does not significantly alter the secondary face of the molecule. Thus, for instance, the distances and angles between the six interglycosidic oxygen atoms ($O4^n$), as well as the radii of the gravity center of the hexagon formed by these $O4^n$ oxygen atoms are quite similar in both X-ray structures. The most significant differences are observed in the tilt angles made by the $O4^n$ mean plane and the mean planes through the glucose units principally in residues II and V adjacent to the trioxocane rings. What do not seem to be affected either are the 4C_1 chair geometries of the six glucose units, as shown by the Cremer–Pople puckering parameters which describe slightly distorted chairs similar to those found in the permethylated α -CD (see Tables S2 and S3).³²

Figure 1. X-ray crystal structure of **15**. C blue, O red, 1,3,5-trioxocane ring yellow-green, H atoms have been omitted by clarity. Ellipsoids are set at 50% probability.

Scheme 3. HAT for the 6^{I,III}-diol- β -CD **17**

We next focused our attention on applying the C–H functionalization to 1,3-diol derivatives. The reaction of 6^{I,III}-diol- β -CD **17**^{17a} under the usual conditions produced one compound derived from the mono-abstraction, the acetate **18** in 21% yield together with four compounds in 47% overall yield arising from double abstraction: the diacetate **19** with incorporation of two external nucleophiles, the two possible mono-trioxocane–mono-acetyl derivatives **20** and **21**, and the spiro ortho ester–trioxocane **22** in which only internal nucleophiles are implicated (Scheme 3).

Curiously, the expected bis(trioxocane) was not detected in the crude reaction mixture, even after longer reaction times.

Analogously, the incorporation of the acetate has taken place with inversion at C5 and transformation of the sugar into a β -L-idose unit. This appears to be a general trend for all compounds even in the cases of compounds **13** and **19** where two units in a 1C_4 inverted chair conformation exist as part of the heptameric ring.

On the other hand, the positional isomers **20** and **21** can be differentiated by a careful study using 2D HSQC and HMBC and 1D TOCSY and ROESY experiments. The H1^I and H4^{II} 1D ROESY correlation that has been observed in both compounds can be used to distinguish between both isomers. The H4^{II} protons, that have been clearly identified by 1D TOCSY, appear at 3.90 ppm (d, ${}^3J_{3^{II},4^{II}} = 9.0$ Hz) for compound **20** and at somewhat lower field 4.11 ppm (d, ${}^3J_{3^{II},4^{II}} = 2.9$ Hz) for the isomer **21**, which undoubtedly confirms the proposed structures.

Moreover, in compound **22** where two positional isomers could be a priori possible we were able to assign the correct structure, since the 1D ROESY experiment showed a correlation between H1^{III} and H4^{IV} [(3.60 ppm (dd, $J = 9.2, 9.2$ Hz)]. In the other hypothetical isomer (spiro ortho ester at unit I and trioxocane at unit III) the analogous ROESY interaction would have been between H1^I and H4^{II} near the trioxocane and this last proton should be a doublet. Although two stereoisomers at the spiro quaternary carbon at C1^{II} are possible, only one has been isolated and the configuration tentatively assigned as *R*. Molecular mechanics calculations show that the *R*-isomer is more stable by 6 kcal/mol than the *S*-isomer. The stereochemistry is supposed to be stereoelectronically controlled, in the *R*-isomer the alcohol approaches the oxacarbenium ion by the α -axial direction to maximize the anomeric effect.³³ Additional support was secured by examination of the 1H NMR spectrum, revealing a downfield displacement for the *pro-S* H6^{III} proton [4.24 (dd, $J = 9.1, 7.9$

Hz)], which in this stereoisomer presents a 1,3-diaxial interaction with the C1^{II}–O^{II} bond. An obvious experiment that could be important for the determination of this stereochemistry such as the study of NOE correlations from H2^{II} could not be performed due to signal overlap. Fortunately, this problem does not exist in the ¹H NMR spectrum of the analogous spiro ortho ester **30** and the results confirm the proposed stereochemistry (vide infra).

In contrast with the previous results, when the reaction is performed with the hitherto unknown 6^{I,III}-diol- α -CD **23**, we only obtained the bis- and the two possible mono-trioxocanes **24**, **25** and **26** respectively, in 66% overall yield, not detecting products with inverted β -L-idose units in the molecule (Scheme 4). This is in agreement with the results obtained in the 6^{I,IV}-diol series where we did not find inverted sugar units in the reaction of 6^{I,IV}-diol- α -CD **14** (Scheme 2).

Scheme 4. HAT for the 6^{I,III}-diol- α -CD **23**

Although, all structures were analogously determined by NMR spectroscopy the preparation of the acetyl derivatives **27** and **28** from both mono-trioxocanes was necessary to differentiate these positional isomers. The NOE interaction between H1^I and H4^{II} [4.26 ppm (d, $J = 9.2$ Hz)] in compound **27** and the corresponding correlation between H4^{VI} and H1^V [5.04 ppm (d, $J = 3.2$ Hz)] in the isomer **28** firmly established the proposed structures.

Finally, to complete the study of the diols, the reactions of 1,2-diols of β - and α -CDs were carried out. The reaction of the 6^{I,II}-diol- β -CD **29**^{17a} under the usual oxidative conditions led to the formation of four compounds in moderate overall yield: the spiro ortho ester–trioxocane **30** (5%), the ten-membered lactone **31** (10%) and a mixture of two products, **32** and **33**, which after acetylation was readily separated as the mono-trioxocane **34** and the δ -lactone **35**, in 22% and 11% yield respectively (Scheme 5). The relative position of the spiro ortho ester with respect to the trioxocane rings in **30** and the primary acetate with respect to the trioxocane in **34** was readily established by spectroscopic means. The ring coupling constants for the sugar units involved were determined by 1D TOCSY and ROESY experiments but in any case, the alternative structures for the positional isomers should have a very different ¹H and ¹³C NMR pattern. The spiro quaternary carbon stereochemistry C1^I in compound **30** was assigned as *R* on the basis discussed above for analogous spiro ortho ester **22**. The absence of NOE interactions between H2^I and the *pro-S* H6^{II}, which was expected for the *S*-isomer, provides additional support for the anomeric configuration as *R*.

The ten-membered lactone **31** possesses a one-carbon dehomologated skeleton and among its more important structural and functional features are: the presence of carboxyl and acetal functions and the disappearance of one of the anomeric carbons of the starting β -CD. The protons of the sugar residues I and II can be differentiated by 1D TOCSY and all the above appears to confirm the

decanolide structure proposed, while additional support is provided by HMBC 1,3-correlations, being of special significance that observed between the carboxyl carbon at C5^I and the two protons at H6^{II}.

Scheme 5. HAT for the 6^{I,II}-diol-β-CD 29

The δ-lactone **35** has also a one carbon dehomologated skeleton and the more notable features of its structure are the large deshielding observed for the chemical shift of the anomeric hydrogen at H^I [5.56 ppm (d, *J* = 3.2 Hz)] and the 1,3-HMBC correlation of this proton with the carboxylic carbon at C5^I.

According to these results, the formation of all products described in Scheme 5 could be explained in terms of which of the two primary alkoxy radicals (6^I-O-yl or 6^{II}-O-yl) is generated first. In this sense, compound **30** should be formed by the 6^I-O-yl radical 1,8-abstraction in the first place followed by a second 1,6-abstraction of the 6^{II}-O-yl radical to generate the spiro ortho ester. Clearly, the primary alcohol **32** should be an intermediate in the formation of **30**. On the other

hand, the mechanism for the formation of lactones **31** and **33** from diol **29** certainly implies a prior abstraction of hydrogen at H5^I by the 6^{II}-O-yl radical to give the trioxocane **VIII** (Scheme 6). The excess of reagent generates a new 6^I-O-yl radical from the free primary alcohol which by β -scission with loss of formaldehyde produces a C5^I tertiary radical **IX**.³⁴ This intermediate evolves following two competitive paths: (i) it may experience a second β -scission of the C1^I-O^I bond leading to the C1^I-radical **X**, which by one-electron oxidation and nucleophilic attack by the acetate anion finally gives the ten-membered lactone **31** and (ii) it can be directly stabilized by oxidation–nucleophilic attack to give the δ -lactone **33** previous hydrolysis of ortho ester intermediate **XI**. Neither intermediate **VIII** nor **XI** could be detected in the crude reaction mixture.

Scheme 6. Proposed mechanistic pathway for the formation of lactones **31** and **33**

Analogously to the β -CD derivative, the C–H functionalization of the 6^{I,II}-diol- α -CD **36**³⁵ proceeded in a similar way, giving the corresponding ten-membered lactone **37**, the mono-trioxocane **38** and the δ -lactone **39** in 51% overall yield (Scheme 7). All these compounds show NMR features similar to those of the respective compounds **31**, **34** and **35** and their formation can be explained by a mechanism identical with that described for the β -CD model (Scheme 6).

Although, as commented previously, the formation of the 1,2-bis(trioxocane)s in α - and β -CDs may be thermodynamically possible, we have been unable to detect any of them. Therefore, the possibility of a second 1,8-HAT on the logical precursors, the isolated mono-trioxocanes **32** and **38**, was studied by molecular mechanics.²⁸ In the minimized structures of these compounds the distances between the 6^{II}-O-yl radical and the extractable hydrogens at H5^I are excessively long (4.7 and 5.5 Å, respectively) and 1,8-HAT reactions should be clearly unfavorable (see Figure S2 and Table S4 in the SI for more details). Notwithstanding, the alternative 1,6-HAT of the H1^I appears possible in the case of compound **32** ($dO6^{II}-H1^I = 2.7$ Å) that would explain the formation of spiro ortho ester **30** in the β -CD series. This 1,6-HAT reaction is very unlikely in the α -CD series, since in **38** a calculated distance $O6^{II}-H1^I$ of 4.6 Å would prevent the formation of the corresponding spiro ortho ester.

Scheme 7. HAT for the 6^{II}-diol- α -CD **36**

To gain insight into the reaction mechanism and clarify the different behavior of the 6^{I,II}-diols in the C–H functionalization with respect to the other positional isomers, we carried out the process with the corresponding diol in a more simple and conformationally flexible molecule such as the hexamethyl β -maltose derivative **41** obtained in three steps from D-(+)-maltose through the silyl-ether derivatives **40 α** and **40 β** (Scheme 8). In this case, the reaction generated a complex mixture from which we were able to isolate the ten-membered lactone **42** together with compound **43** in only 20% overall yield. Both compounds were found to be unstable toward chromatographic purification. This instability does not prevent complete characterization but is presumably responsible for the small yield obtained.

Scheme 8. HAT for the 6^{I,II}-diol- β -maltose **41**

The structure and stereochemistry of the ten-membered lactone **42**, where all ring protons are directly observable in the ¹H NMR spectrum, can be now more conveniently and unambiguously studied. The NMR data obtained are in quite good agreement with those previously described for the ten-membered lactones **31** and **37**, which had been obtained mostly using 1D TOCSY. The

presence of NOE interactions between H1^I and all the protons positioned on the β -face of the decanolide ring (H2^I, H4^I, H4^{II}, and *pro-S* H6^{II}) seems to indicate a stereoselective α -attack of the nucleophile and an *R* configuration for the C1^I. The relative position of the involved ring protons and the $^3J_{H,H}$ coupling constants has been checked on a minimized structure where the ten-membered lactone adopts a boat-chair-chair (BCC) conformation with an (*R*)-configuration for the C1^I.³⁶

While the decanolide formation could be explained by the mechanism shown above, the new disaccharide **43** could arise from initial 1,6-hydrogen abstraction by the 6^I-*O*-yl radical from the proximal methoxyl group at C4^I followed by oxidation and cyclization to form a 1,3-dioxane ring.³⁷ Then, a second 1,8-abstraction now by the 6^{II}-*O*-yl radical generates a C5^I-radical which finally collapses to the oxacarbenium ion and the incorporation of acetate with inversion of configuration. Also in this case, the coupling constants for the vicinal ring protons account for a preferred ¹C₄ chair conformation for the L-idose unit. The occurrence of this compound sheds some light on the mechanism, the less hindered environment permitting this second 1,8-abstraction which in neither case was observed when the more restricted 6^{I,II}-diols of β - and α -CDs were used, namely compounds **29** (Scheme 5) and **36** (Scheme 7).

Until now, only mono- and di-alcohols have been investigated. We thought that this study would not be complete without trying the reaction with per-6-ol models derived from β - and α -CDs, 2^{I-VII},3^{I-VII}-tetradeca-*O*-methyl- β -cyclomaltoheptaose^{38,5f} and 2^{I-VI},3^{I-VI}-dodeca-*O*-methyl- α -cyclomaltohexaose,^{39,5f} to find out if we can access to polyfunctionalized compounds through multiple radical abstractions. In both substrates, several different conditions were screened in which the reagents stoichiometry, temperature, and time were varied, to no avail, only intractable

mixtures of products being observed in all instances. Such a result is not very surprising if we consider the many possibilities of abstraction and the presumed instability of the products formed.

CONCLUSIONS

In summary, we have successfully applied for the first time the remote C–H functionalization logic to CD systems. The process is initiated by the 6^I-O-yl radical which abstracts with complete regioselectivity the hydrogen atom at C5^{II} located in the adjacent D-glucose by a favored geometrically restricted nine-membered transition state. Using this methodology with monoalcohols derived from α -, β -, and γ -CDs two types of structurally modified CDs can be obtained in moderate to good yields: a) a new stable 1,3,5-trioxocane ring is formed between the two glucopyranose units involved and b) one of the ⁴C₁ glucopyranose residues has been transformed into a ¹C₄ β -L-idose unit by inversion of configuration at C5^{II}. Interestingly, in the case of α -CD derivative **7**, the conformation of the β -L-idose ring is solvent-dependent, and the ¹C₄ conformer is favored in CDCl₃ while the equilibrium is strongly shifted toward the ⁴C₁ chair in C₆D₆ solution. This phenomenon that can be readily detected at 26 °C by 1D TOCSY experiments is not observable in β - and γ -CD analogs **3**, **4**, and **10**.⁴⁰

This methodology was also applied to 6^{I,II}-, 6^{I,III}-, and 6^{I,IV}-diols of α - and β -CDs with the intention of assessing the viability of two hydrogen abstractions in a simultaneous or tandem fashion, a hitherto unknown process.²⁷

The 6^{I,IV}-diol- β -CD derivative **11** behaved as if the two primary alcohols were independent, the expected products with two trioxocane rings **12** and two inverted β -L-idose units **13** being formed in good overall yield (Scheme 2). In the reaction of 6^{I,IV}-diol- α -CD derivative **14** a bis(trioxocane)

15 was also formed. However, in this more restricted hexameric ring, the corresponding products with one or two β -L-idose units were not detected.

Among the products that can be generated by a double 1,8-abstraction in the reaction of 6^{I,III}-diol- β -CD **17**, three (**19**, **20** and **21**) out of four possible have been obtained (Scheme 3). The only one that could not be isolated was the corresponding bis(trioxocane). Instead, the trioxocane–spiro ortho ester **22**, formed also by a double abstraction, this time 1,8- followed by 1,6-HAT, was obtained. Unexpectedly, any attempt to cyclize the plausible intermediates **19–21** by acid catalysis failed to produce the bis(trioxocane). A mixture of chromatographically more polar unstable compounds presumably containing CD ring fragmentation products was obtained in all cases.

In sharp contrast to the situation encountered above with 6^{I,III}-diol- β -CD **17**, the reaction of 6^{I,III}-diol- α -CD **23** led to the bis(trioxocane) **24** as the major product. (Scheme 4). Apart from the acid instability of the intermediates, we have no satisfactory explanation at the moment to account for the fact that the 1,3-bis(trioxocane) is easily formed in the α -CD and not in the β -CD reaction.

In the case of the 6^{I,II}-diol- of β - and α -CD, **29** and **36** respectively, the proximity of the two alkoxyl radicals in adjacent sugar units, facilitates the possibility of interaction between them. This situation which has not been presented in the previous diols is responsible for the formation of the ten-membered lactones (**31** and **37**) and the δ -lactones (**35** and **39**). These compounds are obtained by the proposed mechanism (vide supra) where the two alkoxyl radicals are involved in the formation of the lactonic rings (Schemes 5, 6, and 7).

To the best of our knowledge, this is the first time that a radical protocol is applied to create structural differentiation on the primary face of CDs. Moreover, the mild reaction conditions and the good efficiency are remarkable features that make this process a powerful tool to access

modified CDs and obtain macrocyclic rings with a different range of functionalization, otherwise difficult to achieve, and with potential synthetic and pharmaceutical applications.

EXPERIMENTAL SECTION

General Experimental Methods. Melting points were measured on a hot-stage apparatus. Optical rotations were recorded on a polarimeter at a wavelength of 589 nm at room temperature in CHCl₃ solutions. IR spectra were recorded on a FT-IR spectrophotometer in film. ¹H NMR spectra were determined at 500 MHz in CDCl₃ or C₆D₆. Chemical shifts are reported in parts per million (ppm) and are calibrated to residual solvent peaks (CHCl₃ 7.26 ppm and C₆H₆ 7.15 ppm). ¹³C NMR spectra were determined at 125.7 MHz in CDCl₃ or C₆D₆. Chemical shifts are reported in parts per million (ppm) and are calibrated to residual solvent peaks (CHCl₃ 77.0 ppm and C₆H₆ 128.0 ppm). NMR peaks assignments and stereochemistries have been established using COSY, TOCSY, DEPT, HMBC, HSQC, and ROESY experiments. Low and high resolution mass spectra were recorded with a TOF analyzer spectrometer by using electrospray (ESI⁺). Flash column chromatography was performed on Merck silica gel 60 PF (0.063–0.2 mm). Sensitive compounds were purified by medium-pressure column chromatography using TLC silica gel 60 F₂₅₄, scraped from Merck Millipore aluminum sheets (Product No. 1055540001), as adsorbent. Reaction progress was monitored by thin-layer chromatography (TLC) carried out on 0.25 mm coated commercial silica gel plates impregnated with a fluorescent indicator (254 nm). The spray reagents for TLC analysis were conducted with 0.5% vanillin in H₂SO₄–EtOH (4:1) and further heating until development of color. Commercially available reagents and solvents were analytical grade or were purified by standard procedures prior to use.

Oxidative HAT of 2^{I-VII},3^{I-VII},6^{II-VII}-icosa-O-methyl-β-cyclomaltoheptaose (1) with DIB and iodine. Method A: A solution of alcohol **1**^{17b} (50 mg, 0.035 mmol) in dry CH₂Cl₂ (2.4 mL)

containing DIB (33.4 mg, 0.105 mmol) and I₂ (15.5 mg, 0.06 mmol) was stirred under nitrogen at 30 °C for 0.75 h while irradiated with two 80 W tungsten-filament lamps. An excess of solid Na₂S₂O₃ was then added and stirring continued until complete disappearance of the iodine color. The reaction mixture was then filtered and concentrated under reduced pressure. Silica gel [Merck 60 PF (0.063–0.2 mm)] column chromatography of the reaction residue (hexanes–acetone, 65:35) afforded cyclo-5^{VII},6^I-anhydro-(5^{VII}*R*)-(2,3,6-tri-*O*-methyl- α -D-*xyl*o-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl- α -D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl]₅ (**2**) (30 mg, 0.021 mmol, 60%): colorless oil, [α]_D +138.5 (*c* 1.78, CHCl₃); IR (film): 2929, 1143, 1107, 1042 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.365 (s, 3H), 3.371 (s, 9H), 3.376 (s, 3H), 3.384 (s, 3H), 3.461 (s, 3H), 3.465 (s, 3H), 3.48 (s, 3H), 3.49 (s, 3H), 3.50 (s, 6H), 3.51 (s, 3H), 3.58 (s, 3H), 3.60 (s, 3H), 3.62 (s, 6H), 3.63 (s, 3H), 3.64 (s, 3H), 3.69 (s, 3H), 5.06 (d, *J* = 3.5 Hz, 1H), 5.06 (d, *J* = 3.5 Hz, 1H), 5.07 (d, *J* = 3.8 Hz, 1H), 5.08 (d, *J* = 3.2 Hz, 1H), 5.14 (d, *J* = 3.5 Hz, 1H), 5.20 (d, *J* = 4.4 Hz, 1H), 5.21 (d, *J* = 3.8 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.78 (CH₃), 57.95 (CH₃), 58.04 (CH₃), 58.36 (CH₃), 58.51 (CH₃), 58.58 (CH₃), 58.86 (3 × CH₃), 59.01 (CH₃), 59.03 (3 × CH₃), 60.91 (CH₃), 61.04 (CH₃), 61.26 (CH₃), 61.37 (CH₃), 61.65 (2 × CH₃), 62.17 (CH₃), 64.81 (CH₂), 66.88 (CH), 70.74 (CH), 70.78 (CH), 70.90 (CH), 70.92 (CH₂), 70.96 (CH), 70.98 (CH), 70.98 (CH₂), 71.23 (CH₂), 71.47 (CH₂), 71.76 (CH₂), 71.94 (CH₂), 77.62 (CH), 79.18 (CH), 79.20 (CH), 79.21 (CH), 80.07 (CH), 80.16 (CH), 80.20 (CH), 80.78 (CH), 81.18 (CH), 81.20 (CH), 81.46 (CH), 81.51 (CH), 81.57 (CH), 81.70 (CH), 81.81 (2 × CH), 82.06 (2 × CH), 82.21 (CH), 82.30 (CH), 82.96 (CH), 96.97 (CH), 97.98 (CH), 98.24 (CH), 99.02 (CH), 99.06 (CH), 99.15 (CH), 99.39 (CH), 101.04 (C); MS (ESI⁺-TOF): *m/z* (%) 1435 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₆₂H₁₀₈NaO₃₅ 1435.6569; found 1435.6605. Anal. calcd for C₆₂H₁₀₈O₃₅: C, 52.68; H, 7.70. Found: C, 52.31; H, 7.57.

Method B: A solution of alcohol **1** (100 mg, 0.071 mmol) in dry CH₂Cl₂ (2.9 mL) containing DIB (50.3 mg, 0.156 mmol) and I₂ (18 mg, 0.071 mmol) was stirred under nitrogen at 30 °C for 0.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then poured into 10% aqueous Na₂S₂O₃, extracted with CH₂Cl₂, dried over Na₂SO₄, and concentrated. The residue was purified by silica gel [Merck 60 PF (0.063–0.2 mm)] column chromatography (hexanes–acetone, 65:35) to give **2** (36.3 mg, 0.026 mmol, 36%) and cyclo-(5*R*)-5^{VII}-*O*-acetyl-2,3,6-tri-*O*-methyl- α -D-xylo-hexos-5-ulopyranosyl-(1 $\rightarrow$ 4)-2,3-di-*O*-methyl- α -D-glucopyranosyl-[(1 $\rightarrow$ 4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl]₅ (**3**) (62.9 mg, 0.043 mmol, 61%). Compound **3**: colorless oil, $[\alpha]_D = +134.5$ (*c* 1.32, CHCl₃); IR (film): 3524, 2929, 1734, 1109, 1041 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.06 (s, 3H), 3.14 (dd, *J* = 10.1, 3.5 Hz, 1H), 3.15 (dd, *J* = 10.1, 3.8 Hz, 1H), 3.18 (dd, *J* = 9.5, 3.2 Hz, 1H), 3.19 (dd, *J* = 10.1, 3.5 Hz, 1H), 3.20 (dd, *J* = 10.1, 3.5 Hz, 1H), 3.22 (dd, *J* = 10.1, 3.5 Hz, 1H), 3.31 (dd, *J* = 9.8, 9.8 Hz, 1H), 3.367 (s, 6H), 3.373 (s, 3H), 3.38 (s, 3H), 3.39 (s, 3H), 3.40 (s, 3H), 3.42 (s, 3H), 3.45 (s, 3H), 3.475 (s, 3H), 3.478 (s, 3H), 3.49 (s, 3H), 3.51 (s, 3H), 3.53 (s, 3H), 3.58 (s, 3H), 3.61 (s, 3H), 3.62 (s, 6H), 3.637 (s, 6H), 3.644 (s, 3H), 3.96 (d, *J* = 10.1 Hz, 1H, H6a^{VII}), 3.99 (d, *J* = 9.8 Hz, 1H, H6b^{VII}), 4.04 (br d, *J* = 1.9 Hz, 1H, H4^{VII}), 4.20 (dd, *J* = 2.5, 2.5 Hz, 1H, H3^{VII}), 4.31 (br d, *J* = 11.7 Hz, 1H), 5.01 (d, *J* = 3.2 Hz, 1H), 5.04 (d, *J* = 3.2 Hz, 1H), 5.060 (d, *J* = 2.8 Hz, 1H), 5.061 (d, *J* = 4.1 Hz, 1H), 5.12 (d, *J* = 3.8 Hz, 1H), 5.14 (d, *J* = 1.9 Hz, 1H, H1^{VII}), 5.18 (d, *J* = 3.5 Hz, 1H); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H3^{VII}, 4.20 ppm): δ 3.41 (br s, 1H, H2^{VII}), 4.04 (br d, *J* = 1.9 Hz, 1H, H4^{VII}), 5.14 (d, *J* = 1.9 Hz, 1H, H1^{VII}); ¹H NMR (500 MHz, C₆D₆): δ 1.72 (s, 3H), 3.10 (dd, *J* = 9.1, 3.2 Hz, 1H), 3.13 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.19 (s, 3H), 3.20 (s, 3H), 3.26 (s, 3H), 3.27 (s, 3H), 3.28 (s, 3H), 3.30 (s, 6H), 3.31 (s, 3H), 3.32 (s, 3H), 3.39 (s, 3H), 3.40 (s, 6H), 3.41 (s, 3H), 3.46 (s, 3H), 3.60 (s, 3H), 3.68 (s, 3H), 3.74 (s, 3H), 3.75 (s, 3H), 3.76 (s, 3H), 3.80 (s, 3H), 5.07 (d, *J* =

3.2 Hz, 1H), 5.10 (d, $J = 2.8$ Hz, 1H), 5.20 (d, $J = 3.2$ Hz, 1H), 5.27 (d, $J = 3.8$ Hz, 1H), 5.32 (d, $J = 3.5$ Hz, 1H), 5.45 (d, $J = 3.8$ Hz, 1H), 5.52 (d, $J = 1.6$ Hz, 1H, H1^{II}); ¹³C NMR (125.7 MHz, CDCl₃): δ 22.08 (CH₃), 57.27 (CH₃), 57.45 (CH₃), 58.04 (CH₃), 58.37 (CH₃), 58.65 (CH₃), 58.68 (CH₃), 58.72 (CH₃), 58.86 (2 $\times$ CH₃), 58.93 (CH₃), 58.96 (3 $\times$ CH₃), 59.17 (CH₃), 60.16 (CH₂), 61.18 (CH₃), 61.25 (CH₃), 61.34 (CH₃), 61.45 (CH₃), 61.52 (CH₃), 61.67 (CH₃), 70.33 (CH₂, C6^{VII}), 70.60 (CH), 70.80 (CH₂), 70.91 (CH), 70.91 (CH₂), 71.01 (CH, C4^{VII}), 71.13 (2 $\times$ CH), 71.13 (2 $\times$ CH₂), 71.31 (CH₂), 71.35 (CH), 71.47 (CH), 75.22 (CH, C3^{VII}), 76.64 (CH, C2^{VII}), 79.43 (CH), 79.93 (CH), 80.61 (CH), 81.20 (CH), 81.31 (CH), 81.47 (CH), 81.59 (CH), 81.74 (2 $\times$ CH), 81.75 (CH), 81.97 (CH), 82.00 (CH), 82.08 (CH), 82.22 (CH), 82.26 (CH), 82.28 (CH), 82.30 (CH), 83.15 (CH), 97.59 (CH, C1^{VII}), 99.25 (3 $\times$ CH), 99.52 (CH), 99.87 (CH), 100.34 (CH), 105.03 (C, C5^{VII}), 170.19 (C); MS (ESI⁺-TOF): m/z (%) 1495 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): m/z [M + Na]⁺ calcd for C₆₄H₁₁₂NaO₃₇ 1495.6780; found 1495.6727. Anal. calcd for C₆₄H₁₁₂O₃₇: C, 52.17; H, 7.66. Found: C, 52.29; H, 7.58.

Oxidative HAT of 2^{I-VII},3^{I-VII},6^{II-VII}-icosa-O-methyl- β -cyclomaltoheptaose (1) with bis(4-tert-butylbenzoyloxy)iodobenzene and iodine. A solution of alcohol **1** (30 mg, 0.021 mmol) in dry CH₂Cl₂ (0.85 mL) containing bis(4-tert-butylbenzoyloxy)iodobenzene (25.8 mg, 0.046 mmol) and I₂ (5.3 mg, 0.021 mmol) was stirred under nitrogen at 25 °C for 1.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 70:30→65:35) to give **2** (13.7 mg, 0.01 mmol, 46%).

Oxidative HAT of 2^{I-VII},3^{I-VII},6^{II-VII}-icosa-O-methyl- β -cyclomaltoheptaose (1) with bis(2,4,6-trimethylbenzoyloxy)iodobenzene and iodine. A solution of alcohol **1** (90 mg, 0.064 mmol) in dry CH₂Cl₂ (2.6 mL) containing bis(2,4,6-trimethylbenzoyloxy)iodobenzene (101 mg, 0.191 mmol)

and I₂ (16.2 mg, 0.064 mmol) was stirred under nitrogen at 28 °C for 2 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 70:30) to give **2** (19.3 mg, 0.014 mmol, 21%) and cyclo-(5*R*)-5^{VII}-*O*-(2,4,6-trimethylbenzoyl)-2,3,6-tri-*O*-methyl- α -D-xylo-hexos-5-ulopyranosyl-(1 $\rightarrow$ 4)-2,3-di-*O*-methyl- α -D-glucopyranosyl-[(1 $\rightarrow$ 4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl]₅ (**4**) (33.1 mg, 0.021 mmol, 33%). Compound **4**: amorphous solid, $[\alpha]_D +132.5$ (*c* 1.10, CHCl₃); IR (film): 2928, 1727, 1455, 1368, 1192, 1107, 1043 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.26 (s, 3H), 2.36 (s, 6H), 3.14 (dd, *J* = 6.9, 3.2 Hz, 1H), 3.17 (m, 5H), 3.21 (dd, *J* = 5.7, 3.8 Hz, 1H), 3.32 (s, 3H), 3.37 (s, 3H), 3.38 (s, 3H), 3.39 (s, 3H), 3.40 (s, 3H), 3.40 (s, 3H), 3.41 (s, 3H), 3.44 (s, 3H), 3.48 (s, 3H), 3.48 (s, 3H), 3.49 (s, 3H), 3.51 (s, 6H), 3.58 (s, 3H), 3.62 (s, 6H), 3.64 (s, 3H), 3.65 (s, 3H), 3.66 (s, 3H), 4.36 (br d, *J* = 12.0 Hz), 5.04 (d, *J* = 2.8 Hz, 1H), 5.07 (m, 3H), 5.13 (d, *J* = 3.8 Hz, 1H), 5.18 (d, *J* = 3.8 Hz, 1H), 5.36 (d, *J* = 1.9 Hz, 1H), 6.81 (s, 2H); ¹H NMR (500 MHz, C₆D₆): δ 2.03 (s, 3H), 2.57 (s, 6H), 3.12 (s, 3H), 3.14 (s, 3H), 3.20 (s, 3H), 3.28 (s, 3H), 3.29 (s, 3H), 3.29 (s, 3H), 3.30 (s, 3H), 3.31 (s, 3H), 3.32 (s, 3H), 3.40 (s, 3H), 3.41 (s, 3H), 3.42 (s, 3H), 3.42 (s, 3H), 3.44 (s, 3H), 3.60 (s, 3H), 3.68 (s, 3H), 3.73 (s, 3H), 3.75 (s, 3H), 3.77 (s, 3H), 3.79 (s, 3H), 4.67 (d, *J* = 9.5 Hz, 1H), 5.09 (d, *J* = 3.2 Hz, 1H), 5.17 (d, *J* = 2.8 Hz, 1H), 5.21 (d, *J* = 3.5 Hz, 1H), 5.26 (d, *J* = 3.8 Hz, 1H), 5.33 (d, *J* = 3.5 Hz, 1H), 5.47 (d, *J* = 3.8 Hz, 1H), 5.74 (d, *J* = 1.9 Hz, 1H), 6.67 (s, 2H); ¹³C NMR (125.7 MHz, CDCl₃): δ 19.53 (2 $\times$ CH₃), 21.08 (CH₃), 57.12 (CH₃), 57.27 (CH₃), 58.07 (CH₃), 58.37 (CH₃), 58.44 (CH₃), 58.68 (CH₃), 58.70 (CH₃), 58.74 (CH₃), 58.88 (2 $\times$ CH₃), 58.95 (CH₃), 58.98 (CH₃), 58.99 (CH₃), 59.19 (CH₃), 60.51 (CH₂), 61.00 (CH₃), 61.28 (CH₃), 61.36 (CH₃), 61.50 (CH₃), 61.56 (CH₃), 61.72 (CH₃), 69.93 (CH₂), 70.62 (CH), 70.87 (CH₂), 70.91 (CH₂), 70.91 (CH), 71.04 (CH), 71.11 (CH), 71.16 (CH₂), 71.20 (CH₂), 71.40 (CH), 71.40 (CH₂), 71.51

(CH), 71.83 (CH), 75.16 (CH), 76.44 (CH), 78.98 (CH), 80.10 (CH), 80.63 (CH), 81.31 (CH), 81.39 (CH), 81.52 (CH), 81.63 (CH), 81.78 (2 × CH), 81.84 (CH), 81.94 (CH), 81.954 (CH), 82.13 (CH), 82.26 (CH), 82.31 (CH), 82.36 (2 × CH), 83.19 (CH), 97.40 (CH), 99.13 (CH), 99.26 (CH), 99.40 (CH), 99.57 (CH), 99.88 (CH), 100.26 (CH), 106.38 (C), 128.37 (2 × CH), 131.24 (C), 135.26 (2 × C), 139.10 (C), 169.51 (C); MS (ESI⁺-TOF): *m/z* (%) 1599 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₇₂H₁₂₀NaO₃₇ 1599.7406; found: 1599.7413. Anal. calcd for C₇₂H₁₂₀O₃₇: C, 54.81; H, 7.67. Found: C, 54.60; H, 7.66.

Oxidative HAT of 2^{I-VI},3^{I-VI},6^{II-VI}-heptadeca-O-methyl-α-cyclomaltohexaose (5). Method A: A solution of alcohol **5**²⁵ (30 mg, 0.025 mmol) in dry CH₂Cl₂ (1 mL) containing DIB (17.6 mg, 0.055 mmol) and I₂ (6.3 mg, 0.025 mmol) was stirred under nitrogen at 21 °C for 1 h while irradiated with two 80 W tungsten-filament lamps. An excess of solid Na₂S₂O₃ was then added and stirring continued until complete disappearance of the iodine color. The reaction mixture was then filtered and concentrated under reduced pressure. Silica gel [Merck 60 PF (0.063–0.2 mm)] column chromatography of the reaction residue (hexanes–acetone, 65:35) afforded cyclo-5^{VI},6^I-anhydro-(5^{VI}R)-(2,3,6-tri-*O*-methyl-α-D-xylo-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl-α-D-glucopyranosyl]₄ (**6**) (17.7 mg, 0.015 mmol, 59%) as a colorless oil: [α]_D +127.6 (*c* 1.24, CHCl₃); IR (film): 3052, 2929, 2832 1454, 1365, 1196, 1107 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.12 (dd, *J* = 10.1, 3.2 Hz, 1H), 3.14 (dd, *J* = 9.9, 3.3 Hz, 1H), 3.15 (dd, *J* = 9.3, 3.6 Hz, 1H), 3.18 (dd, *J* = 9.8, 3.8 Hz, 1H), 3.19 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.25 (dd, *J* = 9.8, 3.2 Hz, 1H), 3.357 (s, 3H), 3.360 (s, 3H), 3.37 (s, 3H), 3.378 (s, 3H), 3.379 (s, 3H), 3.469 (s, 3H), 3.470 (s, 3H), 3.483 (s, 3H), 3.488 (s, 3H), 3.493 (s, 3H), 3.51 (s, 3H), 3.58 (s, 3H), 3.60 (s, 3H), 3.627 (s, 3H), 3.632 (s, 3H), 3.70 (s, 3H), 3.73 (s, 3H), 4.98 (d, *J* = 3.8 Hz, 1H), 5.00 (d, *J* = 3.5 Hz, 1H), 5.03 (d, *J* = 3.8 Hz, 1H), 5.04 (d, *J* = 3.5 Hz, 1H), 5.06 (d, *J* = 3.2 Hz,

1H), 5.19 (d, $J = 3.5$ Hz, 1H); ^{13}C NMR (125.7 MHz, CDCl_3): δ 57.65 (CH_3), 57.80 ($2 \times \text{CH}_3$), 57.96 (CH_3), 58.31 (CH_3), 58.34 (CH_3), 58.67 (CH_3), 58.72 (CH_3), 58.96 (CH_3), 59.00 (CH_3), 59.07 (CH_3), 61.26 (CH_3), 61.45 (CH_3), 61.51 (CH_3), 61.89 (CH_3), 61.98 (CH_3), 62.22 (CH_3), 63.83 (CH_2), 66.20 (CH), 70.87 (CH), 70.92 ($2 \times \text{CH}$), 71.03 (CH_2), 71.22 (CH_2), 71.55 (CH_2), 71.55 (CH), 71.88 (CH_2), 71.97 (CH_2), 78.28 (CH), 80.19 (CH), 80.59 (CH), 80.72 (CH), 80.84 (CH), 81.04 (CH), 81.06 (CH), 81.25 (CH), 81.41 (CH), 81.51 (CH), 81.72 (CH), 82.00 (CH), 82.07 (CH), 82.10 (CH), 82.29 (CH), 82.31 (CH), 82.59 (CH), 82.67 (CH), 97.35 (CH), 97.59 (CH), 98.85 (CH), 99.55 (CH), 99.94 (CH), 100.08 (CH), 100.79 (C); ^1H NMR (500 MHz, C_6D_6): δ 3.15 (dd, $J = 9.8, 3.5$ Hz, 1H), 3.16 (dd, $J = 9.1, 4.4$ Hz, 1H), 3.19 (dd, $J = 9.8, 3.8$ Hz, 1H), 3.20 (dd, $J = 9.9, 3.3$ Hz, 1H), 3.24 (dd, $J = 9.8, 3.2$ Hz, 1H), 3.25 (s, 3H), 3.268 (s, 3H), 3.273 (s, 3H), 3.28 (s, 3H), 3.30 (s, 3H), 3.31 (s, 3H), 3.317 (s, 3H), 3.320 (s, 3H), 3.34 (s, 3H), 3.46 (s, 3H), 3.50 (s, 3H), 3.55 (dd, $J = 8.8, 7.9$ Hz, 1H), 3.67 (s, 3H), 3.68 (s, 3H), 3.70 (s, 3H), 3.80 (s, 3H), 3.82 (s, 3H), 3.83 (s, 3H), 4.16 (dd, $J = 9.5, 9.5$ Hz, 1H), 4.27 (d, $J = 9.1$ Hz, 1H), 4.37 (d, $J = 10.1$ Hz, 1H), 4.55 (ddd, $J = 10.1, 5.0, 1.3$ Hz, 1H), 5.02 (d, $J = 3.8$ Hz, 1H), 5.17 (d, $J = 3.3$ Hz, 1H), 5.18 (d, $J = 3.5$ Hz, 1H), 5.19 (d, $J = 3.2$ Hz, 1H), 5.22 (d, $J = 3.5$ Hz, 1H), 5.24 (d, $J = 3.5$ Hz, 1H); ^{13}C NMR (125.7 MHz, C_6D_6): δ 57.22 (CH_3), 57.70 (CH_3), 57.84 (CH_3), 57.93 (CH_3), 58.15 (CH_3), 58.17 (CH_3), 58.61 (CH_3), 58.72 (CH_3), 58.91 (CH_3), 59.00 (CH_3), 59.03 (CH_3), 61.31 (CH_3), 61.53 (CH_3), 61.58 (CH_3), 61.79 (CH_3), 62.08 (CH_3), 62.15 (CH_3), 64.19 (CH_2), 66.85 (CH), 71.42 (CH), 71.64 (CH), 71.67 (CH_2), 71.83 (CH), 72.52 (CH), 72.87 (CH_2), 72.92 ($2 \times \text{CH}_2$), 73.10 (CH_2), 79.14 (CH), 81.49 (CH), 81.60 ($2 \times \text{CH}$), 81.69 (CH), 81.76 (CH), 81.89 (CH), 82.03 (CH), 82.09 (CH), 82.35 (CH), 82.67 (CH), 82.92 (CH), 82.94 ($2 \times \text{CH}$), 82.97 (CH), 83.34 (CH), 83.37 (CH), 83.48 (CH), 98.07 (CH), 98.58 (CH), 99.11 (CH), 99.17 (CH), 99.95 (CH), 100.42 (CH), 101.31 (C); MS (ESI^+ -TOF): m/z (%) 1231 [$(\text{M} + \text{Na})^+$, 100]; HRMS (ESI^+ -TOF): m/z [$\text{M} + \text{Na}]^+$ calcd

for $C_{53}H_{92}NaO_{30}$ 1231.5571; found 1231.5543. Anal. calcd for $C_{53}H_{92}O_{30}$: C, 52.64; H, 7.67. Found: C, 52.46; H, 7.76.

Method B: A solution of alcohol **5** (45 mg, 0.037 mmol) in dry CH_2Cl_2 (1.5 mL) containing DIB (26.2 mg, 0.081 mmol) and I_2 (4.7 mg, 0.019 mmol) was stirred under nitrogen at 22 °C for 1.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 65:35) to give **6** (14 mg, 0.012 mmol, 31%) and cyclo-(5*R*)-5^{VI}-*O*-acetyl-2,3,6-tri-*O*-methyl- α -D-*xyl*o-hexos-5-ulopyranosyl-(1→4)-2,3-di-*O*-methyl- α -D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl]₄ (**7**) (13.9 mg, 0.011 mmol, 30%).

Compound **7**: colorless oil, $[\alpha]_D +127.8$ (*c* 0.90, $CHCl_3$); IR (film): 3509, 2933, 1758, 1107, 1041 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$): δ 2.05 (s, 3H), 3.15 (dd, *J* = 10.1, 3.2 Hz, 1H), 3.15 (dd, *J* = 10.1, 3.2 Hz, 1H), 3.16 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.17 (dd, *J* = 10.1, 3.5 Hz, 1H), 3.21 (dd, *J* = 9.5, 3.2 Hz, 1H), 3.36 (s, 3H), 3.368 (s, 3H), 3.373 (s, 6H), 3.38 (s, 3H), 3.43 (s, 3H), 3.456 (s, 3H), 3.464 (s, 3H), 3.48 (s, 3H), 3.50 (s, 3H), 3.52 (s, 3H), 3.607 (s, 3H), 3.609 (s, 3H), 3.613 (s, 3H), 3.62 (s, 3H), 3.64 (s, 3H), 3.68 (s, 3H), 3.91 (d, *J* = 10.4 Hz, 1H), 3.98 (dd, *J* = 3.0, 3.0 Hz, 1H), 4.02 (d, *J* = 10.4 Hz, 1H), 4.21 (d, *J* = 3.2 Hz, 1H), 4.23 (m, 1H), 4.97 (d, *J* = 3.5 Hz, 1H), 5.02 (d, *J* = 3.5 Hz, 1H), 5.03 (d, *J* = 3.8 Hz, 1H), 5.05 (d, *J* = 3.2 Hz, 1H), 5.06 (d, *J* = 3.5 Hz, 1H), 5.23 (d, *J* = 2.8 Hz, 1H); 1H NMR (500 MHz, $CDCl_3$, 1D-TOCSY, irradiation at H1^{VI}, 5.23 ppm): δ 3.43 (br s, 1H, H2^{VI}), 3.99 (dd, *J* = 3.2, 3.2 Hz, 1H, H3^{VI}), 4.21 (d, *J* = 2.8 Hz, 1H, H4^{VI}); 1H NMR (500 MHz, C_6D_6): δ 1.89 (s, 3H), 3.12 (dd, *J* = 9.6, 3.3 Hz, 1H), 3.15 (dd, *J* = 9.8, 3.2 Hz, 1H), 3.24 (s, 3H), 3.25 (s, 3H), 3.28 (s, 6H), 3.30 (s, 3H), 3.32 (s, 3H), 3.33 (s, 3H), 3.36 (s, 3H), 3.39 (s, 3H), 3.42 (s, 3H), 3.50 (s, 3H), 3.61 (s, 3H), 3.70 (s, 3H), 3.73 (s, 3H), 3.76 (s, 3H), 3.84 (s, 3H), 3.87 (s, 3H), 4.74 (d, *J* = 7.9 Hz, 1H), 5.04 (d, *J* = 3.2 Hz, 1H), 5.12 (d, *J* = 3.2 Hz, 1H), 5.19

(d, $J = 3.5$ Hz, 1H), 5.20 (d, $J = 3.8$ Hz, 1H), 5.22 (d, $J = 3.5$ Hz, 1H), 5.27 (d, $J = 3.5$ Hz, 1H); ^1H NMR (500 MHz, C_6D_6 , 1D-TOCSY, irradiation at H1^{VI} , 5.27 ppm): δ 3.49 (dd, $J = 8.5, 2.8$ Hz, 1H, H2^{VI}), 3.73 (dd, $J = 7.9, 7.9$ Hz, 1H, H3^{VI}), 4.74 (d, $J = 7.9$ Hz, 1H, H4^{VI}); ^{13}C NMR (125.7 MHz, CDCl_3): δ 21.88 (CH_3), 57.27 (CH_3), 57.74 (CH_3), 57.80 (CH_3), 58.11 (CH_3), 58.33 (CH_3), 58.36 (CH_3), 58.71 (CH_3), 58.82 (CH_3), 58.86 (CH_3), 58.93 (CH_3), 59.04 (CH_3), 59.08 (CH_3), 61.21 (CH_2), 61.48 (CH_3), 61.62 (CH_3), 61.66 (CH_3), 61.77 (CH_3), 61.92 (CH_3), 70.84 (CH), 70.92 (CH_2), 71.14 (CH_2), 71.16 (CH), 71.35 ($2 \times \text{CH}_2$), 71.68 (CH), 71.79 (CH), 71.83 (CH_2), 72.17 (CH), 74.04 (CH), 76.44 (CH), 77.31 (CH), 80.57 (CH), 81.10 (CH), 81.21 (CH), 81.41 (CH), 81.49 (CH), 81.54 (CH), 81.57 (CH), 81.92 (CH), 82.19 (CH), 82.25 (CH), 82.33 ($2 \times \text{CH}$), 82.40 (CH), 82.57 (CH), 82.65 (CH), 97.26 (CH), 98.28 (CH), 99.78 (CH), 99.89 (CH), 100.41 (CH), 101.39 (CH), 103.99 (C), 169.76 (C); ^{13}C NMR (125.7 MHz, C_6D_6): δ 22.36 (CH_3), 57.35 (CH_3), 57.54 (CH_3), 57.81 (CH_3), 57.83 (CH_3), 58.22 ($2 \times \text{CH}_3$), 58.80 (CH_3), 58.82 (CH_3), 58.93 (CH_3), 59.01 (CH_3), 59.87 (CH_3), 60.41 (CH_3), 61.60 (CH_3), 61.71 (CH_3), 61.75 (CH_3), 61.79 (CH_3), 61.80 (CH_3), 62.77 (CH_2), 71.94 (CH), 72.01 (CH), 72.01 (CH_2), 72.17 ($2 \times \text{CH}_2$), 72.31 (CH), 72.60 (CH_2), 72.60 (CH), 73.22 (CH_2), 73.39 (CH), 79.60 (CH), 80.56 (CH), 80.96 (CH), 81.10 (CH), 81.94 (CH), 81.98 (CH), 82.28 (CH), 82.39 (CH), 82.41 (CH), 82.57 ($2 \times \text{CH}$), 82.60 (CH), 82.73 (CH), 82.94 (CH), 83.09 (CH), 83.16 (CH), 83.26 ($2 \times \text{CH}$), 98.68 (CH), 99.22 (CH), 99.58 (CH), 99.99 (CH), 100.28 (CH), 100.62 (CH), 104.57 (C), 169.11 (C); MS (ESI^+ -TOF): m/z (%) 1291 $[(\text{M} + \text{Na})^+, 100]$; HRMS (ESI^+ -TOF): m/z $[(\text{M} + \text{Na})^+]$ calcd for $\text{C}_{55}\text{H}_{96}\text{NaO}_{32}$ 1291.5782; found 1291.5819. Anal. calcd for $\text{C}_{55}\text{H}_{96}\text{O}_{32}$: C, 52.04; H, 7.62. Found: C, 52.25; H, 7.49.

Oxidative HAT of 2^{I-VIII}, 3^{I-VIII}, 6^{II-VIII}-tricosal-O-methyl- γ -cyclomaltooctaose (8). Method A: A solution of alcohol **8**²⁶ (31 mg, 0.019 mmol) in dry CH_2Cl_2 (0.78 mL) containing DIB (113.5 mg, 0.042 mmol) and I_2 (4.8 mg, 0.019 mmol) was stirred under nitrogen at 25 °C for 1 h while

irradiated with two 80 W tungsten-filament lamps. An excess of solid Na₂S₂O₃ was then added and stirring continued until complete disappearance of the iodine color. The reaction mixture was then filtered and concentrated under reduced pressure. Silica gel [Merck 60 PF (0.063–0.2 mm)] column chromatography of the reaction residue (hexanes–acetone, 60:40) afforded cyclo-5^{VIII},6^I-anhydro-(5^{VIII}*R*)-(2,3,6-tri-*O*-methyl- α -D-*xyl*o-hexos-5-ulopyranosyl)-(1 $\rightarrow$ 4)-2,3-di-*O*-methyl- α -D-glucopyranosyl-[(1 $\rightarrow$ 4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl]₆ (**9**) (13.6 mg, 0.008 mmol, 44%): colorless oil, [α]_D +130.9 (*c* 1.380, CHCl₃); IR (film): 2929, 1141, 1104, 1039 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.14–3.29 (m, 8H), 3.34 (s, 3H), 3.36 (s, 3H), 3.37 (s, 3H), 3.377 (s, 3H), 3.379 (s, 3H), 3.39 (s, 3H), 3.459 (s, 3H), 3.464 (s, 3H), 3.47 (s, 3H), 3.48 (s, 3H), 3.491 (s, 3H), 3.495 (s, 6H), 3.50 (s, 3H), 3.51 (s, 3H), 3.54 (s, 3H), 3.58 (s, 3H), 3.59 (s, 3H), 3.603 (s, 3H), 3.606 (s, 3H), 3.611 (s, 3H), 3.639 (s, 3H), 3.643 (s, 3H), 5.08 (d, *J* = 3.8 Hz, 1H), 5.18 (d, *J* = 3.2 Hz, 1H), 5.20 (d, *J* = 3.8 Hz, 1H), 5.21 (d, *J* = 3.8 Hz, 1H), 5.22 (d, *J* = 4.1 Hz, 1H), 5.24 (d, *J* = 2.2 Hz, 1H), 5.25 (d, *J* = 2.8 Hz, 1H), 5.58 (d, *J* = 3.5 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.46 (CH₃), 57.74 (CH₃), 58.34 (CH₃), 58.41 (CH₃), 58.48 (CH₃), 58.51 (CH₃), 58.85 (2 $\times$ CH₃), 58.88 (CH₃), 58.93 (2 $\times$ CH₃), 58.96 (CH₃), 58.99 (CH₃), 59.20 (2 $\times$ CH₃), 59.60 (CH₃), 59.99 (CH₃), 60.37 (CH₃), 60.98 (CH₃), 61.02 (2 $\times$ CH₃), 61.20 (CH₃), 61.70 (CH₃), 64.44 (CH₂), 66.25 (CH), 69.00 (CH), 69.90 (CH), 70.18 (CH), 70.22 (CH₂), 70.55 (CH), 70.78 (CH), 70.91 (CH), 71.04 (CH₂), 71.08 (2 $\times$ CH₂), 71.21 (CH), 71.64 (CH₂), 71.94 (CH₂), 72.18 (CH₂), 74.47 (CH), 77.13 (CH), 77.62 (CH), 77.92 (CH), 78.05 (CH), 78.58 (CH), 79.62 (CH), 79.72 (CH), 80.67 (CH), 81.17 (CH), 81.58 (CH), 81.63 (CH), 81.69 (3 $\times$ CH), 81.81 (CH), 82.28 (CH), 82.31 (CH), 82.46 (CH), 82.61 (CH), 82.76 (CH), 83.02 (CH), 83.18 (CH), 92.88 (CH), 95.20 (CH), 96.85 (CH), 97.59 (CH), 97.84 (CH), 98.35 (CH), 98.82 (CH), 99.55 (CH), 100.64 (C); MS (ESI⁺-TOF): *m/z*

(%) 1639 $[(M + Na)^+, 100]$; HRMS (ESI⁺-TOF): m/z $[M + Na]^+$ calcd for C₇₁H₁₂₄NaO₄₀ 1639.7567; found 1639.7531. Anal. calcd for C₇₁H₁₂₄O₄₀: C, 52.71; H, 7.73. Found: C, 52.86; H, 7.55.

Method B: A solution of alcohol **8** (45 mg, 0.028 mmol) in dry CH₂Cl₂ (1.2 mL) containing DIB (20 mg, 0.062 mmol) and I₂ (3.6 mg, 0.014 mmol) was stirred under nitrogen at 24 °C for 2.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 65:35) to give **9** (15.6 mg, 0.01 mmol, 36%) and cyclo-(5*R*)-5^{VIII}-*O*-acetyl-2,3,6-tri-*O*-methyl- α -D-*xyl*o-hexos-5-ulopyranosyl-(1 $\rightarrow$ 4)-2,3-di-*O*-methyl- α -D-glucopyranosyl-[(1 $\rightarrow$ 4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl]₆ (**10**) (19.2 mg, 0.011 mmol, 41%). Compound **10**: colorless oil, $[\alpha]_D +131.6$ (*c* 0.91, CHCl₃); IR (film): 3539, 2925, 1738, 1152, 1100, 1037 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.06 (s, 3H), 3.16 (dd, *J* = 9.5, 3.2 Hz, 1H), 3.19 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.19 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.19 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.21 (dd, *J* = 9.6, 3.6 Hz, 1H), 3.23 (dd, *J* = 9.5, 3.8 Hz, 1H), 3.26 (dd, *J* = 9.8, 3.8 Hz, 1H), 3.330 (s, 3H), 3.334 (s, 3H), 3.34 (s, 3H), 3.36 (s, 3H), 3.369 (s, 3H), 3.374 (s, 3H), 3.40 (s, 3H), 3.42 (s, 3H), 3.44 (br d, *J* = 3.9 Hz, 1H, H2^{VIII}), 3.473 (s, 6H), 3.476 (s, 3H), 3.477 (s, 3H), 3.51 (s, 3H), 3.556 (s, 3H), 3.558 (s, 3H), 3.58 (s, 3H), 3.60 (s, 6H), 3.62 (s, 3H), 3.64 (s, 3H), 3.649 (s, 3H), 3.654 (s, 3H), 3.71 (s, 3H), 3.99 (d, *J* = 9.8 Hz, 1H), 4.025 (d, *J* = 9.8 Hz, 1H), 4.03 (br s, 1H, H4^{VIII}), 4.24 (dd, *J* = 2.2, 2.2 Hz, 1H, H3^{VIII}), 5.01 (d, *J* = 3.5 Hz, 1H), 5.08 (d, *J* = 3.2 Hz, 1H), 5.09 (d, *J* = 3.5 Hz, 1H), 5.12 (d, *J* = 3.8 Hz, 1H), 5.18 (d, *J* = 3.8 Hz, 1H), 5.19 (d, *J* = 3.5 Hz, 1H), 5.23 (d, *J* = 1.6 Hz, 1H, H1^{VIII}), 5.60 (d, *J* = 4.1 Hz, 1H); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^{II}, 5.23 ppm): δ 3.45 (d, *J* = 3.9 Hz, 1H, H2^{VIII}), 4.03 (br s, 1H, H4^{VIII}), 4.25 (dd, *J* = 2.4, 2.4 Hz, 1H, H3^{VIII}); ¹H NMR (500 MHz, C₆D₆): δ 1.77 (s, 3H), 3.10 (dd, *J* = 9.5, 2.8 Hz, 1H), 3.13 (dd, *J* = 9.9, 3.3 Hz, 1H), 3.19 (s, 3H), 3.21 (s, 3H), 3.22 (s, 3H), 3.27 (s, 3H), 3.29 (m, 6H), 3.296

(s, 3H), 3.304 (s, 3H), 3.31 (s, 3H), 3.322 (s, 3H), 3.325 (s, 3H), 3.35 (s, 3H), 3.36 (s, 3H), 3.37 (s, 3H), 3.39 (s, 3H), 3.46 (s, 3H), 3.59 (s, 3H), 3.65 (s, 3H), 3.70 (s, 3H), 3.72 (s, 3H), 3.726 (s, 3H), 3.733 (s, 3H), 3.81 (s, 3H), 4.30 (dd, $J = 2.5, 2.5$ Hz, 1H), 4.32 (br s), 4.40 (d, $J = 9.8$ Hz, 1H), 4.46 (br d, $J = 12.0$ Hz, 1H), 4.51 (d, $J = 9.8$ Hz, 1H), 5.16 (d, $J = 3.2$ Hz, 1H), 5.17 (d, $J = 3.2$ Hz, 1H), 5.29 (d, $J = 3.5$ Hz, 1H), 5.36 (d, $J = 3.8$ Hz, 1H), 5.37 (d, $J = 3.8$ Hz, 1H), 5.57 (d, $J = 3.8$ Hz, 1H), 5.61 (d, $J = 3.8$ Hz, 1H), 5.65 (d, $J = 1.6$ Hz, 1H); ^{13}C NMR (125.7 MHz, CDCl_3): δ 22.11 (CH_3), 57.40 (CH_3), 58.07 (CH_3), 58.18 (CH_3), 58.38 (CH_3), 58.40 (CH_3), 58.46 (CH_3), 58.60 (CH_3), 58.84 (CH_3), 58.88 (CH_3), 58.96 ($4 \times \text{CH}_3$), 59.10 (CH_3), 59.64 ($2 \times \text{CH}_3$), 60.12 (CH_3), 60.22 (CH_2), 61.02 (CH_3), 61.33 (CH_3), 61.39 (CH_3), 61.46 (CH_3), 61.55 (CH_3), 61.70 (CH_3), 70.18 (CH), 70.42 (CH_2), 70.60 (CH), 70.71 (CH_2), 70.78 (CH), 70.88 (CH_2), 70.92 (CH_2), 70.99 (CH_2), 71.12 (CH), 71.12 (CH_2), 71.21 ($2 \times \text{CH}$), 71.58 (CH), 71.68 (CH_2), 72.36 (CH), 72.48 (CH), 75.45 (CH), 76.33 (CH), 78.79 (CH), 78.99 (CH), 79.35 (CH), 80.43 (CH), 80.45 (CH), 81.37 (CH), 81.57 ($3 \times \text{CH}$), 81.74 ($2 \times \text{CH}$), 81.97 (CH), 82.04 (CH), 82.07 (CH), 82.33 ($2 \times \text{CH}$), 82.38 (CH), 82.57 (CH), 82.60 (CH), 82.99 (CH), 96.50 (CH), 97.53 (CH), 97.85 (CH), 98.07 (CH), 98.71 (CH), 99.05 (CH), 100.00 (CH), 101.56 (CH), 105.34 (C), 170.23 (C); MS (ESI^+ -TOF): m/z (%) 1699 [$(\text{M} + \text{Na})^+$, 100]; HRMS (ESI^+ -TOF): m/z [$\text{M} + \text{Na}]^+$ calcd for $\text{C}_{73}\text{H}_{128}\text{NaO}_{42}$ 1699.7778; found 1699.7756. Anal. calcd for $\text{C}_{73}\text{H}_{128}\text{O}_{42}$: C, 52.26; H, 7.69. Found: C, 52.15; H, 7.53.

2^{I-VI},3^{I-VI},6^{II,III,V,VII}-Hexadeca-O-methyl- α -cyclomaltohexaose (14), 2^{I-VI},3^{I-VI},6^{II,IV-VI}-Hexadeca-O-methyl- α -cyclomaltohexaose (23), and 2^{I-VI},3^{I-VI},6^{III-VI}-Hexadeca-O-methyl- α -cyclomaltohexaose (36). A solution of dry α -cyclodextrin (4.69 g, 4.825 mmol) and imidazole (1.148 g, 16.9 mmol) in dry DMF (246 mL) was added TBDMSCl (2.654 g, 9.7 mmol) in one portion at room temperature under nitrogen and the mixture stirred at this temperature for 2 h. After cooling at 0 °C, NaH (60%, 10.615 g, 265 mmol) was added in small portions and the mixture

stirred for 30 min and then at room temperature for 1 h. After recooling to 0 °C, MeI (34.2 mL, 549 mmol) was then added dropwise and the stirring continued at room temperature overnight. The excess of NaH was destroyed with MeOH and the mixture poured into ice-water and extracted with CHCl₃ (5 × 100 mL). The organic phase was dried over Na₂SO₄ and concentrated under reduced pressure. The residue in dry MeOH (290 mL) was treated with NH₄F (6.28 g, 170 mmol) and heated at reflux temperature under nitrogen for 22.5 h. The solvent was evaporated under reduced pressure and the residue redissolved in CHCl₃ (200 mL), filtered over Celite and concentrated to give a crude mixture (12.15 g) that was purified by column chromatography (CHCl₃ → CHCl₃–MeOH, 96:4) to give the known permethylated α-CD (628 mg, 0.513 mmol, 10%), 2^{I-VI},3^{I-VI},6^{II-VI}-heptadeca-*O*-methyl-α-cyclomaltohexaose (**5**)²⁵ (1602 mg, 1.324 mmol, 27%), and a mixture of the three possible diols that was subjected to a second careful flash chromatography on 60 PF silica gel (0.04–0.063) (CHCl₃–MeOH, 98:2→95:5) to give the diols **14**^{25,29} (385 mg, 0.322 mmol, 7%), **23** (731 mg, 0.611 mmol, 13%), and **36**³⁵ (936 mg, 0.783 mmol, 16%). A more polar fraction containing a mixture of triols and other polyols was not studied. Compound **23**: colorless oil, [α]_D +141.2 (*c* 0.97, CHCl₃); IR (film): 3472, 2929, 1454, 1365, 1107, 1039 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.13–3.19 (m, 6H), 3.389 (s, 3H), 3.397 (s, 3H), 3.398 (s, 6H), 3.489 (s, 3H), 3.492 (s, 3H), 3.495 (s, 6H), 3.50 (s, 6H), 3.63 (s, 3H), 3.647 (s, 6H), 3.649 (s, 3H), 3.650 (s, 3H), 3.66 (s, 3H), 5.03 (d, *J* = 3.8 Hz, 1H), 5.035 (d, *J* = 3.8 Hz, 1H), 5.05 (d, *J* = 3.5 Hz, 1H), 5.06 (d, *J* = 3.5 Hz, 1H), 5.07 (d, *J* = 3.5 Hz, 1H), 5.08 (d, *J* = 3.5 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.85 (2 × CH₃), 57.90 (2 × CH₃), 58.03 (CH₃), 58.08 (CH₃), 58.93 (CH₃), 59.01 (CH₃), 59.09 (CH₃), 59.15 (CH₃), 61.63 (2 × CH₃), 61.75 (2 × CH₃), 61.77 (CH₃), 61.79 (CH₃), 62.32 (CH₂), 62.40 (CH₂), 71.19 (CH), 71.28 (2 × CH), 71.43 (CH₂), 71.51 (CH), 71.53 (CH₂), 71.55 (CH₂), 71.69 (CH₂), 72.48 (CH), 72.65 (CH), 81.24 (CH), 81.28 (3 × CH), 81.35 (CH), 81.40 (CH), 81.74 (CH),

81.97 (CH), 82.00 (CH), 82.06 (2 × CH), 82.12 (CH), 82.17 (2 × CH), 82.22 (2 × CH), 82.29 (CH), 82.35 (CH), 99.36 (CH), 99.58 (CH), 99.84 (CH), 99.87 (2 × CH), 99.90 (CH); MS (ESI⁺-TOF): *m/z* (%) 1214 [(M + NH₄)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + NH₄]⁺ calcd for C₅₂H₉₆NO₃₀ 1214.6017; found 1214.6023. Anal. calcd for C₅₂H₉₂O₃₀: C, 52.17; H, 7.75. Found: C, 52.05; H, 7.61. Compound **36**: colorless oil, [α]_D +143.3 (*c* 1.21, CHCl₃); IR (film): 3468, 2933, 1456, 1365, 1109, 1037 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.12–3.19 (m, 6H), 3.386 (s, 6H), 3.390 (s, 6H), 3.477 (s, 3H), 3.485 (s, 6H), 3.492 (s, 3H), 3.497 (s, 3H), 3.501 (s, 3H), 3.632 (s, 3H), 3.637 (s, 3H), 3.640 (s, 3H), 3.642 (s, 3H), 3.644 (s, 3H), 3.65 (s, 3H), 5.01 (d, *J* = 3.5 Hz, 1H), 5.04 (d, *J* = 3.2 Hz, 4H), 5.08 (d, *J* = 3.5 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.85 (CH₃), 57.90 (3 × CH₃), 57.97 (2 × CH₃), 58.94 (2 × CH₃), 59.00 (CH₃), 59.09 (CH₃), 61.67 (CH₃), 61.72 (3 × CH₃), 61.77 (2 × CH₃), 62.20 (CH₂), 62.54 (CH₂), 71.14 (CH), 71.17 (CH), 71.25 (2 × CH), 71.44 (CH₂), 71.51 (2 × CH₂), 71.60 (CH₂), 72.59 (CH), 72.98 (CH), 81.26 (2 × CH), 81.30 (4 × CH), 81.99 (3 × CH), 82.06 (2 × CH), 82.15 (2 × CH), 82.16 (CH), 82.22 (CH), 82.26 (CH), 82.45 (CH), 82.58 (CH), 99.58 (CH), 99.66 (CH), 99.76 (CH), 99.86 (CH), 99.89 (CH), 99.94 (CH); MS (ESI⁺-TOF): *m/z* (%) 1219 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₅₂H₉₂NaO₃₀ 1219.5571; found 1219.5576. Anal. calcd for C₅₂H₉₂O₃₀: C, 52.17; H, 7.75. Found: C, 52.30; H, 7.74.

Oxidative HAT of 2^{I-VII},3^{I-VII},6^{II,III,V-VII}-nonadeca-O-methyl-β-cyclomaltoheptaose (11). A solution of alcohol **11**^{17a} (80 mg, 0.057 mmol) in dry CH₂Cl₂ (2.3 mL) containing DIB (55 mg, 0.171 mmol) and I₂ (24.6 mg, 0.097 mmol) was stirred under nitrogen at 30 °C for 1 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then poured into 10% aqueous Na₂S₂O₃, extracted with CH₂Cl₂, dried over Na₂SO₄, and concentrated. The residue was purified by silica gel [Merck 60 PF (0.063–0.2 mm)] column chromatography (hexanes–acetone,

65:35→50:50) to give cyclo-5^{VII},6^I-anhydro-(5^{VII}*R*)-(2,3,6-tri-*O*-methyl- α -D-*xylo*-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl- α -D-glucopyranosyl-(1→4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl-(1→4)-5^{III},6^{IV}-anhydro-(5^{III}*R*)-(2,3,6-tri-*O*-methyl- α -D-*xylo*-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl- α -D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl]₂ (**12**) (16.2 mg, 0.012 mmol, 20%), an inseparable mixture of mono-trioxocane–mono-acetyl positional isomers (11.9 mg, 0.008 mmol, 3:2, 14%) and cyclo-(5*R*)-5^{VII}-*O*-acetyl-2,3,6-tri-*O*-methyl- α -D-*xylo*-hexos-5-ulopyranosyl-(1→4)-2,3-di-*O*-methyl- α -D-glucopyranosyl-(1→4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl-(1→4)-(5*R*)-5^{III}-*O*-acetyl-2,3,6-tri-*O*-methyl- α -D-*xylo*-hexos-5-ulopyranosyl-(1→4)-2,3-di-*O*-methyl- α -D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl]₂ (**13**) (42.3 mg, 0.028 mmol, 49%). Compound **12**: colorless oil, $[\alpha]_D^{+110.9}$ (*c* 0.79, CHCl₃); IR (film): 2933, 1454, 1365, 1139, 1065, 1044 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.11 (dd, *J* = 9.8, 3.2 Hz, 1H), 3.13 (dd, *J* = 9.5, 3.2 Hz, 1H), 3.179 (dd, *J* = 9.5, 3.5 Hz, 1H), 3.181 (dd, *J* = 9.5, 3.5 Hz, 1H), 3.21 (dd, *J* = 9.8, 3.8 Hz, 1H), 3.28 (dd, *J* = 9.5, 3.2 Hz, 1H), 3.28 (dd, *J* = 9.5, 3.2 Hz, 1H), 3.37 (s, 3H), 3.378 (s, 3H), 3.380 (s, 6H), 3.39 (s, 3H), 3.465 (s, 3H), 3.468 (s, 3H), 3.47 (s, 3H), 3.478 (s, 3H), 3.484 (s, 3H), 3.50 (s, 3H), 3.52 (s, 3H), 3.59 (s, 3H), 3.601 (s, 3H), 3.604 (s, 3H), 3.62 (s, 3H), 3.63 (s, 3H), 3.67 (s, 3H), 3.69 (s, 3H), 5.02 (d, *J* = 3.5 Hz, 1H), 5.04 (d, *J* = 2.8 Hz, 1H), 5.053 (d, *J* = 3.5 Hz, 1H), 5.058 (d, *J* = 3.8 Hz, 1H), 5.066 (d, *J* = 4.1 Hz, 1H), 5.21 (d, *J* = 3.8 Hz, 1H), 5.22 (d, *J* = 3.5 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.74 (CH₃), 57.94 (2 × CH₃), 58.04 (CH₃), 58.08 (CH₃), 58.33 (CH₃), 58.43 (CH₃), 58.95 (4 × CH₃), 59.06 (CH₃), 61.09 (2 × CH₃), 61.66 (CH₃), 61.86 (CH₃), 61.89 (CH₃), 62.18 (CH₃), 62.25 (CH₃), 64.71 (CH₂, C6^I or C6^{IV}), 65.14 (CH₂, C6^I or C6^{IV}), 66.65 (CH, C5^I or C5^{IV}), 67.21 (CH, C5^I or C5^{IV}), 70.76 (CH₂), 70.85 (CH), 70.87 (CH), 70.92 (CH), 70.98 (CH₂), 71.10 (CH₂), 71.74 (CH₂), 72.05 (CH₂), 77.64 (CH, C4^I or C4^{IV}), 77.79 (CH, C4^I or C4^{IV}), 78.00 (CH),

79.14 (CH), 79.28 (CH), 79.95 (CH), 80.10 (CH), 80.48 (CH), 80.83 (CH), 80.98 (CH), 81.11 (CH), 81.35 (CH), 81.50 (CH), 81.63 (2 × CH), 81.74 (CH), 81.94 (2 × CH), 82.78 (CH), 83.26 (CH), 83.36 (CH), 96.92 (CH), 97.05 (CH), 97.78 (CH), 98.28 (CH), 99.08 (CH), 99.78 (CH, C1^I or C1^{IV}), 100.59 (CH, C1^I or C1^{IV}), 100.77 (C, C5^I or C5^{IV}), 101.17 (C, C5^I or C5^{IV}); MS (ESI⁺-TOF): *m/z* (%) 1419 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₆₁H₁₀₄NaO₃₅ 1419.6256; found 1419.6250. Anal. calcd for C₆₁H₁₀₄O₃₅: C, 52.43; H, 7.50. Found: C, 52.48; H, 7.34.

Some spectroscopic data of the inseparable mixture of mono-trioxocane–mono-acetyl positional isomers could be obtained: colorless oil, ¹H NMR (500 MHz, CDCl₃, complex spectrum, only clearly distinguished signals are reported): δ 2.062 (s, 3H), 2.064 (s, 3H), 4.15 (dd, *J* = 2.5, 2.5 Hz, 1H), 4.17 (dd, *J* = 2.4, 2.4 Hz, 1H), 4.96 (d, *J* = 3.5 Hz, 1H), 5.01 (d, *J* = 3.5 Hz, 1H), 5.041 (d, *J* = 3.5 Hz, 1H), 5.05 (d, *J* = 4.4 Hz, 2H), 5.06 (d, *J* = 3.2 Hz, 2H), 5.07 (d, *J* = 3.2 Hz, 1H), 5.10 (d, *J* = 3.5 Hz, 1H), 5.12 (d, *J* = 3.5 Hz, 1H), 5.14 (d, *J* = 2.2 Hz, 1H), 5.17 (d, *J* = 2.2 Hz, 1H), 5.227 (d, *J* = 3.4 Hz, 1H), 5.229 (d, *J* = 3.5 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃, complex spectrum, only clearly distinguished signals are reported): δ 22.02 (CH₃), 22.06 (CH₃), 60.31 (CH₂), 60.37 (CH₂), 64.84 (CH₂), 64.91 (CH₂), 66.91 (CH), 67.07 (CH), 96.98 (CH), 97.01 (CH), 97.21 (CH), 97.33 (CH), 97.46 (CH), 97.89 (CH), 99.12 (CH), 99.24 (CH), 99.62 (CH), 99.83 (CH), 100.17 (CH), 100.24 (CH), 100.40 (CH), 101.05 (C), 101.45 (C), 101.93 (CH), 104.51 (C), 104.55 (C), 170.14 (C); MS (ESI⁺-TOF): *m/z* (%) 1479 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₆₃H₁₀₈NaO₃₇ 1479.6467; found 1479.6475.

Compound **13**: colorless oil, [α]_D +130.8 (*c* 0.75, CHCl₃); IR (film): 2933, 1732, 1454, 1367, 1193, 1106, 1046 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.04 (s, 6H), 3.12 (dd, *J* = 9.3, 2.7 Hz, 1H), 3.15 (dd, *J* = 6.9, 3.2 Hz, 1H), 3.16 (dd, *J* = 7.6, 3.5 Hz, 1H), 3.22 (dd, *J* = 9.8, 3.2 Hz, 1H), 3.26

(dd, $J = 9.8, 3.5$ Hz, 1H), 3.367 (s, 6H), 3.370 (s, 3H), 3.38 (s, 3H), 3.39 (s, 3H), 3.40 (s, 6H), 3.458 (s, 3H), 3.461 (s, 3H), 3.463 (s, 3H), 3.49 (s, 3H), 3.50 (s, 3H), 3.52 (s, 3H), 3.588 (s, 3H), 3.591 (s, 3H), 3.595 (s, 3H), 3.598 (s, 3H), 3.617 (s, 3H), 3.619 (s, 3H), 3.90 (d, $J = 9.8$ Hz, 1H, H6), 3.95 (d, $J = 9.8$ Hz, 1H, H6), 4.00 (d, $J = 9.8$ Hz, 1H, H6), 4.03 (d, $J = 9.8$ Hz, 1H, H6), 4.05 (br d, $J = 2.5$ Hz, 1H, H4^{VII}), 4.08 (dd, $J = 2.5, 2.5$ Hz, 1H, H3^{III}), 4.16 (dd, $J = 2.5, 2.5$ Hz, 1H, H3^{VII}), 4.33 (br dd, $J = 11.0, 7.3$ Hz, 1H), 4.41 (br dd, $J = 11.5, 5.8$ Hz, 1H), 4.97 (d, $J = 2.8$ Hz, 1H), 4.98 (d, $J = 3.2$ Hz, 1H), 5.03 (d, $J = 3.5$ Hz, 1H), 5.04 (d, $J = 3.2$ Hz, 1H), 5.09 (d, $J = 3.2$ Hz, 1H), 5.11 (d, $J = 1.9$ Hz, 1H, H1^{III}), 5.14 (d, $J = 1.9$ Hz, 1H, H1^{VII}); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^{VII}, 5.14 ppm): δ 3.40 (br s, 1H, H2^{VII}), 4.05 (br s, 1H, H4^{VII}), 4.17 (dd, $J = 2.5, 2.5$ Hz, 1H, H3^{VII}); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^{III}, 5.11 ppm): δ 3.32 (br s, 1H, H2^{III}), 4.02 (br s, 1H, H4^{III}), 4.09 (dd, $J = 2.5, 2.5$ Hz, 1H, H3^{III}); ¹H NMR (500 MHz, C₆D₆, 18 °C): δ 1.74 (s, 3H), 1.78 (s, 3H), 3.16 (s, 3H), 3.18 (s, 3H), 3.19 (s, 3H), 3.21 (s, 3H), 3.26 (s, 3H), 3.270 (s, 3H), 3.274 (s, 6H), 3.30 (s, 9H), 3.40 (s, 3H), 3.61 (s, 3H), 3.62 (s, 3H), 3.66 (s, 3H), 3.72 (s, 3H), 3.822 (s, 3H), 3.825 (s, 3H), 3.85 (s, 3H), 4.44 (d, $J = 9.8$ Hz, 1H), 4.51 (d, $J = 9.8$ Hz, 1H), 5.08 (d, $J = 3.2$ Hz, 1H), 5.09 (d, $J = 3.5$ Hz, 1H), 5.15 (d, $J = 2.5$ Hz, 1H), 5.18 (d, $J = 3.8$ Hz, 1H), 5.19 (d, $J = 2.8$ Hz, 1H), 5.59 (d, $J = 1.3$ Hz, 1H), 5.63 (d, $J = 1.3$ Hz, 1H); ¹H NMR (500 MHz, C₆D₆, 70 °C): δ 1.79 (s, 3H), 1.83 (s, 3H), 3.21 (s, 3H), 3.23 (s, 3H), 3.25 (s, 3H), 3.27 (s, 3H), 3.29 (s, 3H), 3.308 (s, 3H), 3.312 (s, 3H), 3.313 (s, 3H), 3.319 (s, 3H), 3.322 (s, 3H), 3.34 (s, 3H), 3.39 (s, 3H), 3.60 (s, 3H), 3.61 (s, 3H), 3.699 (s, 3H), 3.702 (s, 3H), 3.79 (s, 3H), 3.80 (s, 3H), 3.83 (s, 3H), 4.10 (dd, $J = 11.2, 3.9$ Hz, 1H), 4.40 (d, $J = 9.8$ Hz, 1H), 4.44 (d, $J = 9.8$ Hz, 1H), 5.05 (d, $J = 3.2$ Hz, 1H), 5.07 (d, $J = 3.5$ Hz, 1H), 5.11 (d, $J = 2.5$ Hz, 1H), 5.13 (d, $J = 3.5$ Hz, 1H), 5.16 (d, $J = 2.8$ Hz, 1H), 5.56 (d, $J = 1.6$ Hz, 1H), 5.65 (d, $J = 1.3$ Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃): δ 21.98 (CH₃), 22.03 (CH₃), 57.16 (CH₃), 57.41 (CH₃),

57.68 (CH₃), 57.75 (CH₃), 57.86 (CH₃), 58.84 (CH₃), 58.90 (CH₃), 58.99 (4 × CH₃), 59.03 (CH₃), 59.34 (CH₃), 59.68 (CH₃), 59.91 (CH₂), 60.37 (CH₂), 61.02 (CH₃), 61.11 (CH₃), 61.55 (CH₃), 61.72 (CH₃), 61.77 (CH₃), 70.44 (CH), 70.48 (CH₂), 70.60 (CH₂), 70.66 (CH₂), 70.86 (CH₂), 70.87 (CH₂), 71.08 (CH), 71.30 (2 × CH), 71.59 (CH), 71.67 (CH), 72.16 (CH), 76.11 (CH, C3^{VII}), 76.65 (CH, C2^{VII}), 76.86 (CH, C2^{III}), 77.06 (CH, C3^{III}), 77.99 (CH), 80.39 (CH), 81.55 (CH), 81.60 (2 × CH), 81.67 (CH), 82.02 (CH), 82.06 (CH), 82.15 (CH), 82.17 (CH), 82.20 (CH), 82.34 (CH), 82.68 (CH), 82.84 (CH), 83.13 (CH), 97.70 (CH, C1^{III}), 98.39 (CH, C1^{VII}), 99.67 (CH), 99.70 (CH), 99.82 (CH), 100.24 (CH), 101.71 (CH), 104.92 (C, C5^{III}), 105.15 (C, C5^{VII}), 170.08 (C), 170.14 (C); MS (ESI⁺-TOF): *m/z* (%) 1539 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₆₅H₁₁₂NaO₃₉ 1539.6678; found 1539.6642. Anal. calcd for C₆₅H₁₁₂O₃₉: C, 51.44; H, 7.44. Found: C, 51.49; H, 7.60.

Oxidative HAT of 2^{I-VI},3^{I-VI},6^{II,III,V,VII}-hexadeca-O-methyl-α-cyclomaltohexaose (14). Method A: A solution of alcohol **14**^{25,29} (90 mg, 0.075 mmol) in dry CH₂Cl₂ (3 mL) containing DIB (53 mg, 0.165 mmol) and I₂ (9.5 mg, 0.038 mmol) was stirred under nitrogen at 26 °C for 1.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 65:35→55:45) to give cyclo-5^{VI},6^I-anhydro-(5^{VI}R)-(2,3,6-tri-O-methyl-α-D-xylo-hexos-5-ulopyranosyl)-(1→4)-2,3-di-O-methyl-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-methyl-α-D-glucopyranosyl-(1→4)-5^{III},6^{IV}-anhydro-(5^{III}R)-(2,3,6-tri-O-methyl-α-D-xylo-hexos-5-ulopyranosyl)-(1→4)-2,3-di-O-methyl-α-D-glucopyranosyl-(1→4)-2,3,6-tri-O-methyl-α-D-glucopyranosyl (**15**) (25.6 mg, 0.021 mmol, 29%) and cyclo-5^{VI},6^I-anhydro-(5^{VI}R)-(2,3,6-tri-O-methyl-α-D-xylo-hexos-5-ulopyranosyl)-(1→4)-2,3-di-O-methyl-α-D-glucopyranosyl-[(1→4)-2,3,6-tri-O-methyl-α-D-glucopyranosyl]₂-(1→4)-2,3-di-O-methyl-α-D-

glucopyranosyl-(1→4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl (**16**) (17.5 mg, 0.015 mmol, 19%).

Compound **15**: Crystalline solid m.p. 250–252 °C (from *n*-hexane–EtOAc); $[\alpha]_D +133.0$ (*c* 1.176, CHCl₃); IR (film): 2929, 1454, 1365, 1139, 1109, 1063 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.14 (dd, *J* = 9.1, 3.5 Hz, 2H), 3.20 (dd, *J* = 9.5, 3.5 Hz, 2H), 3.25 (dd, *J* = 9.8, 3.5 Hz, 2H), 3.368 (s, 6H), 3.369 (s, 6H), 3.47 (s, 6H), 3.48 (s, 6H), 3.50 (s, 6H), 3.53 (dd, *J* = 9.5, 9.5 Hz, 2H), 3.61 (s, 12H), 3.69 (dd, *J* = 9.3, 9.3 Hz, 2H), 3.74 (s, 6H), 3.77 (dd, *J* = 9.5, 9.5 Hz, 2H), 3.93 (d, *J* = 9.5 Hz, 2H), 3.98 (d, *J* = 9.8 Hz, 2H), 4.99 (d, *J* = 3.8 Hz, 2H), 5.02 (d, *J* = 3.5 Hz, 2H), 5.19 (d, *J* = 3.2 Hz, 2H); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.62 (2 × CH₃), 57.80 (2 × CH₃), 58.13 (2 × CH₃), 58.98 (2 × CH₃), 59.14 (2 × CH₃), 61.28 (2 × CH₃), 62.06 (2 × CH₃), 62.14 (2 × CH₃), 64.01 (2 × CH₂), 66.49 (2 × CH), 70.69 (2 × CH₂), 70.91 (2 × CH), 72.25 (2 × CH₂), 78.32 (2 × CH), 80.38 (2 × CH), 80.67 (2 × CH), 80.83 (2 × CH), 81.24 (2 × CH), 81.42 (2 × CH), 81.73 (2 × CH), 82.07 (2 × CH), 82.21 (2 × CH), 97.28 (2 × CH), 98.63 (2 × CH), 99.13 (2 × CH), 100.37 (2 × C); MS (ESI⁺-TOF): *m/z* (%) 1215 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₅₂H₈₈NaO₃₀ 1215.5258; found 1215.5253. Anal. calcd for C₅₂H₈₈O₃₀: C, 52.34; H, 7.43. Found: C, 52.41; H, 7.26. Compound **16**: colorless oil, $[\alpha]_D +108.2$ (*c* 1.48, CHCl₃); IR (film): 3475, 2929, 1454, 1365, 1141, 1107, 1046 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.12–3.21 (m, 5H), 3.25 (dd, *J* = 9.8, 3.2 Hz, 1H), 3.36 (s, 3H), 3.37 (s, 3H), 3.379 (s, 3H), 3.380 (s, 3H), 3.47 (s, 3H), 3.47 (s, 6H), 3.48 (s, 3H), 3.50 (s, 3H), 3.53 (s, 3H), 3.60 (s, 3H), 3.61 (s, 3H), 3.618 (s, 3H), 3.620 (s, 3H), 3.71 (s, 3H), 3.73 (s, 3H), 4.96 (d, *J* = 3.5 Hz, 1H), 4.97 (d, *J* = 3.5 Hz, 1H), 5.03 (d, *J* = 3.5 Hz, 1H), 5.04 (d, *J* = 3.5 Hz, 1H), 5.16 (d, *J* = 3.8 Hz, 1H), 5.19 (d, *J* = 3.5 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.65 (CH₃), 57.83 (CH₃), 57.85 (CH₃), 57.86 (CH₃), 58.39 (CH₃), 58.72 (CH₃), 59.07 (3 × CH₃), 59.09 (CH₃), 61.25 (2 × CH₃), 61.64 (CH₃), 61.89 (CH₃), 61.95 (CH₂), 61.98 (CH₃), 62.25 (CH₃), 64.05 (CH₂), 66.40 (CH), 70.95 (CH₂), 71.03 (CH), 71.14 (CH), 71.39 (CH₂),

71.81 (CH), 72.03 (CH₂), 72.07 (CH₂), 72.10 (CH), 78.18 (CH), 80.09 (CH), 80.37 (CH), 80.46 (CH), 80.75 (CH), 80.83 (CH), 80.86 (CH), 81.26 (CH), 81.33 (CH), 81.50 (CH), 81.61 (CH), 81.65 (CH), 81.79 (CH), 81.96 (CH), 82.14 (CH), 82.45 (CH), 82.59 (CH), 82.78 (CH), 97.30 (CH), 97.97 (CH), 98.34 (CH), 99.39 (2 × CH), 99.52 (CH), 100.79 (C); MS (ESI⁺-TOF): *m/z* (%) 1217 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₅₂H₉₀NaO₃₀ 1217.5415; found 1217.5419. Anal. calcd for C₅₂H₉₀O₃₀: C, 52.25; H, 7.59. Found: C, 52.33; H, 7.37.

Method B: A solution of alcohol **14** (45 mg, 0.038 mmol) in dry CH₂Cl₂ (1.5 mL) containing DIB (30 mg, 0.095 mmol) and I₂ (14.5 mg, 0.057 mmol) was stirred under nitrogen at 28 °C for 1.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 65:35→55:45) to give **15** (13 mg, 0.011 mmol, 29%) and **16** (7.2 mg, 0.006 mmol, 16%).

Method C: A solution of alcohol **14** (47 mg, 0.039 mmol) in dry CH₂Cl₂ (1.6 mL) containing DIB (37.7 mg, 0.117 mmol) and I₂ (16.8 mg, 0.066 mmol) was stirred under nitrogen at 28 °C for 1.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 65:35) to give **15** (15.9 mg, 0.013 mmol, 34%).

Oxidative HAT of mono-trioxocane alcohol (16). A solution of alcohol **16** (12 mg, 0.01 mmol) in dry CH₂Cl₂ (0.45 mL) containing DIB (7 mg, 0.022 mmol) and I₂ (1.3 mg, 0.005 mmol) was stirred under nitrogen at 28 °C for 2 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 65:35) to give bis(trioxocane) **15** (6 mg, 0.005 mmol, 50%).

Oxidative HAT of 2^{I-VII}, 3^{I-VII}, 6^{II,IV-VII}-nonadeca-O-methyl-β-cyclomaltoheptaose (17). A solution of alcohol **17**^{17a} (119 mg, 0.085 mmol) in dry CH₂Cl₂ (3.5 mL) containing DIB (60.2 mg, 0.187 mmol) and I₂ (28 mg, 0.110 mmol) was stirred under nitrogen at 30 °C for 2.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (CHCl₃–MeOH, 99:1→98:2) to give the acetyl derivative **18** as an inseparable mixture of positional isomers (26.1 mg, 0.018 mmol, 21%, 70:30), cyclo-(5*R*)-5^{VII}-*O*-acetyl-2,3,6-tri-*O*-methyl-α-D-xylo-hexos-5-ulopyranosyl-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-(1→4)-(5*R*)-5^{II}-*O*-acetyl-2,3,6-tri-*O*-methyl-α-D-xylo-hexos-5-ulopyranosyl-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl-α-D-glucopyranosyl]₃ (**19**) (19.1 mg, 0.013 mmol, 15%), cyclo-(5*R*)-5^{VII}-*O*-acetyl-2,3,6-tri-*O*-methyl-α-D-xylo-hexos-5-ulopyranosyl-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-(1→4)-5^{II},6^{III}-anhydro-(5^{II}*R*)-(2,3,6-tri-*O*-methyl-α-D-xylo-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl-α-D-glucopyranosyl]₃ (**20**) (24.3 mg, 0.018 mmol, 20%), cyclo-5^{VII},6^I-anhydro-(5^{VII}*R*)-(2,3,6-tri-*O*-methyl-α-D-xylo-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-(1→4)-(5*R*)-5^{II}-*O*-acetyl-2,3,6-tri-*O*-methyl-α-D-xylo-hexos-5-ulopyranosyl-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl-α-D-glucopyranosyl]₃ (**21**) (7 mg, 0.005 mmol, 6%), cyclo-5^{VII},6^I-anhydro-(5^{VII}*R*)-(2,3,6-tri-*O*-methyl-α-D-xylo-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-(1→4)-(1^{II}*R*)-4^{III},6^{III}-*O*-(2,3-di-*O*-methyl-α-D-glucopyranosylidene)-2,3-di-*O*-methyl-α-D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl-α-D-glucopyranosyl]₃ (**22**) (6.9 mg, 0.005 mmol, 6%). Compound **18**: colorless oil, IR (film): 3516, 2933, 1732, 1455, 1368, 1105, 1036 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) (only the major isomer is shown): δ 2.06 (s, 3H), 3.18 (m, 6H), 3.30 (dd, *J* = 9.8, 9.8 Hz, 1H), 3.36 (s, 3H), 3.367 (s, 3H),

3.373 (s, 3H), 3.39 (s, 3H), 3.40 (s, 3H), 3.43 (s, 3H), 3.45 (s, 3H), 3.482 (s, 3H), 3.483 (s, 3H), 3.49 (s, 3H), 3.50 (s, 3H), 3.54 (s, 3H), 3.59 (s, 3H), 3.61 (s, 3H), 3.617 (s, 3H), 3.621 (s, 3H), 3.627 (s, 3H), 3.633 (s, 3H), 3.64 (s, 3H), 3.94 (d, $J = 9.8$ Hz, 1H), 4.02 (d, $J = 9.8$ Hz, 1H), 4.05 (d, $J = 1.9$ Hz, 1H), 4.18 (dd, $J = 2.4, 2.4$ Hz, 1H), 4.30 (dd, $J = 11.2, 5.8$ Hz, 1H), 5.01 (d, $J = 3.2$ Hz, 1H), 5.037 (d, $J = 3.4$ Hz, 1H), 5.044 (d, $J = 3.8$ Hz, 1H), 5.079 (d, $J = 4.1$ Hz, 1H), 5.087 (d, $J = 4.1$ Hz, 1H), 5.12 (d, $J = 1.9$ Hz, 1H), 5.16 (d, $J = 3.8$ Hz, 1H); ^1H NMR (500 MHz, CDCl_3 , 1D-ROESY, irradiation at 2.06 ppm): δ 5.12 (d, $J = 1.9$ Hz, 1H, H1^{VII}); ^{13}C NMR (125.7 MHz, CDCl_3) (only the major isomer is shown): δ 22.10 (CH_3), 57.21 (CH_3), 57.50 (CH_3), 58.24 (CH_3), 58.53 (CH_3), 58.57 (CH_3), 58.88 ($2 \times \text{CH}_3$), 58.91 (CH_3), 58.95 (CH_3), 58.97 ($2 \times \text{CH}_3$), 59.01 (CH_3), 59.20 (CH_3), 60.20 (CH_2), 61.22 (CH_3), 61.23 (CH_3), 61.37 (CH_3), 61.41 (CH_3), 61.50 (CH_3), 61.67 (CH_3), 61.82 (CH_2), 70.33 (CH_2), 70.33 (CH), 71.02 ($2 \times \text{CH}$), 71.02 (CH_2), 71.13 ($2 \times \text{CH}_2$), 71.14 ($2 \times \text{CH}$), 71.27 (CH_2), 71.42 (CH), 72.21 (CH), 75.42 (CH), 76.81 (CH), 79.73 (CH), 80.17 (CH), 80.31 (CH), 81.13 ($2 \times \text{CH}$), 81.52 (CH), 81.62 (CH), 81.66 ($2 \times \text{CH}$), 81.73 ($2 \times \text{CH}$), 81.90 (CH), 82.02 (CH), 82.30 (CH), 82.33 (CH), 82.44 ($2 \times \text{CH}$), 83.67 (CH), 97.69 (CH), 99.10 (CH), 99.35 (CH), 99.37 (CH), 99.41 (CH), 99.62 (CH), 100.10 (CH), 104.99 (C), 170.18 (C); MS (ESI^+ -TOF): m/z (%) 1481 [$(\text{M} + \text{Na})^+$, 100]; HRMS (ESI^+ -TOF): m/z [$\text{M} + \text{Na}]^+$ calcd for $\text{C}_{63}\text{H}_{110}\text{NaO}_{37}$ 1481.6624; found 1481.6647. Anal. calcd for $\text{C}_{63}\text{H}_{110}\text{O}_{37}$: C, 51.84; H, 7.60. Found: C, 51.60; H, 7.45. Compound **19**: colorless oil, $[\alpha]_{\text{D}} +118.9$ (c 1.34, CHCl_3); IR (film): 3521, 2928, 1732, 1455, 1368, 1195, 1105, 1041 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 2.04 (s, 3H), 2.05 (s, 3H), 3.16 (dd, $J = 9.8, 3.8$ Hz, 2H), 3.17 (dd, $J = 9.5, 3.2$ Hz, 1H), 3.21 (dd, $J = 9.8, 3.5$ Hz, 1H), 3.25 (dd, $J = 9.9, 3.3$ Hz, 1H), 3.30 (dd, $J = 9.8, 9.8$ Hz, 1H), 3.32 (dd, $J = 2.2, 2.2$ Hz, 1H, H2), 3.36 (s, 3H), 3.37 (s, 3H), 3.38 (s, 3H), 3.39 (s, 3H), 3.40 (s, 3H), 3.41 (s, 3H), 3.42 (s, 3H), 3.46 (s, 3H), 3.47 (s, 3H), 3.479 (s, 3H), 3.482 (s, 3H), 3.53 (s, 3H), 3.54 (s, 3H), 3.586 (s, 3H),

3.593 (s, 3H), 3.60 (s, 3H), 3.61 (s, 3H), 3.62 (s, 3H), 3.64 (s, 3H), 4.01 (br d, $J = 3.2$ Hz, 1H, H4), 4.04 (dd, $J = 2.5, 2.5$ Hz, 1H, H3), 4.06 (d, $J = 2.2$ Hz, 1H, H4), 4.18 (dd, $J = 2.5, 2.5$ Hz, 1H, H3), 4.99 (d, $J = 3.2$ Hz, 1H), 5.00 (d, $J = 4.1$ Hz, 1H), 5.07 (d, $J = 2.2$ Hz, 1H, H1), 5.079 (d, $J = 3.5$ Hz, 1H), 5.082 (d, $J = 3.5$ Hz, 1H), 5.10 (d, $J = 3.5$ Hz, 1H), 5.12 (d, $J = 1.9$ Hz, 1H, H1); ^1H NMR (500 MHz, C_6D_6): δ 1.68 (s, 3H), 1.84 (s, 3H), 3.01 (dd, $J = 9.1, 2.8$ Hz, 1H), 3.10 (dd, $J = 9.5, 3.5$ Hz, 1H), 3.14 (s, 3H), 3.21 (s, 3H), 3.22 (s, 3H), 3.22 (s, 3H), 3.24 (s, 3H), 3.28 (s, 3H), 3.31 (s, 3H), 3.35 (s, 3H), 3.36 (s, 3H), 3.40 (s, 3H), 3.41 (s, 6H), 3.42 (s, 3H), 3.48 (s, 3H), 3.65 (s, 3H), 3.66 (s, 6H), 3.69 (s, 3H), 3.79 (s, 3H), 5.00 (d, $J = 2.8$ Hz, 1H), 5.14 (d, $J = 3.2$ Hz, 1H), 5.18 (d, $J = 3.2$ Hz, 1H), 5.20 (d, $J = 3.5$ Hz, 1H), 5.32 (d, $J = 3.8$ Hz, 1H), 5.48 (d, $J = 2.5$ Hz, 1H), 5.53 (d, $J = 2.2$ Hz, 1H); ^1H NMR (500 MHz, CDCl_3 , 1D-TOCSY, irradiation at H1^{II} or ^{VII}, 5.12 ppm): δ 3.42 (br s, 1H, H2), 4.05 (br s, 1H, H4), 4.22 (br s, 1H, H3); ^1H NMR (500 MHz, CDCl_3 , 1D-TOCSY, irradiation at H1^{VII} or ^{II}, 5.07 ppm): δ 3.36 (br s, 1H, H2), 4.08 (dd, $J = 2.5, 2.5$ Hz, 1H, H3), 4.09 (br s, 1H, H4); ^1H NMR (500 MHz, CDCl_3 , 2D-ROESY): both acetates show NOE interactions with their respective anomeric hydrogens: H1^{VII} and H1^{II}; ^{13}C NMR (125.7 MHz, CDCl_3): δ 22.05 (CH_3), 22.08 (CH_3), 57.33 (CH_3), 57.37 (CH_3), 57.58 (CH_3), 58.20 (CH_3), 58.38 (CH_3), 58.71 (CH_3), 58.93 (CH_3), 58.96 ($5 \times \text{CH}_3$), 59.36 (CH_3), 59.94 (CH_2), 60.06 (CH_3), 60.36 (CH_2), 61.14 (CH_3), 61.27 (CH_3), 61.45 ($2 \times \text{CH}_3$), 61.65 (CH_3), 70.08 (CH), 70.34 (CH_2), 70.57 (CH_2), 70.66 (CH_2), 70.71 (CH_2), 70.88 (CH_2), 70.98 (CH), 71.14 (CH), 71.30 (CH), 71.51 (CH), 71.86 (CH), 72.43 (CH), 75.96 (CH), 77.02 (CH), 77.14 (CH), 77.56 (CH), 78.17 (CH), 80.10 (CH), 81.36 (CH), 81.39 (CH), 81.49 (CH), 81.58 (CH), 81.63 (CH), 81.88 (CH), 81.99 (CH), 82.01 (CH), 82.08 (CH), 82.51 (CH), 82.74 (CH), 83.03 (CH), 83.12 (CH), 97.80 (CH), 97.82 (CH), 99.46 ($2 \times \text{CH}$), 99.59 (CH), 100.49 (CH), 101.81 (CH), 104.33 (C), 105.18 (C), 170.01 (C), 170.12 (C); MS (ESI⁺-TOF): m/z (%) 1539 [$(\text{M} + \text{Na})^+$, 100]; HRMS (ESI⁺-TOF): m/z [$\text{M} + \text{Na}]^+$

calcd for $C_{65}H_{112}NaO_{39}$ 1539.6678; found 1539.6660. Anal. calcd for $C_{65}H_{112}O_{39}$: C, 51.44; H, 7.44. Found: C, 51.48; H, 7.64. Compound **20**: colorless oil, $[\alpha]_D^{+123.5}$ (c 0.96, $CHCl_3$); IR (film): 3540, 2928, 1732, 1455, 1368, 1138, 1105, 1046 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$): δ 2.05 (s, 3H), 3.24 (dd, $J = 10.1, 3.5$ Hz, 1H), 3.25 (dd, $J = 10.1, 3.3$ Hz, 1H), 3.35 (s, 3H), 3.37 (s, 3H), 3.38 (s, 3H), 3.39 (s, 3H), 3.40 (s, 3H), 3.42 (s, 3H), 3.45 (s, 3H), 3.477 (s, 3H), 3.480 (s, 3H), 3.49 (s, 3H), 3.50 (s, 3H), 3.53 (s, 3H), 3.60 (s, 3H), 3.61 (s, 6H), 3.63 (s, 3H), 3.66 (s, 3H), 3.67 (s, 3H), 3.68 (s, 3H), 3.90 (d, $J = 8.8$ Hz, 1H), 4.21 (m, 1H), 4.23 (dd, $J = 2.5, 2.5$ Hz, 1H), 4.27 (br dd, $J = 11.7, 6.3$ Hz, 1H), 4.98 (d, $J = 3.2$ Hz, 1H), 5.00 (d, $J = 3.2$ Hz, 1H), 5.04 (d, $J = 3.5$ Hz, 1H), 5.09 (d, $J = 4.1$ Hz, 1H), 5.13 (d, $J = 3.5$ Hz, 1H), 5.15 (d, $J = 1.9$ Hz, 1H), 5.17 (d, $J = 3.5$ Hz, 1H); 1H NMR (500 MHz, $CDCl_3$, 1D-TOCSY, irradiation at $H1^H$, 5.17 ppm): δ 3.24 (dd, $J = 9.9, 3.7$ Hz, 1H, $H2^H$), 3.64 (dd, $J = 9.2, 9.2$ Hz, 1H, $H3^H$), 3.90 (d, $J = 9.0$ Hz, 1H, $H4^H$); 1H NMR (500 MHz, $CDCl_3$, 1D-TOCSY, irradiation at $H1^L$, 5.00 ppm): δ 3.25 (dd, $J = 9.3, 3.0$ Hz, 1H, $H2^L$), 3.54 (m, 1H, $H6^L$), 3.59 (dd, $J = 9.4, 9.4$ Hz, 1H, $H3^L$), 3.63 (dd, $J = 9.1, 9.1$ Hz, 1H, $H4^L$), 4.21 (br d, $J = 10$ Hz, 1H, $H5^L$), 4.27 (br dd, $J = 12.6, 5.4$ Hz, 1H, $H6^L$); 1H NMR (500 MHz, $CDCl_3$, 1D-ROESY, irradiation at $H1^L$, 5.00 ppm): δ 3.25 (dd, $J = 9.3, 3.3$ Hz, 1H, $H2^L$), 3.90 (d, $J = 9.1$ Hz, 1H, $H4^H$); ^{13}C NMR (125.7 MHz, $CDCl_3$): δ 22.05 (CH_3), 57.42 (CH_3), 57.56 ($2 \times CH_3$), 58.30 (CH_3), 58.39 (CH_3), 58.88 (CH_3), 58.90 (CH_3), 58.93 (CH_3), 58.98 (CH_3), 59.01 (CH_3), 59.04 ($3 \times CH_3$), 60.13 (CH_2), 61.13 ($2 \times CH_3$), 61.40 (CH_3), 61.61 (CH_3), 61.69 (CH_3), 62.06 (CH_3), 63.85 (CH_2), 67.06 (CH), 70.48 (CH_2), 70.74 (CH), 70.77 (CH_2), 70.90 (CH), 70.90 (CH_2), 71.03 (CH_2), 71.08 (CH), 71.43 (CH), 72.16 (CH_2), 72.83 (CH), 75.62 (CH), 76.57 (CH), 78.46 (CH), 79.02 (CH), 80.24 (CH), 80.32 (CH), 80.35 (CH), 80.63 (CH), 81.03 (CH), 81.48 (CH), 81.57 (CH), 81.69 ($2 \times CH$), 81.73 (CH), 81.77 ($2 \times CH$), 82.21 (CH), 82.71 (CH), 83.09 (CH), 83.38 (CH), 97.20 (CH), 97.31 (CH), 98.31 (CH), 98.45 (CH), 99.61 (CH), 100.31 (CH), 100.35 (C), 102.03

(CH), 105.25 (C), 170.26 (C); MS (ESI⁺-TOF): *m/z* (%) 1479 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₆₃H₁₀₈NaO₃₇ 1479.6467; found 1479.6483. Anal. calcd for C₆₃H₁₀₈O₃₇: C, 51.92; H, 7.47. Found: C, 52.16; H, 7.75. Compound **21**: colorless oil, [α]_D +110.6 (*c* 0.36, CHCl₃); IR (film): 3526, 2928, 1732, 1455, 1368, 1143, 1107, 1046 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.06 (s, 3H), 3.12 (dd, *J* = 10.1, 3.5 Hz, 1H), 3.15 (dd, *J* = 9.1, 3.2 Hz, 1H), 3.20 (dd, *J* = 9.8, 3.8 Hz, 1H), 3.35 (s, 3H), 3.37 (s, 9H), 3.40 (s, 3H), 3.43 (s, 3H), 3.46 (s, 3H), 3.47 (s, 6H), 3.48 (s, 3H), 3.51 (s, 3H), 3.56 (s, 3H), 3.61 (s, 9H), 3.64 (s, 3H), 3.64 (s, 3H), 3.66 (s, 3H), 3.67 (s, 3H), 3.82 (dd, *J* = 10.7, 10.7 Hz, 1H, H6^I), 3.95 (d, *J* = 9.8 Hz, 1H, H6^{II}), 4.06 (d, *J* = 9.8 Hz, 1H, H6^{II}), 4.11 (br s, 2H, H4^{II} and H3^{II}), 4.37 (ddd, *J* = 12.0, 6.6, 1.6 Hz, 1H, H6^{III}), 5.01 (d, *J* = 3.2 Hz, 1H), 5.03 (d, *J* = 3.5 Hz, 1H), 5.04 (d, *J* = 4.4 Hz, 1H), 5.08 (d, *J* = 1.9 Hz, 1H), 5.163 (d, *J* = 3.2 Hz, 1H), 5.166 (d, *J* = 2.9 Hz, 1H), 5.21 (d, *J* = 3.8 Hz, 1H); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^{II}, 5.08 ppm): δ 3.24 (br s, 1H, H2^{II}), 4.109 (dd, *J* = 2.9, 2.9 Hz, 1H, H3^{II}), 4.111 (d, *J* = 2.9 Hz, 1H, H4^{II}); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^I, 5.01 ppm): δ 3.16 (br d, *J* = 10.1 Hz, 1H, H2^I), 3.42 (dd, *J* = 9.3, 9.3 Hz, 1H, H3^I), 3.46 (dd, *J* = 9.0, 9.0 Hz, 1H, H4^I), 3.65 (m, 1H, H5^I), 3.98 (dd, *J* = 9.2, 2.8 Hz, 1H, H6^I); ¹H NMR (500 MHz, CDCl₃, 1D-ROESY, irradiation at H1^I, 5.01 ppm): δ 4.11 (d, *J* = 2.9 Hz, 1H, H4^{II}); ¹³C NMR (125.7 MHz, CDCl₃): δ 22.13 (CH₃), 57.08 (CH₃), 57.54 (CH₃), 57.84 (CH₃), 58.14 (CH₃), 58.20 (CH₃), 58.84 (CH₃), 58.86 (CH₃), 58.89 (CH₃), 58.98 (CH₃), 59.04 (CH₃), 59.10 (CH₃), 59.14 (CH₃), 59.89 (CH₃), 60.37 (CH₂), 60.90 (CH₃), 61.25 (CH₃), 61.35 (CH₃), 61.67 (CH₃), 61.73 (CH₃), 62.10 (CH₃), 63.91 (CH₂), 67.13 (CH), 69.00 (CH), 70.29 (CH₂), 70.45 (CH), 70.95 (CH), 70.95 (CH₂), 71.33 (CH), 71.47 (CH₂), 71.54 (CH), 71.54 (CH₂), 71.82 (CH₂), 75.65 (CH), 76.98 (CH), 77.20 (CH), 77.55 (CH), 79.22 (CH), 79.90 (CH), 80.36 (CH), 80.86 (CH), 80.96 (CH), 80.99 (CH), 81.07 (CH), 81.36 (CH), 81.79 (CH), 81.87 (CH), 81.95 (CH), 81.97 (CH), 82.34

(CH), 82.87 (CH), 83.09 (CH), 83.45 (CH), 97.08 (CH), 97.66 (CH), 98.06 (CH), 98.21 (CH), 98.77 (CH), 99.10 (CH), 99.28 (CH), 100.76 (C), 105.18 (C), 170.26 (C); MS (ESI⁺-TOF): *m/z* (%) 1479 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₆₃H₁₀₈NaO₃₇ 1479.6467; found 1479.6459. Anal. calcd for C₆₃H₁₀₈O₃₇: C, 51.92; H, 7.47. Found: C, 52.14; H, 7.39.

Compound **22**: colorless oil, [α]_D +116.9 (*c* 0.46, CHCl₃); IR (film): 2928, 1455, 1370, 1159, 1102, 1046 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.099 (d, *J* = 9.8 Hz, 1H), 3.10 (dd, *J* = 9.5, 3.5 Hz, 1H), 3.24 (dd, *J* = 9.8, 9.8 Hz, 1H), 3.30 (dd, *J* = 9.5, 3.5 Hz, 1H), 3.34 (s, 3H), 3.37 (s, 3H), 3.38 (s, 6H), 3.39 (s, 3H), 3.47 (s, 6H), 3.48 (s, 3H), 3.49 (s, 3H), 3.54 (s, 3H), 3.57 (s, 3H), 3.575 (s, 3H), 3.582 (s, 3H), 3.59 (s, 6H), 3.618 (s, 3H), 3.619 (s, 3H), 3.70 (s, 3H), 3.74 (s, 3H), 4.24 (dd, *J* = 9.1, 7.9 Hz, 1H), 4.30 (ddd, *J* = 10.7, 7.9, 7.9 Hz, 1H), 5.02 (d, *J* = 3.5 Hz, 1H), 5.06 (d, *J* = 3.5 Hz, 1H), 5.09 (d, *J* = 3.2 Hz, 1H), 5.094 (d, *J* = 3.2 Hz, 1H), 5.23 (d, *J* = 3.5 Hz, 1H), 5.30 (d, *J* = 3.8 Hz, 1H); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^{III}, 5.30 ppm): δ 3.20 (dd, *J* = 9.6, 3.8 Hz, 1H, H2^{III}), 3.59 (dd, *J* = 9.2, 9.2 Hz, 1H, H3^{III}), 3.64 (dd, *J* = 9.4, 9.4 Hz, 1H, H6^{III}), 3.68 (dd, *J* = 9.2, 9.2 Hz, 1H, H4^{III}), 4.24 (dd, *J* = 9.0, 9.0 Hz, 1H, H6^{III}), 3.99 (ddd, *J* = 10.4, 8.0, 8.0 Hz, 1H, H5^{III}); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^I, 5.23 ppm): δ 3.31 (dd, *J* = 9.3, 3.9 Hz, 1H, H2^I), 3.78 (dd, *J* = 9.6, 9.6 Hz, 1H, H3^I), 3.85 (d, *J* = 9.5 Hz, 1H, H4^I); ¹H NMR (500 MHz, CDCl₃, 1D-ROESY, irradiation at H1^{III}, 5.30 ppm): δ 3.21 (dd, *J* = 9.7, 3.8 Hz, 1H, H2^{III}), 3.60 (dd, *J* = 9.2, 9.2 Hz, 1H, H4^{IV}); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.84 (CH₃), 57.88 (CH₃), 58.02 (CH₃), 58.26 (CH₃), 58.34 (CH₃), 58.81 (CH₃), 58.83 (CH₃), 58.94 (CH₃), 58.98 (CH₃), 59.38 (CH₃), 59.89 (CH₃), 60.75 (2 × CH₃), 61.01 (CH₃), 61.10 (CH₃), 61.50 (CH₃), 61.85 (CH₃), 61.96 (CH₃), 62.28 (CH₃), 62.53 (CH), 62.79 (CH₂), 65.12 (CH₂), 66.50 (CH), 70.27 (CH), 70.96 (CH₂), 71.08 (CH), 71.11 (CH), 71.16 (CH₂), 71.42 (CH₂), 71.73 (CH₂), 71.94 (CH), 72.18 (CH₂), 74.72 (CH), 77.17 (CH), 77.61 (CH), 78.77 (CH), 79.92 (CH), 80.57 (CH), 80.83 (CH),

81.03 (CH), 81.14 (CH), 81.31 (CH), 81.46 (CH), 81.47 (CH), 81.90 (CH), 82.00 (CH), 82.07 (CH), 82.27 (CH), 82.48 (CH), 82.60 (CH), 83.37 (CH), 83.56 (CH), 83.91 (CH), 96.87 (CH), 99.44 (2 × CH), 99.86 (CH), 100.34 (CH), 100.47 (CH), 101.28 (C), 111.08 (C); MS (ESI⁺-TOF): *m/z* (%) 1419 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₆₁H₁₀₄NaO₃₅ 1419.6256; found 1419.6287. Anal. calcd for C₆₁H₁₀₄O₃₅: C, 52.43; H, 7.50. Found: C, 52.18; H, 7.74.

Oxidative HAT of 2^{I-VI}, 3^{I-VI}, 6^{II,IV-VI}-hexadeca-O-methyl-α-cyclomaltohexaose (23). A solution of alcohol **23** (120 mg, 0.10 mmol) in dry CH₂Cl₂ (4 mL) containing DIB (71 mg, 0.22 mmol) and I₂ (25.4 mg, 0.10 mmol) was stirred under nitrogen at 28 °C for 1.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 65:35→60:40) to give cyclo-5^{II},6^{III}-anhydro-(5^{II}*R*)-(2,3,6-tri-*O*-methyl-α-D-*xylo*-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl-α-D-glucopyranosyl]₂-(1→4)-5^{VI},6^I-anhydro-(5^{VI}*R*)-(2,3,6-tri-*O*-methyl-α-D-*xylo*-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl (**24**) (33.4 mg, 0.028, 28%), cyclo-5^{II},6^{III}-anhydro-(5^I*R*)-(2,3,6-tri-*O*-methyl-α-D-*xylo*-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl-α-D-glucopyranosyl]₃-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl (**25**) (22 mg, 0.018 mmol, 18%), and cyclo-5^{VI},6^I-anhydro-(5^{VI}*R*)-(2,3,6-tri-*O*-methyl-α-D-*xylo*-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-(1→4)-2,3,6-tri-*O*-methyl-α-D-glucopyranosyl-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl-α-D-glucopyranosyl]₂ (**26**) (24 mg, 0.020 mmol, 20%). Compound **24**: colorless oil, [α]_D +124.1 (*c* 1.70, CHCl₃); IR (film): 2928, 1453, 1368, 1140, 1107, 1060 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.14 (m, 4H), 3.22 (dd, *J* = 9.1, 3.8 Hz, 1H), 3.24

(dd, $J = 9.5, 3.5$ Hz, 1H), 3.35 (s, 3H), 3.36 (s, 6H), 3.37 (s, 3H), 3.466 (s, 3H), 3.469 (s, 3H), 3.485 (s, 3H), 3.491 (s, 6H), 3.494 (s, 3H), 3.60 (s, 3H), 3.62 (s, 3H), 3.63 (s, 3H), 3.68 (s, 3H), 3.70 (s, 3H), 3.71 (s, 3H), 4.98 (d, $J = 3.8$ Hz, 1H), 5.00 (d, $J = 3.2$ Hz, 2H), 5.03 (d, $J = 3.8$ Hz, 1H), 5.15 (d, $J = 3.5$ Hz, 1H), 5.16 (d, $J = 3.5$ Hz, 1H); ^{13}C NMR (125.7 MHz, CDCl_3): δ 57.59 (CH_3), 57.70 (CH_3), 57.92 (CH_3), 58.11 (CH_3), 58.38 (CH_3), 58.62 (CH_3), 58.76 (CH_3), 58.95 (CH_3), 59.09 (CH_3), 59.14 (CH_3), 61.27 (CH_3), 61.32 (CH_3), 61.52 (CH_3), 61.86 (CH_3), 61.94 (CH_3), 62.14 (CH_3), 63.44 (CH_2), 63.91 (CH_2), 65.60 (CH), 66.37 (CH), 70.48 (CH), 71.03 (CH), 71.57 (CH_2), 71.67 (CH_2), 71.81 (CH_2), 72.90 (CH_2), 78.05 (CH), 78.23 (CH), 79.77 (CH), 79.91 (CH), 80.07 (CH), 80.74 (CH), 80.82 (CH), 80.97 (CH), 81.14 (CH), 81.16 (CH), 81.19 (CH), 81.23 (CH), 81.34 (CH), 81.79 (CH), 82.37 (CH), 82.44 (CH), 82.60 (CH), 83.29 (CH), 96.36 (CH), 96.48 (CH), 97.37 (CH), 97.53 (CH), 100.15 (CH), 100.21 (CH), 100.47 (C), 100.78 (C); MS (ESI $^+$ -TOF): m/z (%) 1215 [$(\text{M} + \text{Na})^+$, 100]; HRMS (ESI $^+$ -TOF): m/z [$\text{M} + \text{Na}]^+$ calcd for $\text{C}_{52}\text{H}_{88}\text{NaO}_{30}$ 1215.5258; found 1215.5237. Anal. calcd for $\text{C}_{52}\text{H}_{88}\text{O}_{30}$: C, 52.34; H, 7.43. Found: C, 52.42; H, 7.43. Compound **25**: colorless oil, $[\alpha]_{\text{D}} +123.7$ (c 1.81, CHCl_3); IR (film): 3494, 2933, 1454, 1365, 1109, 1039 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 3.11 (dd, $J = 10.1, 3.5$ Hz, 1H), 3.13 (dd, $J = 10.4, 3.5$ Hz, 1H), 3.15 (dd, $J = 9.8, 3.2$ Hz, 1H), 3.18 (dd, $J = 10.1, 3.5$ Hz, 1H), 3.20 (dd, $J = 9.8, 3.5$ Hz, 1H), 3.25 (dd, $J = 9.6, 3.3$ Hz, 1H), 3.35 (s, 3H), 3.369 (s, 3H), 3.371 (s, 3H), 3.38 (s, 3H), 3.476 (s, 3H), 3.479 (s, 3H), 3.487 (s, 3H), 3.490 (s, 6H), 3.495 (s, 3H), 3.58 (s, 3H), 3.60 (s, 3H), 3.638 (s, 3H), 3.644 (s, 3H), 3.70 (s, 3H), 3.71 (s, 3H), 4.98 (d, $J = 3.8$ Hz, 1H), 4.99 (d, $J = 3.8$ Hz, 1H), 5.00 (d, $J = 3.5$ Hz, 1H), 5.01 (d, $J = 3.5$ Hz, 1H), 5.08 (d, $J = 3.5$ Hz, 1H), 5.17 (d, $J = 3.2$ Hz, 1H); ^{13}C NMR (125.7 MHz, CDCl_3): δ 57.71 (CH_3), 57.84 ($2 \times \text{CH}_3$), 58.17 (CH_3), 58.42 (CH_3), 58.49 (CH_3), 58.95 ($2 \times \text{CH}_3$), 59.00 (CH_3), 59.14 (CH_3), 61.28 (CH_3), 61.33 (CH_3), 61.61 (CH_3), 61.90 (CH_3), 61.94 (CH_3), 62.06 (CH_2), 62.20 (CH_3), 63.76 (CH_2), 66.25 (CH), 70.96 (CH),

71.05 (CH₂), 71.40 (CH), 71.52 (CH₂), 71.62 (CH), 72.12 (CH), 72.12 (CH₂), 72.22 (CH₂), 78.45 (CH), 80.44 (2 × CH), 80.81 (CH), 80.94 (CH), 81.01 (CH), 81.06 (CH), 81.19 (CH), 81.35 (CH), 81.44 (CH), 81.76 (CH), 81.93 (CH), 82.09 (CH), 82.12 (CH), 82.33 (2 × CH), 82.55 (CH), 82.59 (CH), 97.44 (CH), 97.80 (CH), 98.64 (CH), 99.10 (CH), 99.78 (CH), 100.04 (CH), 100.69 (C); MS (ESI⁺-TOF): *m/z* (%) 1217 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₅₂H₉₀NaO₃₀ 1217.5415; found 1217.5405. Anal. calcd for C₅₂H₉₀O₃₀: C, 52.25; H, 7.59. Found: C, 51.98; H, 7.48. Compound **26**: colorless oil, [α]_D+112.0 (*c* 1.65, CHCl₃); IR (film): 3475, 2933, 1454, 1367, 1111, 1044 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.10 (dd, *J* = 10.1, 3.5 Hz, 1H), 3.13 (dd, *J* = 10.1, 3.5 Hz, 1H), 3.15 (dd, *J* = 9.2, 3.8 Hz, 1H), 3.18 (dd, *J* = 9.8, 3.8 Hz, 1H), 3.19 (dd, *J* = 9.8, 3.2 Hz, 1H), 3.25 (dd, *J* = 9.6, 3.3 Hz, 1H), 3.35 (s, 3H), 3.37 (s, 3H), 3.37 (s, 3H), 3.38 (s, 3H), 3.47 (s, 3H), 3.47 (s, 3H), 3.48 (s, 3H), 3.48 (s, 3H), 3.49 (s, 3H), 3.53 (s, 3H), 3.59 (s, 3H), 3.60 (s, 3H), 3.63 (s, 3H), 3.63 (s, 3H), 3.70 (s, 3H), 3.74 (s, 3H), 4.96 (d, *J* = 3.8 Hz, 1H), 5.01 (d, *J* = 3.8 Hz, 1H), 5.03 (d, *J* = 3.5 Hz, 1H), 5.04 (d, *J* = 3.2 Hz, 1H), 5.07 (d, *J* = 3.5 Hz, 1H), 5.19 (d, *J* = 3.5 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.67 (CH₃), 57.82 (CH₃), 57.84 (CH₃), 57.99 (CH₃), 58.39 (CH₃), 58.47 (CH₃), 58.80 (CH₃), 59.00 (2 × CH₃), 59.09 (CH₃), 61.28 (CH₃), 61.50 (CH₃), 61.54 (CH₃), 61.93 (CH₃), 61.97 (CH₃), 62.25 (CH₃), 62.48 (CH₂), 63.86 (CH₂), 66.28 (CH), 70.87 (CH), 71.03 (CH), 71.10 (CH), 71.12 (CH₂), 71.24 (CH₂), 71.83 (CH₂), 71.99 (CH₂), 72.77 (CH), 78.30 (CH), 80.46 (CH), 80.57 (CH), 80.73 (CH), 80.78 (CH), 81.02 (2 × CH), 81.31 (CH), 81.42 (CH), 81.50 (CH), 81.75 (CH), 81.89 (CH), 81.97 (CH), 82.11 (CH), 82.30 (CH), 82.50 (CH), 82.60 (CH), 82.70 (CH), 97.36 (CH), 97.75 (CH), 98.77 (CH), 99.57 (CH), 99.86 (CH), 100.04 (CH), 100.80 (C); MS (ESI⁺-TOF): *m/z* (%) 1217 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₅₂H₉₀NaO₃₀ 1217.5415; found 1217.5427. Anal. calcd for C₅₂H₉₀O₃₀: C, 52.25; H, 7.59. Found: C, 52.30; H, 7.51.

*Cyclo-5^{II},6^{III}-anhydro-(5^{II}R)-(2,3,6-tri-O-methyl- α -D-xylo-hexos-5-ulopyranosyl)-(1 $\rightarrow$ 4)-2,3-di-O-methyl- α -D-glucopyranosyl-[(1 $\rightarrow$ 4)-2,3,6-tri-O-methyl- α -D-glucopyranosyl]₃-(1 $\rightarrow$ 4)-6^I-O-acetyl-2,3-di-O-methyl- α -D-glucopyranosyl (**27**). A solution of alcohol **25** (16.7 mg, 0.014 mmol) in dry pyridine (0.9 mL) containing Ac₂O (0.3 mL) and DMAP (0.2 mg, 0.001 mmol) was stirred at room temperature for 16 h. The mixture was then poured into 10% aqueous HCl and extracted with CHCl₃. The organic layer was washed with aqueous saturated NaHCO₃, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was then purified by silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (CHCl₃–MeOH, 99.5:0.5) to give acetyl-trioxocane **27** (14.5 mg, 0.012 mmol, 84%) as a colorless oil: $[\alpha]_D^{+113.2}$ (*c* 1.45, CHCl₃); IR (film): 2929, 1742, 1456, 1365, 1109, 1044 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.07 (s, 3H), 3.19 (dd, *J* = 9.8, 3.2 Hz, 2H), 3.25 (dd, *J* = 9.8, 3.2 Hz, 1H), 3.35 (s, 3H), 3.37 (s, 6H), 3.383 (s, 3H), 3.477 (s, 3H), 3.482 (s, 3H), 3.489 (s, 3H), 3.490 (s, 3H), 3.495 (s, 3H), 3.50 (s, 3H), 3.59 (s, 3H), 3.60 (s, 3H), 3.63 (s, 6H), 3.70 (s, 3H), 3.72 (s, 3H), 4.08 (dd, *J* = 11.2, 3.0 Hz, 1H), 4.18 (dd, *J* = 12.0, 4.1 Hz, 1H), 4.38 (dd, *J* = 12.0, 1.6 Hz, 1H), 5.02 (m, 3H), 5.03 (d, *J* = 3.2 Hz, 1H), 5.06 (d, *J* = 3.2 Hz, 1H), 5.19 (d, *J* = 3.5 Hz, 1H); ¹H NMR (500 MHz, C₆D₆): δ 1.87 (s, 3H), 3.26 (s, 6H), 3.28 (s, 3H), 3.29 (s, 3H), 3.29 (s, 3H), 3.32 (s, 6H), 3.37 (s, 3H), 3.39 (s, 3H), 3.48 (s, 3H), 3.65 (s, 3H), 3.68 (s, 3H), 3.70 (s, 3H), 3.80 (s, 3H), 3.84 (s, 3H), 3.85 (s, 3H), 4.06 (dd, *J* = 10.7, 10.7 Hz, 1H, H6^{III}), 4.61 (m, 2H, H5^I and H6^I), 5.02 (br d, *J* = 10.7 Hz, 1H, H6^I), 5.08 (d, *J* = 3.8 Hz, 1H), 5.13 (d, *J* = 3.8 Hz, 1H), 5.17 (d, *J* = 3.5 Hz, 1H, H1^{II}), 5.18 (d, *J* = 4.1 Hz, 1H), 5.20 (d, *J* = 3.5 Hz, 1H), 5.22 (d, *J* = 3.5 Hz, 1H, H1^I); ¹H NMR (500 MHz, C₆D₆, 1D-TOCSY, irradiation at H6^I, 5.02 ppm): δ 3.21 (dd, *J* = 9.6, 3.4 Hz, 1H, H2^I), 3.58 (dd, *J* = 9.0, 9.0 Hz, 1H, H4^I), 3.83 (dd, *J* = 9.1, 9.1 Hz, 1H, H3^I), 4.61 (m, 2H, H5^I and H6^I), 5.22 (d, *J* = 2.9 Hz, 1H, H1^I); ¹H NMR (500 MHz, C₆D₆, 1D-TOCSY, irradiation at H1^{II}, 5.17 ppm): δ 3.25 (dd, *J**

= 9.6, 2.7 Hz, 1H, H2^{II}), 4.15 (dd, J = 9.3, 9.3 Hz, 1H, H3^{II}), 4.26 (d, J = 9.4 Hz, 1H, H4^{II}); ¹H NMR (500 MHz, CDCl₃, 1D-ROESY, irradiation at H1^I, 5.22 ppm): δ 4.26 (d, J = 9.2 Hz, 1H, H4^{II}); ¹³C NMR (125.7 MHz, CDCl₃): δ 20.98 (CH₃), 57.77 (CH₃), 57.83 (2 $\times$ CH₃), 58.12 (CH₃), 58.20 (CH₃), 58.39 (CH₃), 58.92 (CH₃), 58.99 (CH₃), 59.09 (CH₃), 59.17 (CH₃), 61.30 (CH₃), 61.56 (CH₃), 61.89 (CH₃), 62.02 (CH₃), 62.30 (CH₃), 63.91 (CH₂), 64.07 (CH₂), 66.10 (CH), 69.20 (CH), 70.75 (CH₂), 70.86 (CH), 71.21 (CH₂), 71.33 (CH₂), 71.38 (CH), 71.48 (CH), 72.02 (CH₂), 78.26 (CH), 80.03 (CH), 80.60 (CH), 80.61 (CH), 80.83 (CH), 81.04 (CH), 81.06 (CH), 81.15 (CH), 81.35 (CH), 81.42 (CH), 81.79 (2 $\times$ CH), 82.09 (CH), 82.11 (CH), 82.16 (CH), 82.35 (CH), 82.50 (CH), 82.60 (CH), 97.39 (CH), 97.46 (CH), 99.09 (CH), 99.35 (CH), 100.05 (CH), 100.71 (CH), 100.75 (C), 170.86 (C); ¹³C NMR (125.7 MHz, C₆D₆): δ 20.78 (CH₃), 57.24 (CH₃), 57.67 (CH₃), 57.78 (2 $\times$ CH₃), 58.15 (CH₃), 58.25 (CH₃), 58.84 (CH₃), 58.97 (CH₃), 59.01 (CH₃), 59.10 (CH₃), 61.29 (CH₃), 61.56 (CH₃), 61.65 (CH₃), 61.79 (CH₃), 62.11 (CH₃), 62.14 (CH₃), 64.31 (CH₂), 64.68 (CH₂), 66.70 (CH), 69.93 (CH), 71.74 (CH₂), 71.79 (CH), 72.23 (CH), 72.25 (CH₂), 72.50 (CH), 72.72 (CH₂), 73.00 (CH₂), 79.05 (CH), 81.53 (CH), 81.57 (CH), 81.60 (CH), 81.63 (CH), 81.82 (CH), 81.84 (CH), 82.04 (CH), 82.13 (2 $\times$ CH), 82.68 (CH), 82.72 (CH), 82.96 (CH), 83.00 (CH), 83.06 (CH), 83.17 (CH), 83.31 (CH), 83.36 (CH), 98.06 (CH), 98.52 (CH), 99.08 (CH), 99.18 (CH), 99.93 (CH), 100.88 (CH), 101.20 (C), 170.11 (C); MS (ESI⁺-TOF): m/z (%) 1259 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): m/z [M + Na]⁺ calcd for C₅₄H₉₂NaO₃₁ 1259.5520; found 1259.5526. Anal. calcd for C₅₄H₉₂O₃₁: C, 52.42; H, 7.49. Found: C, 52.35; H, 7.56.

*Cyclo-5^{VI},6^I-anhydro-(5^{VI}R)-(2,3,6-tri-O-methyl- α -D-xylo-hexos-5-ulopyranosyl)-(1 $\rightarrow$ 4)-2,3-di-O-methyl- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-2,3,6-tri-O-methyl- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-6^{III}-O-acetyl-2,3-di-O-methyl- α -D-glucopyranosyl-[(1 $\rightarrow$ 4)-2,3,6-tri-O-methyl- α -D-glucopyranosyl]₂ (**28**). A solution of alcohol **26** (24 mg, 0.02 mmol) in dry pyridine (0.9 mL) containing Ac₂O (0.3*

mL) and DMAP (0.3 mg, 0.002 mmol) was stirred at room temperature for 14 h. The mixture was then poured into 10% aqueous HCl and extracted with CHCl₃. The organic layer was washed with aqueous saturated NaHCO₃, dried over Na₂SO₄ and concentrated under reduced pressure. The residue was then purified by silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (CHCl₃–MeOH, 99.5:0.5) to give acetyl-trioxocane **28** (10 mg, 0.008 mmol, 40%), as a colorless oil: [α]_D +130.8 (*c* 0.98, CHCl₃); IR (film): 2929, 1744, 1454, 1367, 1109, 1046 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.07 (s, 3H), 3.179 (dd, *J* = 10.1, 3.5 Hz, 1H), 3.198 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.198 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.257 (dd, *J* = 9.5, 3.2 Hz, 1H), 3.34 (s, 3H), 3.37 (s, 3H), 3.381 (s, 3H), 3.384 (s, 3H), 3.47 (s, 3H), 3.476 (s, 3H), 3.489 (s, 3H), 3.494 (s, 3H), 3.50 (s, 3H), 3.52 (s, 3H), 3.59 (s, 3H), 3.60 (s, 3H), 3.638 (s, 3H), 3.642 (s, 3H), 3.70 (s, 3H), 3.73 (s, 3H), 3.93 (d, *J* = 9.5 Hz, 1H, H4^{VII}), 4.39 (dd, *J* = 12.1, 4.3 Hz, 1H, H6^{III}), 4.56 (dd, *J* = 12.3, 1.9 Hz, 1H, H6^{III}), 4.98 (d, *J* = 3.8 Hz, 2H), 5.04 (d, *J* = 3.5 Hz, 1H), 5.05 (d, *J* = 3.5 Hz, 2H), 5.19 (d, *J* = 3.2 Hz, 1H, H1^I); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H6^{III}, 4.56 ppm): δ 3.14 (dd, *J* = 10.0, 3.3 Hz, 1H, H2^{III}), 3.57 (dd, *J* = 9.1, 9.1 Hz, 1H, H4^{III}), 3.69 (dd, *J* = 9.4, 9.4 Hz, 1H, H3^{III}), 3.77 (m, 1H, H5^{III}), 4.40 (dd, *J* = 11.7, 3.9 Hz, 1H, H6^{III}), 5.05 (d, *J* = 2.5 Hz, 1H, H1^{III}); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^{VI}, 5.19 ppm): δ 3.26 (dd, *J* = 9.7, 3.2 Hz, 1H, H2^{VI}), 3.72 (dd, *J* = 9.3, 9.3 Hz, 1H, H3^{VI}), 3.94 (d, *J* = 9.4 Hz, 1H, H4^{VI}); ¹H NMR (500 MHz, CDCl₃, 1D-ROESY, irradiation at H4^{VI}, 3.93 ppm): δ 5.04 (d, *J* = 3.2 Hz, 1H, H1^V); ¹³C NMR (125.7 MHz, CDCl₃): δ 20.90 (CH₃), 57.69 (CH₃), 57.82 (CH₃), 58.11 (2 $\times$ CH₃), 58.28 (CH₃), 58.46 (CH₃), 58.83 (CH₃), 58.93 (CH₃), 59.05 (CH₃), 59.10 (CH₃), 61.29 (CH₃), 61.48 (CH₃), 61.59 (CH₃), 61.85 (CH₃), 62.08 (CH₃), 62.27 (CH₃), 63.69 (CH₂), 63.85 (CH₂), 66.21 (CH), 69.89 (CH), 70.77 (CH₂), 70.86 (CH), 70.98 (CH), 71.26 (CH), 71.35 (CH₂), 71.56 (CH₂), 71.96 (CH₂), 78.29 (CH), 79.87 (CH), 80.61 (CH), 80.76 (2 $\times$ CH), 81.04 (CH), 81.09 (CH), 81.17 (CH),

81.39 (CH), 81.51 (CH), 81.75 (CH), 81.94 (CH), 82.10 (CH), 82.17 (CH), 82.38 (CH), 82.49 (CH), 82.71 (2 × CH), 97.32 (CH), 97.37 (CH), 99.50 (CH), 99.61 (CH), 99.78 (CH), 100.17 (CH), 100.83 (C), 170.55 (C); MS (ESI⁺-TOF): *m/z* (%) 1259 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₅₄H₉₂NaO₃₁ 1259.5520; found 1259.5504. Anal. calcd for C₅₄H₉₂O₃₁: C, 52.42; H, 7.49. Found: C, 52.20; H, 7.65.

Oxidative HAT of 2^{I-VII}, 3^{I-VII}, 6^{III-VII}-nonadeca-O-methyl-β-cyclomaltoheptaose (29). A solution of alcohol **29**^{17a} (160 mg, 0.114 mmol) in dry CH₂Cl₂ (4.6 mL) containing DIB (110 mg, 0.34 mmol) and I₂ (49 mg, 0.19 mmol) was stirred under nitrogen at 28 °C for 2.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 65:35→55:45) to give cyclo-5^{VII},6^I-anhydro-(5^{VII}*R*)-(2,3,6-tri-*O*-methyl-α-D-xylo-hexos-5-ulopyranosyl)-(1→4)-(1^I*R*)-4^{II},6^{II}-*O*-(2,3-di-*O*-methyl-D-glucopyranosylidene)-2,3-di-*O*-methyl-α-D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl-α-D-glucopyranosyl]₄ (**30**) (8 mg, 0.0057 mmol, 5%), ten-membered lactone **31** (17.1 mg, 0.012 mmol, 11%), and a mixture (54.1 mg) of two alcohols **32** and **33** that was separated after acetylation as mentioned below. To a solution of this mixture in anhydrous pyridine (3 mL) were added Ac₂O (1 mL) and DMAP (1 mg). After 14 h at room temperature, the solution was poured into ice-water and extracted with CH₂Cl₂. The organic phase was successively washed with aqueous solutions of HCl (10%) and saturated NaHCO₃, dried over Na₂SO₄, and concentrated under reduced pressure. The residue (86.5 mg) was purified by silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (CHCl₃–MeOH, 99:1) to give cyclo-5^{VII},6^I-anhydro-(5^{VII}*R*)-(2,3,6-tri-*O*-methyl-α-D-xylo-hexos-5-ulopyranosyl)-(1→4)-2,3-di-*O*-methyl-α-D-glucopyranosyl-(1→4)-6^{II}-*O*-acetyl-2,3-di-*O*-methyl-α-D-glucopyranosyl-[(1→4)-2,3,6-tri-*O*-methyl-α-D-glucopyranosyl]₄ (**34**) (36

mg, 0.025 mmol, 22%) and the lactone **35** (16 mg, 0.013 mmol, 11%). Compound **30**: colorless oil, $[\alpha]_D +108.0$ (c 0.45, CHCl_3); IR (film): 2925, 1454, 1369, 1143, 1091, 1042 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3): δ 3.06 (d, $J = 9.5$ Hz, 1H), 3.17 (dd, $J = 9.5, 3.7$ Hz, 1H), 3.19 (dd, $J = 9.5, 3.2$ Hz, 1H), 3.209 (dd, $J = 9.2, 4.1$ Hz, 1H), 3.211 (dd, $J = 9.5, 3.5$ Hz, 1H), 3.22 (dd, $J = 9.5, 3.8$ Hz, 1H), 3.27 (dd, $J = 9.8, 3.8$ Hz, 1H), 3.33 (s, 3H), 3.35 (s, 3H), 3.37 (s, 3H), 3.39 (s, 3H), 3.39 (s, 3H), 3.47 (s, 3H), 3.47 (s, 3H), 3.50 (s, 3H), 3.51 (s, 3H), 3.55 (s, 3H), 3.56 (s, 3H), 3.59 (s, 9H), 3.64 (s, 3H), 3.64 (s, 3H), 3.66 (s, 3H), 3.70 (s, 3H), 3.71 (s, 3H), 4.22 (dd, $J = 10.4, 8.2$ Hz, 1H), 5.04 (d, $J = 3.5$ Hz, 1H), 5.07 (d, $J = 3.2$ Hz, 2H), 5.20 (d, $J = 3.8$ Hz, 1H), 5.23 (d, $J = 4.4$ Hz, 1H), 5.34 (d, $J = 4.1$ Hz, 1H); ^1H NMR (500 MHz, CDCl_3 , 1D-TOCSY, irradiation at H2^I , 3.06 ppm): δ 3.40 (dd, $J = 9.7, 9.7$ Hz, 1H, H3^I), 3.54 (dd, $J = 9.3, 9.3$ Hz, 1H, H4^I), 3.75 (m, 2H, H6^I and H5^I), 3.90 (dd, $J = 9.9, 9.9$ Hz, 1H, H6^I); ^1H NMR (500 MHz, CDCl_3 , 1D-TOCSY, irradiation at H6^{II} , 4.22 ppm): δ 3.21 (dd, $J = 9.6, 4.3$ Hz, 1H, H2^{II}), 3.57 (dd, $J = 9.2, 9.2$ Hz, 1H, H3^{II}), 3.63 (dd, $J = 10.3, 6.8$ Hz, 1H, H6^{II}), 3.72 (dd, $J = 10.0, 10.0$ Hz, 1H, H4^{II}), 4.00 (m, 1H, H5^{II}), 5.23 (d, $J = 4.0$ Hz, 1H, H1^{II}); ^{13}C NMR (125.7 MHz, CDCl_3): δ 57.80 (CH_3), 57.88 (CH_3), 58.07 (CH_3), 58.22 (CH_3), 58.91 (CH_3), 59.02 ($2 \times \text{CH}_3$), 59.04 (CH_3), 59.14 (CH_3), 59.44 (CH_3), 60.04 (CH_3), 60.57 (CH_3), 60.70 (CH_3), 60.96 (CH_3), 61.07 (CH_3), 61.18 (CH_3), 61.67 (CH_3), 61.70 (CH_3), 61.84 (CH_2), 62.04 (CH_3), 63.66 (CH), 64.36 (CH_2), 67.62 (CH), 70.05 (CH), 70.07 (CH), 71.06 (CH), 71.09 (CH_2), 71.41 (CH), 71.49 (CH_2), 71.83 (CH_2), 71.84 (CH_2), 71.93 (CH_2), 74.10 (CH), 77.50 (CH), 77.87 (CH), 78.37 (CH), 79.20 (CH), 80.18 (CH), 80.35 (CH), 81.02 (CH), 81.05 (CH), 81.11 (CH), 81.37 (CH), 81.70 (CH), 81.80 (CH), 81.88 (CH), 81.92 (CH), 82.28 (CH), 82.34 (CH), 82.45 (CH), 82.48 (CH), 82.76 (CH), 84.92 (CH), 97.04 (CH), 97.99 (CH), 98.61 (CH), 98.83 (CH), 99.81 (CH), 100.31 (CH), 101.04 (C), 111.58 (C); MS (ESI^+ -TOF): m/z (%) 1419 [(M + Na) $^+$, 100]; HRMS (ESI^+ -TOF): m/z [M + Na] $^+$ calcd for $\text{C}_{61}\text{H}_{104}\text{NaO}_{35}$ 1419.6256; found

1419.6281. Anal. calcd for C₆₁H₁₀₄O₃₅: C, 52.43; H, 7.50. Found: C, 52.35; H, 7.73. Compound **31**: colorless oil, [α]_D +121.8 (*c* 0.68, CHCl₃); IR (film): 2929, 1755, 1745, 1454, 1367, 1161, 1106, 1039 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.14 (s, 3H), 3.04 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.16 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.16 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.18 (dd, *J* = 9.8, 3.2 Hz, 1H), 3.19 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.24 (dd, *J* = 9.5, 3.8 Hz, 1H), 3.35 (s, 3H), 3.361 (s, 3H), 3.365 (s, 3H), 3.37 (s, 3H), 3.38 (s, 3H), 3.46 (s, 6H), 3.485 (s, 3H), 3.49 (s, 3H), 3.51 (s, 3H), 3.53 (s, 3H), 3.58 (s, 3H), 3.59 (s, 3H), 3.61 (s, 3H), 3.62 (s, 3H), 3.63 (s, 3H), 3.66 (s, 3H), 3.69 (s, 3H), 3.73 (s, 3H), 4.36 (ddd, *J* = 9.9, 9.9, 5.8 Hz, 1H), 4.58 (dd, *J* = 10.7, 5.7 Hz, 1H), 4.96 (d, *J* = 3.8 Hz, 1H), 5.00 (d, *J* = 3.5 Hz, 1H), 5.09 (d, *J* = 3.8 Hz, 2H), 5.17 (d, *J* = 3.5 Hz, 1H), 5.26 (d, *J* = 3.8 Hz, 1H), 6.30 (d, *J* = 1.9 Hz, 1H); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H5^{II}, 4.36 ppm): δ 3.05 (dd, *J* = 9.9, 3.4 Hz, 1H, H2^{II}), 3.45 (dd, *J* = 8.8, 8.8 Hz, 1H, H3^{II}), 3.55 (dd, *J* = 9.3, 9.3 Hz, 1H, H4^{II}), 3.81 (dd, *J* = 10.4, 10.4 Hz, 1H, H6^{II}), 4.59 (dd, *J* = 10.8, 5.7 Hz, 1H, H6^{II}), 5.00 (d, *J* = 2.9 Hz, 1H, H1^{II}); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^I, 6.30 ppm): δ 3.34 (d, *J* = 9.0 Hz, 1H, H2^I), 3.60 (m, 1H, H3^I), 3.90 (d, *J* = 9.4 Hz, 1H, H4^I); ¹H NMR (500 MHz, CDCl₃, 1D-ROESY, irradiation at H1^I, 6.30 ppm): δ 3.34 (d, *J* = 7.1 Hz, 1H, H2^I), 3.55 (dd, *J* = 9.3, 9.3 Hz, 1H, H4^{II}), 3.90 (d, *J* = 9.4 Hz, 1H, H4^I); ¹³C NMR (125.7 MHz, CDCl₃): δ 21.43 (CH₃), 57.86 (CH₃), 58.29 (2 × CH₃), 58.39 (CH₃), 58.40 (CH₃), 58.83 (CH₃), 58.94 (CH₃), 58.99 (CH₃), 59.01 (CH₃), 59.04 (2 × CH₃), 60.97 (CH₃), 61.25 (CH₃), 61.50 (CH₃), 61.69 (2 × CH₃), 61.73 (CH₃), 62.20 (2 × CH₃), 63.34 (CH), 65.84 (CH₂), 70.17 (CH), 70.69 (CH), 70.82 (CH₂), 70.93 (2 × CH), 71.09 (CH), 71.12 (CH₂), 71.14 (CH₂), 71.35 (CH₂), 71.66 (CH₂), 78.64 (CH), 79.61 (CH), 80.14 (CH), 80.52 (CH), 80.64 (CH), 80.89 (CH), 81.32 (2 × CH), 81.42 (CH), 81.58 (CH), 81.64 (CH), 81.68 (CH), 81.81 (2 × CH), 81.84 (CH), 82.01 (CH), 82.05 (CH), 82.13 (CH), 82.27 (CH), 83.42 (CH), 84.59 (CH), 94.21 (CH), 97.86 (CH), 98.70 (CH), 98.83 (CH), 99.11 (CH), 99.38

(CH), 99.98 (CH), 170.81 (C), 170.98 (C); MS (ESI⁺-TOF): m/z (%) 1449 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): m/z [M + Na]⁺ calcd for C₆₂H₁₀₆NaO₃₆ 1449.6362; found 1449.6360. Anal. calcd for C₆₂H₁₀₆O₃₆: C, 52.17; H, 7.48. Found: C, 51.91; H, 7.48. Compound **34**: colorless oil, [α]_D +105.2 (*c* 0.94, CHCl₃); IR (film): 2933, 1745, 1454, 1369, 1161, 1109, 1041 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.08 (s, 3H), 3.13 (dd, J = 9.5, 3.5 Hz, 1H), 3.28 (dd, J = 9.6, 3.6 Hz, 1H), 3.368 (s, 3H), 3.373 (s, 3H), 3.38 (s, 6H), 3.40 (s, 3H), 3.46 (s, 6H), 3.50 (s, 9H), 3.51 (s, 6H), 3.58 (s, 3H), 3.61 (s, 3H), 3.62 (s, 3H), 3.62 (s, 3H), 3.64 (s, 3H), 3.65 (s, 3H), 3.69 (s, 3H), 4.29 (dd, J = 12.3, 3.8 Hz, 1H), 4.49 (dd, J = 12.0, 1.9 Hz, 1H), 4.92 (d, J = 3.5 Hz, 1H), 5.07 (d, J = 3.5 Hz, 1H), 5.074 (d, J = 3.8 Hz, 1H), 5.09 (d, J = 3.5 Hz, 1H), 5.13 (d, J = 3.5 Hz, 1H), 5.20 (d, J = 3.8 Hz, 1H), 5.23 (d, J = 3.8 Hz, 1H); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^I, 4.92 ppm): δ 3.14 (dd, J = 9.0, 2.8 Hz, 1H, H2^I), 3.53 (dd, J = 8.7, 8.7 Hz, 1H, H4^I), 3.59 (dd, J = 9.5, 9.5 Hz, 1H, H3^I); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H6^{II}, 4.29 ppm): δ 3.19 (dd, J = 9.7, 3.9 Hz, 1H, H2^{II}), 3.40 (dd, J = 9.2, 9.2 Hz, 1H, H3^{II}), 3.57 (dd, J = 9.7, 9.7 Hz, 1H, H4^{II}), 4.49 (br d, J = 11.6 Hz, 1H, H6^{II}), 5.08 (d, J = 3.3 Hz, 1H, H1^{II}); ¹H NMR (500 MHz, CDCl₃, 1D-ROESY, irradiation at H1^I, 4.92 ppm): δ 3.14 (dd, J = 9.4, 3.2 Hz, 1H, H2^I), 3.56 (dd, J = 9.4, 9.4 Hz, 1H, H4^{II}); ¹³C NMR (125.7 MHz, CDCl₃): δ 20.84 (CH₃), 57.86 (CH₃), 57.89 (CH₃), 58.09 (CH₃), 58.42 (CH₃), 58.45 (CH₃), 58.72 (CH₃), 58.88 (CH₃), 58.97 (CH₃), 59.00 (2 $\times$ CH₃), 59.07 (CH₃), 59.11 (CH₃), 60.81 (CH₃), 61.02 (CH₃), 61.35 (CH₃), 61.55 (CH₃), 61.66 (CH₃), 61.85 (CH₃), 62.16 (CH₃), 63.36 (CH₂), 64.58 (CH₂), 67.04 (CH), 69.46 (CH), 70.67 (CH), 70.89 (CH), 70.96 (CH), 70.96 (CH₂), 70.99 (CH), 71.03 (CH₂), 71.36 (CH₂), 71.74 (CH₂), 71.83 (CH₂), 77.62 (CH), 78.85 (CH), 79.05 (CH), 80.19 (CH), 80.29 (CH), 80.51 (CH), 80.82 (CH), 81.13 (CH), 81.21 (CH), 81.31 (CH), 81.42 (CH), 81.46 (CH), 81.51 (CH), 81.79 (2 $\times$ CH), 81.80 (CH), 81.83 (CH), 81.98 (CH), 82.27 (CH), 82.35 (CH), 82.67 (CH), 97.02 (CH), 97.81 (CH), 98.95 (CH),

99.02 (CH), 99.03 (CH), 99.39 (CH), 99.49 (CH), 101.12 (C), 170.50 (C); MS (ESI⁺-TOF): *m/z* (%) 1463 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₆₃H₁₀₈NaO₃₆ 1463.6518; found 1463.6530. Anal. calcd for C₆₃H₁₀₈O₃₆: C, 52.49; H, 7.55. Found: C, 52.58; H, 7.63.

Compound **35**: colorless oil, [α]_D +120.3 (*c* 0.64, CHCl₃); IR (film): 2929, 1745, 1454, 1369, 1159, 1107, 1041 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.10 (s, 3H), 3.18 (dd, *J* = 9.8, 3.8 Hz, 4H), 3.25 (dd, *J* = 9.8, 3.8 Hz, 1H), 3.35 (s, 3H), 3.37 (s, 3H), 3.38 (s, 3H), 3.385 (s, 3H), 3.389 (s, 3H), 3.45 (dd, *J* = 9.8, 2.8 Hz, 1H), 3.49 (s, 3H), 3.49 (s, 9H), 3.51 (s, 3H), 3.54 (s, 3H), 3.60 (s, 3H), 3.62 (s, 9H), 3.63 (s, 3H), 3.64 (s, 3H), 3.67 (s, 6H), 3.95 (dd, *J* = 9.5, 9.5 Hz, 1H), 3.99 (ddd, *J* = 9.8, 3.9, 1.7 Hz, 1H), 4.17 (d, *J* = 8.5 Hz, 1H), 4.21 (ddd, *J* = 10.1, 1.9, 1.9 Hz, 1H), 4.29 (dd, *J* = 12.5, 3.9 Hz, 1H), 4.45 (dd, *J* = 12.3, 1.9 Hz, 1H), 5.11 (d, *J* = 3.5 Hz, 1H), 5.12 (d, *J* = 3.8 Hz, 1H), 5.13 (d, *J* = 3.8 Hz, 1H), 5.17 (d, *J* = 3.8 Hz, 1H), 5.23 (d, *J* = 3.8 Hz, 1H), 5.25 (d, *J* = 3.2 Hz, 1H), 5.56 (d, *J* = 3.2 Hz, 1H); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^I, 5.56 ppm): δ 3.45 (dd, *J* = 9.6, 2.9 Hz, 1H, H2^I), 3.96 (dd, *J* = 9.0, 9.0 Hz, 1H, H3^I), 4.18 (d, *J* = 8.8 Hz, 1H, H4^I); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H6^{II}, 4.45 ppm): δ 3.19 (dd, *J* = 9.7, 3.4 Hz, 1H, H2^{II}), 3.57 (dd, *J* = 9.3, 9.3 Hz, 1H, H3^{II}), 3.71 (dd, *J* = 9.5, 9.5 Hz, 1H, H4^{II}), 3.99 (m, 1H, H5^{II}), 4.30 (dd, *J* = 12.4, 3.8 Hz, 1H, H6^{II}), 5.12 (d, *J* = 3.0 Hz, 1H, H1^{II}); ¹³C NMR (125.7 MHz, CDCl₃): δ 20.85 (CH₃), 58.16 (CH₃), 58.22 (CH₃), 58.28 (CH₃), 58.42 (CH₃), 58.62 (CH₃), 58.79 (CH₃), 58.97 (2 × CH₃), 59.02 (CH₃), 59.06 (CH₃), 59.13 (CH₃), 59.18 (CH₃), 60.53 (CH₃), 61.22 (CH₃), 61.23 (CH₃), 61.27 (CH₃), 61.43 (CH₃), 61.47 (2 × CH₃), 62.87 (CH₂), 68.67 (CH), 70.77 (CH₂), 70.77 (CH), 70.88 (CH), 70.90 (CH), 70.92 (CH), 70.99 (CH₂), 71.12 (CH), 71.14 (CH₂), 71.21 (CH₂), 71.41 (CH₂), 78.45 (CH), 78.63 (CH), 78.80 (CH), 79.29 (CH), 79.98 (CH), 80.03 (CH), 80.19 (CH), 80.39 (CH), 80.77 (CH), 81.31 (CH), 81.46 (CH), 81.71 (3 × CH), 81.80 (CH), 81.97 (CH), 82.14 (CH), 82.19 (CH), 82.27 (2 × CH), 82.38 (CH), 97.91 (CH), 98.11 (CH),

98.64 (CH), 99.02 (CH), 99.11 (CH), 99.22 (CH), 99.60 (CH), 168.56 (C), 170.41 (C); MS (ESI⁺-TOF): m/z (%) 1449 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): m/z [M + Na]⁺ calcd for C₆₂H₁₀₆NaO₃₆ 1449.6362; found 1449.6410. Anal. calcd for C₆₂H₁₀₆O₃₆: C, 52.17; H, 7.48. Found: C, 52.46; H, 7.40.

Oxidative HAT of 2^{I-VI},3^{I-VI},6^{III-VI}-hexadeca-O-methyl- α -cyclomaltohexaose (36). A solution of alcohol **36**³⁵ (150 mg, 0.125 mmol) in dry CH₂Cl₂ (5 mL) containing DIB (88 mg, 0.27 mmol) and I₂ (32 mg, 0.125 mmol) was stirred under nitrogen at 28 °C for 1.5 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 65:35→55:45) to give the ten-membered lactone **37** (23 mg, 0.019 mmol, 16%), cyclo-5^{VI},6^I-anhydro-(5^{VI}R)-(2,3,6-tri-*O*-methyl- α -D-xylo-hexos-5-ulopyranosyl)-[(1→4)-2,3-di-*O*-methyl- α -D-glucopyranosyl]₂-[(1→4)-2,3,6-tri-*O*-methyl- α -D-glucopyranosyl]₃ (**38**) (37 mg, 0.031 mmol, 25%), and the lactone-alcohol **39** (14.6 mg, 0.012 mmol, 10%). Compound **37**: colorless oil, [α]_D +131.7 (*c* 1.31, CHCl₃); IR (film): 2929, 1760, 1745, 1454, 1367, 1107, 1046 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.12 (s, 3H), 3.09 (dd, *J* = 9.9, 3.3 Hz, 1H), 3.12 (dd, *J* = 10.1, 3.2 Hz, 1H), 3.17 (dd, *J* = 9.8, 3.5 Hz, 2H), 3.20 (dd, *J* = 10.1, 3.5 Hz, 1H), 3.36 (s, 3H), 3.36 (s, 3H), 3.38 (s, 3H), 3.38 (s, 3H), 3.44 (s, 3H), 3.48 (s, 3H), 3.49 (s, 3H), 3.50 (s, 3H), 3.52 (s, 6H), 3.55 (s, 3H), 3.59 (s, 3H), 3.60 (s, 3H), 3.60 (s, 3H), 3.70 (s, 3H), 3.74 (s, 3H), 3.87 (dd, *J* = 11.0, 3.8 Hz, 1H), 3.92 (dd, *J* = 10.7, 10.7 Hz, 1H), 3.94 (dd, *J* = 10.4, 3.2 Hz, 1H), 4.09 (d, *J* = 5.7 Hz, 1H), 4.33 (ddd, *J* = 10.1, 4.1, 1.6 Hz, 1H), 4.48 (dd, *J* = 10.7, 5.4 Hz, 1H), 4.61 (ddd, *J* = 10.1, 10.1, 5.4 Hz, 1H), 4.95 (d, *J* = 3.5 Hz, 2H), 5.02 (d, *J* = 3.5 Hz, 1H), 5.07 (d, *J* = 3.2 Hz, 2H), 6.37 (d, *J* = 1.3 Hz, 1H); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^I, 6.37 ppm): δ 3.59 (d, *J* = 7.7 Hz, 1H, H2^I), 3.73 (m, 1H, H3^I), 4.09 (d, *J* = 5.8 Hz, 1H, H4^I); ¹H NMR (500 MHz, CDCl₃, 1D-

TOCSY, irradiation at H5^{II}, 4.61 ppm): δ 3.08 (dd, J = 9.9, 3.3 Hz, 1H, H2^{II}), 3.44 (dd, J = 9.1, 9.1 Hz, 1H, H3^{II}), 3.59 (dd, J = 9.6, 9.6 Hz, 1H, H4^{II}), 3.91 (dd, J = 10.6, 10.6 Hz, 1H, H6^{II}), 4.48 (dd, J = 10.8, 5.3 Hz, 1H, H6^{II}), 4.94 (d, J = 2.5 Hz, 1H, H1^{II}); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H5^{VI}, 4.33 ppm): δ 3.19 (dd, J = 9.9, 2.9 Hz, 1H, H2^{VI}), 3.49 (dd, J = 9.6, 9.6 Hz, 1H, H4^{VI}), 3.68 (dd, J = 9.6, 9.6 Hz, 1H, H3^{VI}), 4.94 (d, J = 2.7 Hz, 1H, H1^{VI}); ¹H NMR (500 MHz, CDCl₃, 1D-ROESY, irradiation at H1^I, 6.37 ppm): δ 3.59 (dd, J = 9.3, 9.3 Hz, 1H, H4^{II}), 4.09 (d, J = 5.5 Hz, 1H, H4^I); ¹H NMR (500 MHz, CDCl₃, 1D-ROESY, irradiation at H4^I, 4.09 ppm): δ 4.95 (d, J = 3.5 Hz, 1H, H1^{VI}); ¹³C NMR (125.7 MHz, CDCl₃): δ 21.48 (CH₃), 57.71 (CH₃), 57.76 (CH₃), 58.02 (CH₃), 58.25 (CH₃), 58.33 (CH₃), 58.56 (CH₃), 58.89 (CH₃), 58.91 (CH₃), 58.99 (CH₃), 60.13 (CH₃), 60.68 (CH₃), 61.30 (CH₃), 61.40 (CH₃), 61.66 (CH₃), 61.99 (CH₃), 62.10 (CH₃), 62.60 (CH), 66.24 (CH₂), 70.79 (CH), 70.82 (CH), 71.07 (CH₂), 71.17 (CH), 71.35 (2 $\times$ CH₂), 71.39 (CH), 71.51 (CH₂), 79.60 (CH), 81.04 (CH), 81.11 (2 $\times$ CH), 81.14 (CH), 81.26 (CH), 81.40 (CH), 81.43 (CH), 81.52 (2 $\times$ CH), 81.65 (CH), 81.83 (2 $\times$ CH), 81.90 (CH), 81.96 (2 $\times$ CH), 82.33 (CH), 83.00 (CH), 94.66 (CH), 98.56 (CH), 98.90 (CH), 99.53 (CH), 99.64 (CH), 99.80 (CH), 170.02 (C), 170.23 (C); MS (ESI⁺-TOF): m/z (%) 1245 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): m/z [M + Na]⁺ calcd for C₅₃H₉₀NaO₃₁ 1245.5364; found 1245.5369. Anal. calcd for C₅₃H₉₀O₃₁: C, 52.04; H, 7.42. Found: C, 52.15; H, 7.33. Compound **38**: colorless oil, [α]_D +134.3 (c 1.32, CHCl₃); IR (film): 3475, 2929, 1454, 1367, 1139, 1107, 1046 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.10–3.17 (m, 4H), 3.19 (dd, J = 9.9, 3.3 Hz, 1H), 3.25 (dd, J = 9.8, 3.2 Hz, 1H), 3.35 (s, 3H), 3.36 (s, 3H), 3.369 (s, 3H), 3.372 (s, 3H), 3.46 (s, 6H), 3.48 (s, 3H), 3.49 (s, 3H), 3.50 (s, 3H), 3.51 (s, 3H), 3.58 (s, 3H), 3.60 (s, 3H), 3.62 (s, 3H), 3.64 (s, 3H), 3.70 (s, 3H), 3.73 (s, 3H), 5.00 (d, J = 3.8 Hz, 1H), 5.01 (d, J = 3.8 Hz, 1H), 5.025 (d, J = 3.8 Hz, 1H), 5.033 (d, J = 4.1 Hz, 1H), 5.06 (d, J = 3.2 Hz, 1H), 5.18 (d, J = 3.5 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.66

(CH₃), 57.82 (CH₃), 57.94 (2 × CH₃), 58.34 (CH₃), 58.51 (CH₃), 58.74 (CH₃), 58.79 (CH₃), 59.07 (CH₃), 59.14 (CH₃), 61.26 (CH₃), 61.44 (CH₃), 61.52 (CH₃), 61.86 (CH₂), 61.93 (CH₃), 61.98 (CH₃), 62.24 (CH₃), 63.80 (CH₂), 66.28 (CH), 70.90 (CH), 70.93 (CH), 71.24 (CH₂), 71.57 (CH), 71.80 (CH₂), 71.82 (CH₂), 71.94 (CH₂), 72.04 (CH), 78.29 (CH), 80.35 (CH), 80.56 (CH), 80.74 (CH), 80.96 (CH), 81.03 (CH), 81.07 (CH), 81.26 (CH), 81.40 (2 × CH), 81.72 (CH), 81.96 (CH), 82.01 (2 × CH), 82.23 (CH), 82.31 (CH), 82.59 (CH), 82.72 (CH), 97.35 (CH), 97.79 (CH), 98.77 (CH), 99.62 (CH), 99.90 (CH), 100.07 (CH), 100.81 (C); MS (ESI⁺-TOF): *m/z* (%) 1217 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₅₂H₉₀NaO₃₀ 1217.5415; found 1217.5419. Anal. calcd for C₅₂H₉₀O₃₀: C, 52.25; H, 7.59. Found: C, 52.43; H, 7.61. Compound **39**: colorless oil, [α]_D +111.4 (c 0.96, CHCl₃); IR (film): 3468, 2929, 1757, 1454, 1367, 1137, 1109, 1044 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.13–3.20 (m, 3H), 3.23 (dd, *J* = 9.8, 3.5 Hz, 1H), 3.38 (s, 3H), 3.385 (s, 6H), 3.39 (s, 3H), 3.48 (s, 6H), 3.49 (s, 3H), 3.50 (s, 3H), 3.51 (s, 3H), 3.58 (s, 3H), 3.63 (s, 6H), 3.64 (s, 3H), 3.65 (s, 3H), 3.66 (s, 3H), 3.69 (s, 3H), 3.87 (dd, *J* = 8.5, 8.5 Hz, 1H), 4.03 (d, *J* = 8.5 Hz, 1H), 4.08–4.15 (m, 1H), 4.24 (ddd, *J* = 10.1, 2.8, 1.6 Hz, 1H), 5.06 (d, *J* = 3.5 Hz, 2H), 5.065 (d, *J* = 3.8 Hz, 1H), 5.12 (d, *J* = 3.5 Hz, 1H), 5.16 (d, *J* = 3.5 Hz, 1H), 5.47 (d, *J* = 2.8 Hz, 1H); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^I, 5.47 ppm): δ 3.45 (dd, *J* = 10.0, 2.7 Hz, 1H, H2^I), 3.88 (dd, *J* = 9.3, 9.3 Hz, 1H, H3^I), 4.03 (d, *J* = 8.7 Hz, 1H, H4^I); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H5^{VI}, 4.24 ppm): δ 3.24 (dd, *J* = 9.7, 3.6 Hz, 1H, H2^{VI}), 3.60 (dd, *J* = 10.0, 9.4 Hz, 1H, H4^{VI}), 3.69 (dd, *J* = 9.4, 9.4 Hz, 1H, H3^{VI}), 3.89 (dd, *J* = 10.7, 3.1 Hz, 1H, H6^{VI}), 5.17 (d, *J* = 2.9 Hz, 1H, H1^{VI}); ¹H NMR (500 MHz, CDCl₃, 1D-ROESY, irradiation at H4^I, 4.03 ppm): δ 5.16 (d, *J* = 3.4 Hz, 1H, H1^{VI}); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.91 (4 × CH₃), 58.35 (CH₃), 58.91 (2 × CH₃), 58.98 (2 × CH₃), 59.14 (CH₃), 61.24 (CH₃), 61.56 (CH₃), 61.56 (CH₂), 61.62 (CH₃), 61.65 (CH₃), 61.75 (2 × CH₃), 71.08 (2 × CH),

71.08 (CH₂), 71.13 (CH), 71.21 (CH₂), 71.25 (CH₂), 71.34 (CH₂), 71.36 (CH), 71.65 (CH), 80.02 (CH), 80.13 (CH), 80.29 (CH), 81.20 (CH), 81.23 (CH), 81.26 (CH), 81.34 (CH), 81.51 (CH), 81.78 (CH), 81.84 (2 × CH), 81.89 (CH), 81.97 (CH), 82.01 (CH), 82.11 (2 × CH), 82.16 (CH), 82.32 (CH), 99.26 (CH), 99.39 (CH), 99.68 (CH), 99.74 (CH), 100.34 (CH), 100.37 (CH), 169.42 (C); MS (ESI⁺-TOF): *m/z* (%) 1203 [(M + Na)⁺, 100] HRMS (ESI⁺-TOF): *m/z* [M + Na]⁺ calcd for C₅₁H₈₈NaO₃₀ 1203.5258; found 1203.5254. Anal. calcd for C₅₁H₈₈O₃₀: C, 51.86; H, 7.51. Found: C, 51.74; H, 7.40.

Methyl 6-O-tert-Butyldiphenylsilyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl-(1→4)-6-O-tert-butyldiphenylsilyl-2,3-di-O-methyl-β-D-glucopyranoside (40β) and Methyl 6-O-tert-Butyldiphenylsilyl-2,3,4-tri-O-methyl-α-D-glucopyranosyl-(1→4)-6-O-tert-butyldiphenylsilyl-2,3-di-O-methyl-α-D-glucopyranoside (40α). To a solution of dry D-(+)-maltose (5 g, 14.6 mmol), imidazole (8.9 g, 131.6 mmol), and DMAP (8.9 g, 73.1 mmol) in dry DMF (75 mL) was added TBDPSCl (22.8 mL, 87.7 mmol) at 0 °C. The mixture was stirred at room temperature for 20 h, poured into water, and extracted with CH₂Cl₂. The organic phase was washed with HCl (10%), saturated aqueous NaHCO₃, and concentrated under reduced pressure to give a residue that was dried over P₂O₅ in a high vacuum desiccator for 24 h and used in the subsequent reaction as a mixture without further purification. NaH (60%, 7 g, 175 mmol) was added in portions to a solution of the crude residue (32 g) in dry DMF (1 mL) cooled to 0 °C and the mixture stirred at this temperature for 1 h. MeI (13.7 mL, 219.3 mmol) was then added dropwise and the stirring continued for 3 h at room temperature. The excess of NaH was destroyed with MeOH and the mixture poured into water, extracted with CH₂Cl₂ and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexanes–EtOAc, 9:1→8:2) and only the disilylated anomeric isomers **40β** (4.3 g, 4.76 mmol, 33%) and **40α** (1.6 g, 1.78 mmol, 12%)

were studied. Compound **40β**: $R_f = 0.49$ (*n*-hexane–EtOAc, 7:3), colorless oil, $[\alpha]_D +44.5$ (*c* 1.19, CHCl₃); IR (film): 2933, 1148, 1104 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 0.94 (s, 9H), 1.00 (s, 9H), 3.04 (dd, $J = 9.1, 7.9$ Hz, 1H), 3.12 (dd, $J = 9.6, 3.9$ Hz, 1H), 3.31 (m, 1H), 3.39 (m, 3H), 3.45 (dd, $J = 8.8, 8.8$ Hz, 1H), 3.48 (m, 2H), 3.53 (s, 3H), 3.53 (s, 3H), 3.57 (s, 3H), 3.59 (s, 3H), 3.60 (s, 3H), 3.64 (s, 3H), 3.66 (dd, $J = 9.8, 8.8$ Hz, 1H), 3.74 (dd, $J = 11.0, 5.7$ Hz, 1H), 3.85 (dd, $J = 11.0, 2.2$ Hz, 1H), 4.17 (d, $J = 7.6$ Hz, 1H), 5.55 (d, $J = 4.1$ Hz, 1H), 7.15–7.66 (m, 20H); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^I, 4.17 ppm): δ 3.04 (dd, $J = 8.8, 8.1$ Hz, 1H, H2^I), 3.41 (m, 1H, H5^I), 4.45 (dd, $J = 8.9, 8.9$ Hz, 1H, H3^I), 3.66 (dd, $J = 9.3, 9.3$ Hz, 1H, H4^I), 3.74 (dd, $J = 11.2, 5.9$ Hz, 1H, H6a^I), 3.84 (dd, $J = 10.9, 2.3$ Hz, 1H, H6b^I); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^{II}, 5.55 ppm): δ 3.11 (dd, $J = 9.3, 3.4$ Hz, 1H, H2^{II}), 3.31 (m, 1H, H5^{II}), 3.37 (m, 2H, H3^{II} and H4^{II}), 3.46 (br d, $J = 11.1$ Hz, 1H, H6a^{II}), 3.52 (br d, $J = 11.3$ Hz, 1H, H6b^{II}); ¹³C NMR (125.7 MHz, CDCl₃): δ 19.23 (C), 19.31 (C), 26.79 (3 × CH₃), 26.81 (3 × CH₃), 56.67 (CH₃), 59.15 (CH₃), 59.58 (CH₃), 60.16 (CH₃), 60.18 (CH₃), 60.71 (CH₃), 62.14 (CH₂), 63.61 (CH₂), 71.89 (CH), 72.06 (CH), 75.11 (CH), 78.84 (CH), 81.90 (CH), 83.38 (CH), 83.77 (CH), 86.41 (CH), 96.12 (CH), 104.04 (CH), 127.43 (2 × CH), 127.47 (2 × CH), 127.49 (2 × CH), 127.54 (2 × CH), 129.36 (CH), 129.43 (CH), 129.47 (2 × CH), 133.27 (C), 133.34 (C), 133.72 (C), 133.86 (C), 135.38 (2 × CH), 135.56 (2 × CH), 135.77 (4 × CH); MS (ESI⁺-TOF): m/z (%) 925 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): m/z [M + Na]⁺ calcd for C₅₀H₇₀NaO₁₁Si₂ 925.4354; found 925.4366. Anal. calcd for C₅₀H₇₀O₁₁Si₂: C, 66.49; H, 7.81. Found: C, 66.75; H, 7.93. Compound **40α**: $R_f = 0.42$ (*n*-hexane–EtOAc, 7:3), colorless oil, $[\alpha]_D +86.3$ (*c* 1.067, CHCl₃); IR (film): 2933, 1156, 1104, 1029 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 0.94 (s, 9H), 0.99 (s, 9H), 3.11 (dd, $J = 9.8, 4.1$ Hz, 1H), 3.17 (dd, $J = 9.6, 3.6$ Hz, 1H), 3.36 (s, 3H), 3.51 (s, 6H), 3.56 (s, 3H), 3.60 (s, 3H), 3.63 (s, 3H), 4.78 (d, $J = 3.5$ Hz, 1H), 5.55 (d, $J = 4.1$ Hz, 1H), 7.16–7.66 (m, 20H); ¹³C NMR

(125.7 MHz, CDCl₃): δ 19.24 (C), 19.30 (C), 26.81 (6 $\times$ CH₃), 54.59 (CH₃), 58.69 (CH₃), 59.52 (CH₃), 60.00 (CH₃), 60.14 (CH₃), 60.70 (CH₃), 62.22 (CH₂), 63.63 (CH₂), 70.66 (CH), 71.92 (CH), 72.48 (CH), 78.86 (CH), 81.93 (CH), 82.43 (CH), 83.37 (CH), 83.52 (CH), 96.27 (CH), 96.50 (CH), 127.42 (2 $\times$ CH), 127.44 (2 $\times$ CH), 127.46 (2 $\times$ CH), 127.53 (2 $\times$ CH), 129.35 (CH), 129.39 (CH), 129.43 (CH), 129.45 (CH), 133.38 (C), 133.41 (C), 133.77 (C), 133.88 (C), 135.48 (2 $\times$ CH), 135.60 (2 $\times$ CH), 135.72 (2 $\times$ CH), 135.80 (2 $\times$ CH); MS (ESI⁺-TOF): m/z (%) 925 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): m/z [M + Na]⁺ calcd for C₅₀H₇₀NaO₁₁Si₂ 925.4354; found 925.4358. Anal. calcd for C₅₀H₇₀O₁₁Si₂: C, 66.49; H, 7.81. Found: C, 66.10; H, 7.92.

Methyl 2,3,4-Tri-O-methyl- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-2,3-di-O-methyl- β -D-glucopyranoside (41). To a solution of **40 β** (2 g, 2.2 mmol) in THF (50 mL) was added TBAF (1 M in THF, 6.6 mL, 6.6 mmol) and the mixture stirred at room temperature for 7 h. The THF was removed under vacuum and the resulting oil purified by column chromatography (hexanes–EtOAc, 3:7 $\rightarrow$ EtOAc) to give the compound **41** (675 mg, 1.58 mmol, 72%) as a colorless oil; [α]_D +74.1 (*c* 1.077, CHCl₃); IR (film): 3460, 2936, 1144, 1081, 1029 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 3.00 (dd, *J* = 9.8, 8.8 Hz, 1H), 3.03 (dd, *J* = 9.1, 7.9 Hz, 1H), 3.15 (dd, *J* = 9.8, 4.1 Hz, 1H), 3.35 (ddd, *J* = 9.8, 2.8, 2.8 Hz, 1H), 3.43 (dd, *J* = 10.4, 9.1 Hz, 1H), 3.43 (dd, *J* = 8.8, 8.8 Hz, 1H), 3.52 (s, 3H), 3.53 (s, 3H), 3.55 (s, 3H), 3.57 (s, 3H), 3.58 (s, 3H), 3.60 (s, 3H), 3.63 (s, 3H), 3.65 (dd, *J* = 11.4, 6.0 Hz, 1H), 3.81 (dd, *J* = 12.3, 2.8 Hz, 1H), 3.85 (dd, *J* = 12.3, 3.2 Hz, 1H), 3.85 (dd, *J* = 11.7, 2.2 Hz, 1H), 3.88 (dd, *J* = 9.5, 9.5 Hz, 1H), 4.19 (d, *J* = 7.9 Hz, 1H), 5.61 (d, *J* = 4.1 Hz, 1H); ¹³C NMR (125.7 MHz, CDCl₃): δ 57.0 (CH₃), 59.9 (CH₃), 60.1 (CH₃), 60.2 (CH₃), 60.6 (CH₃), 60.8 (CH₃), 60.9 (CH₂), 61.9 (CH₂), 71.3 (CH), 72.2 (CH), 74.2 (CH), 80.5 (CH), 81.8 (CH), 83.5 (CH), 84.3 (CH), 86.5 (CH), 96.5 (CH), 104.3 (CH); MS (ESI⁺-TOF): m/z (%) 449 [(M + Na)⁺, 100]; HRMS

(ESI⁺-TOF): m/z $[M + Na]^+$ calcd for C₁₈H₃₄NaO₁₁ 449.1999; found 449.1994. Anal. calcd for C₁₈H₃₄O₁₁: C, 50.70; H, 8.04. Found: C, 50.35; H, 8.24.

Oxidative HAT of Methyl 2,3,4-Tri-O-methyl- α -D-glucopyranosyl-(1 $\rightarrow$ 4)-2,3-di-O-methyl- β -D-glucopyranoside (41). A solution of alcohol **41** (100 mg, 0.235 mmol) in dry CH₂Cl₂ (9.4 mL) containing DIB (166.5 mg, 0.516 mmol) and I₂ (60 mg, 0.235 mmol) was stirred under nitrogen at 32 °C for 3 h while irradiated with two 80 W tungsten-filament lamps. The reaction mixture was then directly loaded onto a silica gel (TLC Silica gel 60 F₂₅₄, scraped from Merck Aluminum sheets) column chromatography (hexanes–acetone, 60:40 $\rightarrow$ 25:75) to give the ten-membered lactone **42** (11 mg, 0.024 mmol, 9%) and the acetyl-derivative **43** (11 mg, 0.023 mmol, 10%). Compound **42**: colorless oil, $[\alpha]_D -24.2$ (c 0.520, CHCl₃); IR (film): 2938, 1746, 1455, 1372, 1126, 1095 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.13 (s, 3H), 2.89 (dd, J = 9.3, 7.7 Hz, 1H, H2^{II}), 3.15 (dd, J = 8.8, 8.8 Hz, 1H, H3^{II}), 3.31 (dd, J = 7.7, 2.0 Hz, 1H, H2^I), 3.45 (s, 3H), 3.49 (s, 3H), 3.53 (s, 3H), 3.56 (dd, J = 8.4, 8.4 Hz, 1H, H3^I), 3.59 (s, 3H), 3.60 (s, 3H), 3.61 (s, 3H), 3.62 (dd, J = 9.1, 9.1 Hz, 1H, H4^{II}), 3.75 (d, J = 8.8 Hz, 1H, H4^I), 3.80 (ddd, J = 9.8, 9.8, 5.4 Hz, 1H, H5^{II}), 4.12 (d, J = 7.9 Hz, 1H, H1^{II}), 4.18 (dd, J = 11.4, 9.8 Hz, 1H, H6^{II}), 4.59 (dd, J = 11.2, 5.2 Hz, 1H, H6^{II}), 6.23 (d, J = 2.2 Hz, 1H, H1^I); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^I, 6.23 ppm): δ 3.31 (dd, J = 7.8, 1.9 Hz, 1H, H2^I), 3.56 (dd, J = 8.4, 8.4 Hz, 1H, H3^I), 3.76 (d, J = 8.7 Hz, 1H, H4^I); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H2^{II}, 2.89 ppm): δ 3.15 (dd, J = 8.9, 8.9 Hz, 1H, H3^{II}), 3.63 (dd, J = 9.2, 9.2 Hz, 1H, H4^{II}), 3.81 (ddd, J = 9.3, 9.3, 5.4 Hz, 1H, H5^{II}), 4.13 (d, J = 7.8 Hz, 1H, H1^{II}), 4.19 (dd, J = 10.6, 10.6 Hz, 1H, H6^{II}), 4.60 (dd, J = 11.0, 5.2 Hz, 1H, H6^{II}); ¹³C NMR (125.7 MHz, CDCl₃): δ 21.34 (CH₃), 57.08 (CH₃), 59.00 (CH₃), 60.43 (CH₃), 61.64 (2 $\times$ CH₃), 62.00 (CH₃), 65.14 (CH₂, C6^{II}), 67.32 (CH, C5^{II}), 81.51 (CH, C4^I), 82.37 (CH, C4^{II}), 83.04 (CH, C3^I), 83.22 (CH, C2^{II}), 83.88 (CH, C2^I), 84.71 (CH, C3^{II}), 94.51 (CH, C1^I), 103.82 (CH,

C1^{II}), 170.32 (C), 170.60 (C); MS (ESI⁺-TOF): m/z (%) 475 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): m/z [M + Na]⁺ calcd for C₁₉H₃₂NaO₁₂ 475.1791; found 475.1793. Anal. calcd for C₁₉H₃₂O₁₂: C, 50.44; H, 7.13. Found: C, 50.16; H, 7.21. Compound **43**: colorless oil, [α]_D +43.8 (*c* 0.820, CHCl₃); IR (film): 3520, 2933, 1745, 1456, 1369, 1107, 1081, 1055 cm⁻¹; ¹H NMR (500 MHz, CDCl₃): δ 2.05 (s, 3H), 3.05 (dd, J = 9.1, 7.6 Hz, 1H, H2^{II}), 3.29 (ddd, J = 9.8, 3.0, 3.0 Hz, 1H, H5^{II}), 3.34 (dd, J = 9.0, 9.0 Hz, 1H, H3^{II}), 3.47 (s, 3H), 3.52 (s, 3H), 3.56 (s, 3H), 3.58 (s, 3H), 3.61 (s, 3H), 3.78 (dd, J = 9.5, 9.5 Hz, 1H, H4^{II}), 3.86 (dd, J = 12.3, 2.8 Hz, 1H, H6^{II}), 3.94 (d, J = 12.0 Hz, 1H, H6^I), 4.09 (dd, J = 12.3, 3.2 Hz, 1H, H6^{II}), 4.09 (d, J = 1.6 Hz, 1H, H4^I), 4.18 (d, J = 7.6 Hz, 1H, H1^{II}), 4.59 (d, J = 11.7 Hz, 1H, H6^I), 4.69 (d, J = 6.3 Hz, 1H), 5.09 (d, J = 6.3 Hz, 1H), 5.58 (d, J = 2.5 Hz, 1H, H1^I); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H2^{II}, 3.05 ppm): δ 3.29 (ddd, J = 9.9, 2.9, 2.9 Hz, 1H, H5^{II}), 3.34 (dd, J = 9.0, 9.0 Hz, 1H, H3^{II}), 3.78 (dd, J = 9.4, 9.4 Hz, 1H, H4^{II}), 3.86 (dd, J = 12.2, 3.4 Hz, 1H, H6^{II}), 4.09 (dd, J = 12.0, 2.4 Hz, 1H, H6^{II}), 4.18 (d, J = 7.6 Hz, 1H, H1^{II}); ¹H NMR (500 MHz, CDCl₃, 1D-TOCSY, irradiation at H1^I, 5.58 ppm): δ 3.62 (m, 2H, H2^I and H3^I), 5.58 (d, J = 2.8 Hz, 1H, H4^I); ¹³C NMR (125.7 MHz, CDCl₃): δ 21.89 (CH₃), 56.82 (CH₃), 57.88 (CH₃), 59.83 (CH₃), 60.23 (CH₃), 60.43 (CH₃), 61.17 (CH₂, C6^{II}), 71.11 (CH₂, C6^I), 74.44 (CH, C4^I), 74.66 (CH, C5^{II}), 75.13 (CH, C4^{II}), 76.40 (CH, C2^I or C3^I), 79.17 (CH, C2^I or C3^I), 84.11 (CH, C2^{II}), 86.22 (CH, C3^{II}), 92.88 (CH₂), 96.45 (C, C5^I), 97.16 (CH, C1^I), 104.29 (CH, C1^{II}), 168.79 (C); MS (ESI⁺-TOF): m/z (%) 505 [(M + Na)⁺, 100]; HRMS (ESI⁺-TOF): m/z [M + Na]⁺ calcd for C₂₀H₃₄NaO₁₃ 505.1897; found 505.1905. Anal. calcd for C₂₀H₃₄O₁₃: C, 49.79; H, 7.10. Found: C, 49.46; H, 7.15.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the [ACS Publications website](#) at DOI:

The material includes crystal structure of **15**; copies of spectra for all new compounds; absolute energy and Cartesian coordinates of minimized structures of compounds **32** and **38** (PDF).

Crystallographic data (CIF).

AUTHOR INFORMATION

Corresponding Author

*angelesmartin@ipna.csic.es

*esuares@ipna.csic.es

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

Financial support by the Investigation Programs of the Ministerio de Economía y Competitividad (CTQ2010-18244), Fundación CajaCanarias (2015-BIO08) and the COST Action CM1201 “Biomimetic Radical Chemistry” is acknowledged. D.A.-D. thanks the Ministerio de Economía y Competitividad for a fellowship. We thank Dr. Shinya Fushinobu (University of Tokyo, <http://www.ric.hi-ho.ne.jp/asfushi/>) for access to the Cremer–Pople parameter calculator.

REFERENCES:

- (1) For reviews on cyclodextrins and their applications, see: (a) Delbianco, M.; Bharate, P.; Varela-Aramburu, S.; Seeberger, P. H. *Chem. Rev.* **2016**, *116*, 1693–1752. (b) Crini, G. *Chem. Rev.* **2014**, *114*, 10940–10975. (c) Todres, Z. V. In *Organic Chemistry in Confining Media*; Springer, Switzerland, **2013**, chap. 1, pp. 1–63. (d) Davis, F.; Higson, S. In *Macrocycles: Construction, Chemistry and Nanotechnology Applications*; John Wiley & Sons, **2011**, pp. 190–254. (e) *Cyclodextrins and Their Complexes*; Dodziuk, H. Ed.; Wiley-VCH: Weinheim, **2006**.
- (2) (a) Simões, S. M. N.; Rey-Rico, A.; Concheiro, A.; Alvarez-Lorenzo, C. *Chem. Commun.* **2015**, *51*, 6275–6289. (b) Rodríguez-Lavado, J.; de la Mata, M.; Jiménez-Blanco, J. L.; García-Moreno, M. I.; Benito, J. M.; Díaz-Quintana, A.; Sánchez-Alcázar, J. A.; Higaki, K.; Nanba, E.; Ohno, K.; Suzuki, Y.; Ortiz Mellet, C.; García Fernández, J. M. *Org. Biomol. Chem.* **2014**, *12*, 2289–2301. (c) Otero-Espinar, F. J.; Blanco-Méndez, J. *Curr. Top. Med. Chem.* **2014**, *14*, 463–551. (d) Ortiz Mellet, C.; García Fernández, J. M.; Benito, J. M. *Chem. Soc. Rev.* **2011**, *40*, 1586–1608. (e) Ortiz Mellet, C.; Benito, J. M.; García Fernández, J. M. *Chem. Eur. J.* **2010**, *16*, 6728–6742. (f) Laza-Knoerr, A. L.; Gref, R.; Couvreur, P. *J. Drug Targeting* **2010**, *18*, 645–656.
- (3) (a) Raynal, M.; Ballester, P.; Vidal-Ferran, A.; van Leeuwen, P. W. N. M. *Chem. Soc. Rev.* **2014**, *43*, 1734–1787. (b) Pedersen, C. M.; Bols, M. In *Organic Synthesis and Molecular Engineering*; Nielsen, M. B. Ed.; Wiley: Hoboken, **2013**; pp. 305–332. (c) Zhou, Y.; Pedersen, C. M.; Bols, M. *Tetrahedron Lett.* **2013**, *54*, 2458–2461. (d) Zhou, Y.; Marinescu, L.; Pedersen, C. M.; Bols, M. *Eur. J. Org. Chem.* **2012**, 6383–6389. (e) Breslow, R. In *Artificial Enzymes*; Wiley-VCH: Weinheim, **2005**.
- (4) (a) Hapiot, F.; Bricout, H.; Menuel, S.; Tilloy, S.; Monflier, E. *Catal. Sci. Technol.* **2014**, *4*, 1899–1908. (b) Kanagaraj, K.; Pitchumani, K. *J. Org. Chem.* **2013**, *78*, 744–751, (c) Liang, L.; Diallo, A. K.; Salmon, L.; Ruiz, J.; Astruc, D. *Eur. J. Inorg. Chem.* **2012**, 2950–2958. (d) Senra, J.

D.; Malta, L. F. B.; Aguiar, L. C. S.; Simas, A. B. C.; Antunes, O. A. C. *Curr. Org. Chem.* **2010**, *14*, 1337–1355. (e) Hapiot, F.; Tilloy, S.; Monflier, E. *Chem. Rev.* **2006**, *106*, 767–781.

(5) For recent examples on modified cyclodextrins, see: (a) Menuel, S.; Dourmert, B.; Saitzek, S.; Ponchel, A.; Delevoye, L.; Monflier, E.; Hapiot, F. *J. Org. Chem.* **2015**, *80*, 6259–6266. (b) Gallego-Yerga, L.; González-Álvarez, M. J.; Mayordomo, N.; Santoyo-González, F.; Benito, J. M.; Ortiz Mellet, C.; Mendicuti, F.; García Fernández, J. M. *Chem. Eur. J.* **2014**, *20*, 6622–6627. (c) Balbuena, P.; Gonçalves-Pereira, R.; Jiménez Blanco, J. L.; García-Moreno, M. I.; Lesur, D.; Ortiz Mellet, C.; García Fernández, J. M. *J. Org. Chem.* **2013**, *78*, 1390–1403. (d) Xiao, S.; Yang, M.; Yu, F.; Zhang, L.; Zhou, D.; Sinaÿ, P.; Zhang, Y. *Tetrahedron* **2013**, *69*, 4053–4060. (e) Zhang, P.; Wing, A.; Cui, L.; Ling, C.-C. *Org. Lett.* **2012**, *14*, 1612–1615. (f) Ghosh, R.; Zhang, P.; Wang, A.; Ling, C.-C. *Angew. Chem., Int. Ed.* **2012**, *51*, 1548–1552. For a review, see: (g) Guieu, S.; Sollogoub, M. In *Modern Synthetic Methods in Carbohydrate Chemistry: From Monosaccharides to Complex Glycoconjugates*; Werz, D. B.; Vidal, S. Eds.; Wiley-VCH: Weinheim, **2013**, pp. 241–283.

(6) (a) Prochowicz, D.; Kornowicz, A.; Justyniak, I.; Lewiński, J. *Coord. Chem. Rev.* **2016**, *306*, 331–345. (b) Harada, A.; Takashima, Y.; Nakahata, M. *Acc. Chem. Res.* **2014**, *47*, 2128–2140. (c) Zerkoune, L.; Angelova, A.; Lesieur, S. *Nanomaterials* **2014**, *4*, 741–765. (d) Gallego-Yerga, L.; Lomazzi, M.; Sansone, F.; Ortiz Mellet, C.; Casnati, A.; García Fernández, J. M. *Chem. Commun.* **2014**, *50*, 7440–7443. (e) Engeldinger, E.; Armspach, D.; Matt, D. *Chem. Rev.* **2003**, *103*, 4147–4173.

(7) (a) Gattuso, G.; Nepogodiev, S. A.; Stoddart, J. F. *Chem. Rev.* **1998**, *98*, 1919–1958. (b) Asthon, P. R.; Gattuso, G.; Königer, R.; Stoddart, J. F.; Williams, D. J. *J. Org. Chem.* **1996**, *61*, 9553–9555. (c) Yamamura, H.; Masuda, H.; Kawase, Y.; Kawai, M.; Butsugan, Y.; Einaga, H. *Chem. Commun.* **1996**, 1069–1070. (d) Asthon, P. R.; Boyd, S. E.; Gattuso, G.; Hartwell, E. Y.; Königer, R.;

- Spencer, N.; Stoddart, J. F. *J. Org. Chem.* **1995**, *60*, 3898–3903. (e) Asthon, P. R.; Ellwood, P.; Staton, I.; Stoddart, J. F. *J. Org. Chem.* **1991**, *56*, 7274–7280. (f) Gadelle, A.; Defaye, J. *Angew. Chem., Int. Ed. Engl.* **1991**, *30*, 78–80. (g) Fujita, K.; Yamamura, H.; Imoto, T.; Tabushi, I. *Chem. Lett.* **1988**, *17*, 543–546.
- (8) (a) Lindner, H. J.; Yuan, D.-Q.; Fujita, K.; Kubo, K.; Lichtenthaler, F. W. *Chem. Commun.* **2003**, 1730–1731. (b) Fujita, K.; Chen, W.-H.; Yuan, D.-Q.; Nogami, Y.; Koga, T.; Fujioka, T.; Mihashi, K.; Immel, S.; Lichtenthaler, F. W. *Tetrahedron: Asymmetry* **1999**, *10*, 1689–1696. (c) Ikeda, H.; Nagano, Y.; Du, Y.; Ikeda, T.; Toda, F. *Tetrahedron Lett.* **1990**, *31*, 5045–5048.
- (9) (a) Ohta, K.; Fujita, K.; Shimada, H.; Ikegami, Y.; Nogami, Y.; Koga, T. *Chem. Phar. Bull.* **1997**, *45*, 631–635. (b) Nogami, Y.; Nasu, K.; Koga, T.; Ohta, K.; Fujita, K.; Immel, S.; Lindner, H. J.; Schmitt, G. E.; Lichtenthaler, F. W. *Angew. Chem., Int. Ed. Engl.* **1997**, *36*, 1899–1902. (c) Fujita, K.; Shimada, H.; Ohta, K.; Nogami, Y.; Nasu, K.; Koga, T. *Angew. Chem., Int. Ed. Engl.* **1995**, *34*, 1621–1622.
- (10) (a) Caira, M. R.; Griffith, V. J.; Nassimbeni, L. R.; van Oudtshoorn, B. *J. Chem. Soc., Perkin Trans. 2*, **1994**, 2071–2072. (b) Steiner, T.; Saenger, W. *Angew. Chem. Int. Ed.* **1998**, *37*, 3404–3407.
- (11) (a) Frihed, T. G.; Bols, M.; Pedersen, C. M. *Eur. J. Org. Chem.* **2016**, 2740–2756. (b) Bouladakis-Arapinis, M.; Lescot, C.; Micouin, L.; Lecourt, T. *Synlett* **2013**, *24*, 2477–2491. (c) Pérez-Martín, I.; Suárez, E. In *Encyclopedia of Radicals in Chemistry, Biology and Materials*; Chatgililoglu, C.; Studer, A. Eds.; Wiley: Chichester, **2012**; Vol. 2, pp. 1131–1174.
- (12) Gilbert, B. C.; Smith, J. R. L.; Taylor, P.; Ward, S.; Whitwood, A. C. *J. Chem. Soc., Perkin Trans. 2* **2000**, 2001–2007.
- (13) (a) Francisco, C. G.; Herrera, A. J.; Kennedy, A. R.; Martín, A.; Melián, D.; Pérez-Martín, I.; Quintanal, L. M.; Suárez, E. *Chem. Eur. J.* **2008**, *14*, 10369–10381. (b) Martín, A. Pérez-Martín,

I.; Quintanal, L. M.; Suárez, E. *Org. Lett.* **2007**, *9*, 1785–1788. (c) Francisco, C. G.; Herrera, A. J.; Kennedy, A. R.; Melián, D.; Suárez, E. *Angew. Chem. Int. Ed.* **2002**, *41*, 856–858. For a recent review on HAT, see: (d) Nechab, M.; Mondal, S.; Bertrand, M. P. *Chem. Eur. J.* **2014**, *20*, 16034–16059.

(14) Since it is generally accepted that a narrow range of distances of approximately 2.5–3.0 Å are required for the abstraction to take place, the distances between the O6 and the extractable hydrogens are indicative of HAT reaction feasibility. (a) Feray, L.; Kuznetsov, N.; Renaud, P. In *Radicals in Organic Synthesis*; Renaud, P.; Sibi, M. P. Eds.; Wiley-VCH: Weinheim, **2001**; Vol. 2, pp. 246–278. (b) Dorigo, A. E.; Houk, K. N. *J. Am. Chem. Soc.* **1987**, *109*, 2195–2197. (c) Dorigo, A. E.; Houk, K. N. *J. Org. Chem.* **1988**, *53*, 1650–1664. (d) Dorigo, A. E.; McCarrick, M. A.; Loncharich, R. J.; Houk, K. N. *J. Am. Chem. Soc.* **1990**, *112*, 7508–7514.

(15) Steiner, T. Saenger, W. *Angew. Chem. Int. Ed.* **1998**, *37*, 3404–3407.

(16) Alvarez-Dorta, D.; León, E. I.; Kennedy, A. R.; Martín, A.; Pérez-Martín, I.; Suárez, E. *Angew. Chem. Int. Ed.* **2015**, *54*, 3674–3678.

(17) (a) Chen, Z.; Bradshaw, J. S.; Shen, Y.-F.; Habata, Y.; Lee, M. L. *J. Org. Chem.* **1997**, *62*, 8529–8534. (b) Chen, Z.; Bradshaw, J. S.; Lee, M. L. *Tetrahedron Lett.* **1996**, *37*, 6831–6834. (c) Yi, G.; Bradshaw, J. S.; Rossiter, B. E.; Malik, A.; Li, W.; Petersson, P.; Markides, K. E.; Lee, M. L. *J. Org. Chem.* **1993**, *58*, 4844–4850. For other procedures for the synthesis of mono- and dihydroxyl permethylated CDs, see: (d) Lecourt, T.; Mallet, J.-M.; Sinaÿ, P. *Carbohydr. Res.* **2003**, *338*, 2417–2419. (e) du Roizel, B.; Baltaze, J.-P.; Sinaÿ, P. *Tetrahedron Lett.* **2002**, *43*, 2371–2373. (f) Kaneda, T.; Fujimoto, T.; Goto, J.; Asano, K.; Yasufuku, Y.; Jung, J. H.; Hosono, C.; Sakata, Y. *Chem. Lett.* **2002**, 514–515. (g) Tanaka, M.; Kawaguchi, Y.; Niinae, T.; Shono, T. *J. Chromatogr.* **1984**, *314*, 193–200.

(18) (a) Sabadini, E.; Egídio, F. C.; Fujiwara, F. Y.; Cosgrove, T. *J. Phys. Chem. B* **2008**, *112*, 3328–3332. (b) Kusmin, A.; Lechner, R. E.; Kammel, M.; Saenger, W. *J. Phys. Chem. B* **2008**, *112*, 12888–12898.

[19] We have found scant information on the synthesis and conformational studies of 1,3,5-trioxocane compounds, see: (a) Burkert, U. *Z. Naturforsch. B* **1980**, *35*, 1479–1481. (b) Anet, F. A. L. In *Conformational Analysis of Medium-Sized Heterocycles*; Glass, R. S. Ed.; VCH: New York, **1988**; pp. 35–95. (c) McGuire, R. R.; Pflug, J. L.; Rakowsky, M. H.; Shackelford, S. A.; Shaffer, A. A. *Heterocycles* **1994**, *38*, 1979–2004. (d) Heller, L.; Schwarz, S.; Perl, V.; Köwitsch, A.; Siewert, B.; Csuk, R. *Eur. J. Med. Chem.* **2015**, *101*, 391–399.

(20) The intermolecular addition of an external nucleophile has previously been observed by us in disaccharide systems but only as a minor side reaction, see: León, E. I.; Martín, A.; Pérez-Martín, I.; Quintanal, L. M.; Suárez, E. *Eur. J. Org. Chem.* **2010**, 5248–5262. See others examples in Ref. 13a.

(21) Coupling constants and dihedrals were calculated with Maestro 9.9.013 on minimized structures using MacroModel and the AMBER* force field with the GB/SA solvent model for CHCl₃, Schrödinger, LLC, New York, NY, 2009. The experimental constants were determined on the basis of 1D TOCSY experiments.

(22) Although, according to the IUPAC nomenclature the unit VII is more usually named as (5*R*)-5^{VII}-*O*-acetyl-2,3,6-tri-*O*-methyl- α -D-xylo-hexos-5-ulopyranosyl we prefer to see it as a 5-*C*-acetoxy- β -L-idopyranosyl derivative, which described better the inversion at C5^{VII} and the ¹C₄ conformation of the pyranose ring and is also alternatively accepted by the IUPAC (see a similar example in Nomenclature of Carbohydrates, Rule 2-Carb-16.1).

- (23) For a recent review on hypervalent iodine compounds and their applications see: (a) Yoshimura, A.; Zhdankin, V. V. *Chem. Rev.* **2016**, *116*, 3328–3435. For the preparation of [Bis(acyloxy)iodo]arenes, see: (b) Varvoglis, A. In *Hypervalent Iodine in Organic Synthesis*; Academic Press: London, **1997**; pp. 11–12. (c) Sharefkin, J. G.; Saltzman, H. *Org. Synth. Coll.* **1973**, *V*, 660–663.
- (24) Courtneidge, J. L.; Luszyk, J.; Pagé, D. *Tetrahedron Lett.* **1994**, *35*, 1003–1006.
- (25) Fenger, T. H.; Bjerre, J.; Bols, M. *ChemBioChem* **2009**, *10*, 2494–2503.
- (26) Chaise, T.; Cardinael, P.; Tisse, S.; Combret, J.-C.; Bouillon, J.-P. *Tetrahedron: Asymmetry* **2008**, *19*, 348–357.
- (27) Only a few reports concerning 1,7-diols for the preparation of 1,6-dioxaspiro[4.4]nonane derivatives through favorable 1,5-HAT reactions have been published, see: (a) González, A. G.; Francisco, C. G.; Freire, R.; Hernández, R.; Salazar, J. A.; Suárez, E. *Tetrahedron Lett.* **1976**, *17*, 2725–2728. (b) Concepción, J. I.; Francisco, C. G.; Hernández, R.; Salazar, J. A.; Suárez, E. *Tetrahedron Lett.* **1984**, *25*, 1953–1956. (c) Urones, J. G.; Basabe, P.; Marcos, I. S.; Martín, D. D.; Sexmero, M. J.; Peral, M. H.; Broughton, H. B. *Tetrahedron* **1992**, *48* 10389–10398. (d) Paolucci, C.; Mazzini, C.; Fava, A. *J. Org. Chem.* **1995**, *60*, 169–175.
- (28) MacroModel, version 9.9.013 and the AMBER* force field with the GB/SA solvent model for CHCl₃, Schrödinger, LLC, New York, NY, 2014.
- (29) Kumprecht, L.; Budesinsky, M.; Bour, P.; Kraus, T. *New J. Chem.* **2010**, *34*, 2254–2260.
- (30) CCDC 1039442 contains the supplementary crystallographic data for the compound **15**. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

- (31) Steiner, T.; Saenger, W. *Carbohydr. Res.* **1996**, 282, 53–63. Crystallographic data were obtained by courtesy of The Cambridge Crystallographic Data Centre (Database code CSD = TEVCEC).
- (32) Cremer, D.; Pople, J. A. *J. Am. Chem. Soc.* **1975**, 97, 1354–1358.
- (33) A similar situation is encountered in spiro ortho ester of disaccharide systems, see: (a) Ashworth, P.; Belagali, S. L.; Casson, S.; Marczak, A.; Kocienski, P. *Tetrahedron* **1991**, 47, 9939–9946. (b) Ohtake, H.; Iimori, T.; Ikegami, S. *Tetrahedron Lett.* **1997**, 38, 3413–3414. (c) Ohtake, H.; Ichiba, N.; Shiro, M.; Ikegami, S. *J. Org. Chem.* **2000**, 65, 8164–8170. (d) Nicolaou, K. C.; Mitchell, H. J.; Fylaktakidou, K. C.; Suzuki, H.; Rodríguez, R. M. *Angew. Chem. Int. Ed.* **2000**, 39, 1089–1093.
- (34) Easy dehomologation of 5-*O*-yl secondary radicals has been described in furanose rings, however the homologous reaction of 6-*O*-yl radicals in pyranose systems has not been observed, see: (a) Guyenne, S.; León, E. I.; Martín, A.; Pérez-Martín, I.; Suárez, E. *J. Org. Chem.* **2012**, 77, 7371–7391. (b) Boto, A.; Hernández, D.; Hernández, R.; Suárez, E. *J. Org. Chem.* **2003**, 68, 5310–5319. For an analogous radical decarboxylation of aldofuranuronic acids, see: (c) Dhavale, D. D.; Tagliavini, E.; Trombini, C.; Umani-Ronchi, A. *Tetrahedron Lett.* **1988**, 29, 6163–6166.
- (35) Armspach, D.; Poorters, L.; Matt, D.; Benmerad, B.; Balegroune, F.; Toupet, L. *Org. Biomol. Chem.* **2005**, 3, 2588–2592.
- (36) Pawar, D. M.; Cain, D.; Gill, G.; Bain, A. D.; Sullivan, R. H.; Noe, E. A. *J. Org. Chem.* **2007**, 72, 25–29.
- (37) This 1,6-HAT reaction between 6-*O*-yl radicals and a methoxyl group at C4 to give a 1,3-dioxane ring, has been previously described by us in glucopyranosyl systems, see: Boto, A.; Hernández, D.; Hernández, R.; Suárez, E. *J. Org. Chem.* **2006**, 71, 1938–1948.

- (38) (a) Carofiglio, T.; Cordioli, M.; Fornasier, R.; Jicsinszky, L.; Tonellato, U. *Carbohydr. Res.* **2004**, 339, 1361–1366. For other procedures for the synthesis of per-2,3-*O*-methyl- β -CD, see: (b) Fügedi, P. *Carbohydr. Res.* **1989**, 192, 366–369. (c) Takeo, K.; Mitoh, H.; Uemura, K. *Carbohydr. Res.* **1989**, 187, 203–221.
- (39) (a) Yi, G.; Bradshaw, J. S.; Rossiter, B. E.; Reese, S. L.; Petersson, P.; Markides, K. E.; Lee, M. L. *J. Org. Chem.* **1993**, 58, 2561–2565. For other procedures for the synthesis of per-2,3-*O*-methyl- α -CD, see: (b) Poorters, L.; Armspach, D.; Matt, D. *Eur. J. Org. Chem.* **2003**, 1377–1381. (c) Ashton, P. R.; Hartwell, E. Y.; Philp, D.; Spencer, N.; Stoddart, J. F. *J. Chem. Soc., Perkin Trans. 2* **1995**, 1263–1277.
- (40) For a solvent-dependent chair inversion equilibrium in a mono-altro- α -CD derivative, see: (a) Yamauchi, K.; Miyawaki, A.; Takashima, Y.; Yamaguchi, H.; Harada, A. *Org. Lett.* **2010**, 12, 1284–1286. For a study on conformation equilibria of related α -L-iduronate residues in disaccharide derived from heparin, see: (b) Sanderson, P. N.; Huckerby, T. N.; Nieduszynski, I. A. *Biochem. J.* **1987**, 243, 175–181.